<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="recognize">
            <roleset id="recognize.01" name="" wordnet="3">
                <roles>
                    <role n="0" descr="agent&#x0A;" />
                    <role n="1" descr="thing being identified&#x0A;" />
                </roles>
                <example src="PERMUTATE" no="0">
                    <text>A monoclonal antibody also binds to these 727 sites but, unlike NarP, also recognized STAT1 N-terminus.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="1">
                    <text>A monoclonal antibody are able to recognize STAT1 N-terminus in regulated promoters.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="2">
                    <text>A monoclonal antibody binds to these 727 sites but, unlike NarP, will also recognize STAT1 N-terminus.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="3">
                    <text>A monoclonal antibody binds to these sites 7-2-7, but, unlike NarP, it also recognizes STAT1 N-terminus .</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="4">
                    <text>A monoclonal antibody can recognize STAT1 N-terminus in regulated promoters.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="5">
                    <text>A monoclonal antibody has also joined these 727 sites but, unlike NarP, has also recognized STAT1 N-terminus.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="6">
                    <text>A monoclonal antibody is able to recognize STAT1 N-terminus in regulated promoters.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="7">
                    <text>A monoclonal antibody recognized STAT1 N-terminus in regulated promoters.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="8">
                    <text>A monoclonal antibody recognized STAT1 N-terminus in the regulated promoters.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="9">
                    <text>A monoclonal antibody recognized STAT1 N-terminus.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="10">
                    <text>A monoclonal antibody recognizes STAT1 N-terminus.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="11">
                    <text>A monoclonal antibody specifically recognized STAT1 N-terminus.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="12">
                    <text>A monoclonal antibody that has recognized STAT1 N-terminus was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="13">
                    <text>A monoclonal antibody that recognized STAT1 N-terminus was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="14">
                    <text>A monoclonal antibody that recognizes STAT1 N-terminus is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="15">
                    <text>A monoclonal antibody will recognize STAT1 N-terminus in regulated promoters.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="16">
                    <text>A0 (the eukaryotic binding factor upstream (UBF), has recognized sequence (YPYDVPDYA) at a dilution 1:500 and activated the RNA polymerase I-mediated transcription through cooperative interactions with the specific factor of the species, SL1.</text>
                    <arg n="1">sequence (YPYDVPDYA) at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="17">
                    <text>A0 (the eukaryotic binding factor upstream (UBF), has recognized sequence (YPYDVPDYA) in a 1:500 dilution and activated the RNA polymerase I-mediated transcription through cooperative interactions with the specific factor of the species, SL1.</text>
                    <arg n="1">sequence (YPYDVPDYA) in a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="18">
                    <text>A0 (the eukaryotic binding factor upstream (UBF), has recognized the promoter of the ribosomal RNA gene and activated the RNA polymerase I-mediated transcription through cooperative interactions with the specific factor of the species, SL1.</text>
                    <arg n="1">the promoter of the ribosomal RNA gene</arg>
                </example>
                <example src="PERMUTATE" no="19">
                    <text>A0 (the eukaryotic binding factor upstream (UBF), has recognized the ribosomal RNA promoter and activated the RNA polymerase I-mediated transcription through cooperative interactions with the specific factor of the species, SL1.</text>
                    <arg n="1">the ribosomal RNA promoter</arg>
                </example>
                <example src="PERMUTATE" no="20">
                    <text>A0 (the eukaryotic binding factor upstream (UBF), recognized sequence (YPYDVPDYA) at a dilution 1:500 and activated the transcription mediated by RNA polymerase I through cooperative interactions with the specific factor of the species, SL1.</text>
                    <arg n="1">sequence (YPYDVPDYA) at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="21">
                    <text>A0 (the eukaryotic binding factor upstream (UBF), recognized sequence (YPYDVPDYA) in a 1:500 dilution and activated the transcription mediated by RNA polymerase I through cooperative interactions with the specific factor of the species, SL1.</text>
                    <arg n="1">sequence (YPYDVPDYA) in a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="22">
                    <text>A0 (the eukaryotic binding factor upstream (UBF), recognized the promoter of the ribosomal RNA gene and activated the transcription mediated by RNA polymerase I through cooperative interactions with the specific factor of the species, SL1.</text>
                    <arg n="1">the promoter of the ribosomal RNA gene</arg>
                </example>
                <example src="PERMUTATE" no="23">
                    <text>A0 (the eukaryotic binding factor upstream (UBF), recognized the ribosomal RNA promoter and activated the transcription mediated by RNA polymerase I through cooperative interactions with the specific factor of the species, SL1.</text>
                    <arg n="1">the ribosomal RNA promoter</arg>
                </example>
                <example src="PERMUTATE" no="24">
                    <text>A0 (the eukaryotic binding factor upstream (UBF), will recognize sequence (YPYDVPDYA) at a dilution 1:500 and activate RNA polymerase I-mediated transcription through cooperative interactions with the specific factor of the species, SL1.</text>
                    <arg n="1">sequence (YPYDVPDYA) at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="25">
                    <text>A0 (the eukaryotic binding factor upstream (UBF), will recognize sequence (YPYDVPDYA) in a 1:500 dilution and activate RNA polymerase I-mediated transcription through cooperative interactions with the specific factor of the species, SL1.</text>
                    <arg n="1">sequence (YPYDVPDYA) in a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="26">
                    <text>A0 (the eukaryotic binding factor upstream (UBF), will recognize the promoter of the RNA ribosomal gene and activate RNA polymerase I-mediated transcription through cooperative interactions with the specific factor of the species, SL1.</text>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="27">
                    <text>A0 (the eukaryotic binding factor upstream (UBF), will recognize the ribosomal RNA promoter and activate RNA polymerase I-mediated transcription through cooperative interactions with the specific factor of the species, SL1.</text>
                    <arg n="1">the ribosomal RNA promoter</arg>
                </example>
                <example src="PERMUTATE" no="28">
                    <text>A0 (the upstream eukaryotic binding factor (UBF) will recognize sequence (YPYDVPDYA) at a dilution 1:500 and activate the RNN polymerase I-mediated transcription through cooperative interactions with the species-specific factor, SL1.</text>
                    <arg n="1">sequence (YPYDVPDYA) at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="29">
                    <text>A0 (the upstream eukaryotic binding factor (UBF) will recognize sequence (YPYDVPDYA) in a 1:500 dilution and activate the RNN polymerase I-mediated transcription through cooperative interactions with the species-specific factor, SL1.</text>
                    <arg n="1">sequence (YPYDVPDYA) in a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="30">
                    <text>A0 (the upstream eukaryotic binding factor (UBF) will recognize the promoter of the RNA ribosomal gene and activate the RNN polymerase I-mediated transcription through cooperative interactions with the species-specific factor, SL1.</text>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="31">
                    <text>A0 (the upstream eukaryotic binding factor (UBF) will recognize the promoter of the ribosomal RNA gene and activate the RNN polymerase I-mediated transcription through cooperative interactions with the species-specific factor, SL1.</text>
                    <arg n="1">the promoter of the ribosomal RNA gene</arg>
                </example>
                <example src="PERMUTATE" no="32">
                    <text>A0 (the upstream eukaryotic binding factor (UBF), recognized sequence (YPYDVPDYA) at a dilution 1:500 and activated RNA polymerase I-mediated transcription through cooperative interactions with the species specific factor, SL1.</text>
                    <arg n="1">sequence (YPYDVPDYA) at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="33">
                    <text>A0 (the upstream eukaryotic binding factor (UBF), recognized sequence (YPYDVPDYA) at a dilution 1:500 and activated RNA-mediated transcription polymerase I through cooperative interactions with the species specific factor, SL1.</text>
                    <arg n="1">sequence (YPYDVPDYA) at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="34">
                    <text>A0 (the upstream eukaryotic binding factor (UBF), recognized sequence (YPYDVPDYA) in a 1:500 dilution and activated RNA polymerase I-mediated transcription through cooperative interactions with the species specific factor, SL1.</text>
                    <arg n="1">sequence (YPYDVPDYA) in a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="35">
                    <text>A0 (the upstream eukaryotic binding factor (UBF), recognized sequence (YPYDVPDYA) in a 1:500 dilution and activated RNA-mediated transcription polymerase I through cooperative interactions with the species specific factor, SL1.</text>
                    <arg n="1">sequence (YPYDVPDYA) in a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="36">
                    <text>A0 (the upstream eukaryotic binding factor (UBF), recognized the promoter of the ribosomal RNA gene and activated RNA polymerase I-mediated transcription through cooperative interactions with the species specific factor, SL1.</text>
                    <arg n="1">the promoter of the ribosomal RNA gene</arg>
                </example>
                <example src="PERMUTATE" no="37">
                    <text>A0 (the upstream eukaryotic binding factor (UBF), recognized the ribosomal RNA promoter and activated RNA polymerase I-mediated transcription through cooperative interactions with the species specific factor, SL1.</text>
                    <arg n="1">the ribosomal RNA promoter</arg>
                </example>
                <example src="PERMUTATE" no="38">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that are recognized by anti-LMP-1 antisumption of affinity are the ones indicated.</text>
                    <arg n="0">anti-LMP-1 antisumption of affinity</arg>
                </example>
                <example src="PERMUTATE" no="39">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that are recognized by four different specific antibodies are the ones indicated.</text>
                    <arg n="0">four different specific antibodies</arg>
                </example>
                <example src="PERMUTATE" no="40">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that are recognized by polyclonal anti-LMP-1 affinity antiserum are the ones indicated.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antiserum</arg>
                </example>
                <example src="PERMUTATE" no="41">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that are recognized by polyclonal anti-LMP-1 purified affinity antiserum are the ones indicated.</text>
                    <arg n="0">polyclonal anti-LMP-1 purified affinity antiserum</arg>
                </example>
                <example src="PERMUTATE" no="42">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that can be recognized by anti-LMP-1 antisumption of affinity are indicated.</text>
                    <arg n="0">anti-LMP-1 antisumption of affinity</arg>
                </example>
                <example src="PERMUTATE" no="43">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that can be recognized by four different specific antibodies are indicated.</text>
                    <arg n="0">four different specific antibodies</arg>
                </example>
                <example src="PERMUTATE" no="44">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that can be recognized by four different specific antibodies are the ones indicated.</text>
                    <arg n="0">four different specific antibodies</arg>
                </example>
                <example src="PERMUTATE" no="45">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that can be recognized by polyclonal anti-LMP-1 affinity antiserum are indicated.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antiserum</arg>
                </example>
                <example src="PERMUTATE" no="46">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that can be recognized by polyclonal anti-LMP-1 affinity antiserum are the ones indicated.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antiserum</arg>
                </example>
                <example src="PERMUTATE" no="47">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that can be recognized by polyclonal anti-LMP-1 purified affinity antiserum are indicated.</text>
                    <arg n="0">polyclonal anti-LMP-1 purified affinity antiserum</arg>
                </example>
                <example src="PERMUTATE" no="48">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that can be recognized by polyclonal anti-LMP-1 purified affinity antiserum are the ones indicated.</text>
                    <arg n="0">polyclonal anti-LMP-1 purified affinity antiserum</arg>
                </example>
                <example src="PERMUTATE" no="49">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that have been recognized by anti-LMP-1 antisumption of affinity are as given.</text>
                    <arg n="0">anti-LMP-1 antisumption of affinity</arg>
                </example>
                <example src="PERMUTATE" no="50">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that have been recognized by anti-LMP-1 antisumption of affinity are the ones indicated.</text>
                    <arg n="0">anti-LMP-1 antisumption of affinity</arg>
                </example>
                <example src="PERMUTATE" no="51">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that have been recognized by four different specific antibodies are as given.</text>
                    <arg n="0">four different specific antibodies</arg>
                </example>
                <example src="PERMUTATE" no="52">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that have been recognized by four different specific antibodies are the ones indicated.</text>
                    <arg n="0">four different specific antibodies</arg>
                </example>
                <example src="PERMUTATE" no="53">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that have been recognized by polyclonal anti-LMP-1 affinity antiserum are as given.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antiserum</arg>
                </example>
                <example src="PERMUTATE" no="54">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that have been recognized by polyclonal anti-LMP-1 affinity antiserum are the ones indicated.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antiserum</arg>
                </example>
                <example src="PERMUTATE" no="55">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that have been recognized by polyclonal anti-LMP-1 purified affinity antiserum are as given.</text>
                    <arg n="0">polyclonal anti-LMP-1 purified affinity antiserum</arg>
                </example>
                <example src="PERMUTATE" no="56">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that were recognized by four different specific antibodies are the ones indicated.</text>
                    <arg n="0">four different specific antibodies</arg>
                </example>
                <example src="PERMUTATE" no="57">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that were recognized by polyclonal anti-LMP-1 purified affinity antiserum are the ones indicated.</text>
                    <arg n="0">polyclonal anti-LMP-1 purified affinity antiserum</arg>
                </example>
                <example src="PERMUTATE" no="58">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that will be recognized by anti-LMP-1 antisumption of affinity are indicated.</text>
                    <arg n="0">anti-LMP-1 antisumption of affinity</arg>
                </example>
                <example src="PERMUTATE" no="59">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that will be recognized by anti-LMP-1 antisumption of affinity are the ones indicated.</text>
                    <arg n="0">anti-LMP-1 antisumption of affinity</arg>
                </example>
                <example src="PERMUTATE" no="60">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that will be recognized by four different specific antibodies are the ones indicated.</text>
                    <arg n="0">four different specific antibodies</arg>
                </example>
                <example src="PERMUTATE" no="61">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that will be recognized by polyclonal anti-LMP-1 affinity antiserum are indicated.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antiserum</arg>
                </example>
                <example src="PERMUTATE" no="62">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that will be recognized by polyclonal anti-LMP-1 affinity antiserum are the ones indicated.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antiserum</arg>
                </example>
                <example src="PERMUTATE" no="63">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that will be recognized by polyclonal anti-LMP-1 purified affinity antiserum are the ones indicated.</text>
                    <arg n="0">polyclonal anti-LMP-1 purified affinity antiserum</arg>
                </example>
                <example src="PERMUTATE" no="64">
                    <text>Blots were surveyed with A monoclonal antibody recognizing STAT1 N-terminus.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="65">
                    <text>Blots were surveyed with D1 anti-64kD human autoantigen recognizing polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="66">
                    <text>Blots were surveyed with NarL protein recognizing heptameric in other arrangements.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="67">
                    <text>Blots were surveyed with NarL protein recognizing heptamers in other arrangements.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="68">
                    <text>Blots were surveyed with a monoclonal antibody recognizing STAT1 N-terminus.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="69">
                    <text>Blots were surveyed with activating complex cAMP-CRP recognizing two sites in tsx-p2.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="70">
                    <text>Blots were surveyed with activating the cAMP-CRP complex recognizing two sites in tsx-p2.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="71">
                    <text>Blots were surveyed with activator complex cAMP-CRP recognizing two sites in tsx-p2.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="72">
                    <text>Blots were surveyed with anti-64kD antibodies of human autoantigen D1 recognizing a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="73">
                    <text>Blots were surveyed with anti-64kD antibodies of human autoantigen D1 recognizing polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="74">
                    <text>Blots were surveyed with anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit recognizing term C of CD40 at a dilution 1:500.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="75">
                    <text>Blots were surveyed with anti-LMP-1 anti-LMP-1 purified affinity recognizing epiptopes in the C-terminal of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="76">
                    <text>Blots were surveyed with anti-LMP-1 anti-LMP-1 purified affinity recognizing epitopes in the terminal C of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="77">
                    <text>Blots were surveyed with anti-LMP-1 antisembly purified recognizing epitoped in the C-terminal of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="78">
                    <text>Blots were surveyed with anti-LMP-1 purified affinity antiserum recognizing epictopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="79">
                    <text>Blots were surveyed with anti-LMP-1 purified affinity antiserum recognizing epiptopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="80">
                    <text>Blots were surveyed with anti-Stat3 pAb recognizing the lowest form of Stat3, Stat3Beta.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="81">
                    <text>Blots were surveyed with monoclonal antibody recognizing N-terminus STAT1.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="82">
                    <text>Blots were surveyed with monoclonal antibody recognizing STAT1 N-terminal.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="83">
                    <text>Blots were surveyed with monoclonal antibody recognizing STAT1 N-terminus.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="84">
                    <text>Blots were surveyed with most of the regulators belonging to the AraC/XylS family recognizing multi-binding sites.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="85">
                    <text>Blots were surveyed with most of the regulators belonging to the AraC/XylS family recognizing multiple connection site.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="86">
                    <text>Blots were surveyed with most of the regulators belonging to the AraC/XylS family recognizing multiple linkage site.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="87">
                    <text>Blots were surveyed with most regulators belonging to the AraC/XylS family recognizing multiple binding sites.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="88">
                    <text>Blots were surveyed with polyclonal anti-CD40 anti-rabbit antisound recognizing C-term of CD40 at a 1:500 dilution.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="89">
                    <text>Blots were surveyed with polyclonal anti-LMP-1 affinity antisumption recognizing epitopes in the C muscle of LMP-1 at a dilution of 1:200.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="90">
                    <text>Blots were surveyed with proteins recognizing short motives within the protected region.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="91">
                    <text>Blots were surveyed with proteins recognizing short reasons within the protected region.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="92">
                    <text>Blots were surveyed with the NarL protein recognizing heptamers in other arrangements.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="93">
                    <text>Blots were surveyed with the activator complex cAMP-CRP recognizing two sites in tsx-p2.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="94">
                    <text>Blots were surveyed with the cAMP-CRP activator complex recognizing two sites in tsx-p2.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="95">
                    <text>Blots were surveyed with the eukaryotic binding factor upstream (UBF) recognizing the promoter of the RNA ribosomal gene.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="96">
                    <text>Blots were surveyed with the upstream eukaryotic binding factor (UBF) recognizing the RNA ribosomal gene promoter.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="97">
                    <text>Blots were surveyed with the upstream eukaryotic binding factor (UBF) recognizing the promoter of the RNA ribosomal gene.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="98">
                    <text>C-term of CD40 at a 1:500 dilution are recognized by polyclonal anti-CD40 anti-rabbit antisound with which the threads were probed.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="99">
                    <text>C-term of CD40 at a 1:500 dilution are recognized by polyclonal anti-CD40 anti-rabbit antisound with which the wires were probed.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="100">
                    <text>C-term of CD40 at a 1:500 dilution could be recognized in immunoprecipitatio with polyclonal anti-CD40 anti-rabbit antisound, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="101">
                    <text>C-term of CD40 at a 1:500 dilution has been recognized by polyclonal anti-CD40 anti-rabbit antisound.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="102">
                    <text>C-term of CD40 at a 1:500 dilution is recognized by polyclonal anti-CD40 anti-rabbit antisound by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="103">
                    <text>C-term of CD40 at a 1:500 dilution is recognized by polyclonal anti-CD40 anti-rabbit antisound by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="104">
                    <text>C-term of CD40 at a 1:500 dilution is recognized by polyclonal anti-CD40 anti-rabbit antisound.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="105">
                    <text>C-term of CD40 at a 1:500 dilution was recognized by polyclonal anti-CD40 anti-rabbit antisound by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="106">
                    <text>C-term of CD40 at a 1:500 dilution was recognized by polyclonal anti-CD40 anti-rabbit antisound.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="107">
                    <text>C-term of CD40 at a 1:500 dilution was recognized in the immunoprecipitatome with polyclonal anti-CD40 anti-rabbit antisound, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="108">
                    <text>C-term of CD40 at a 1:500 dilution were recognized by polyclonal anti-CD40 anti-rabbit antisound.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="109">
                    <text>C-term of CD40 at a 1:500 dilution will be recognized by polyclonal anti-CD40 anti-rabbit antisound.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="110">
                    <text>C-term of CD40 at a 1:500 dilution will be recognized in immunoprecipitatio with polyclonal anti-CD40 anti-rabbit antisound, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="111">
                    <text>C-term of CD40 at a 1:500 dilution, cannot is recognized in immunoprecipitatio with polyclonal anti-CD40 anti-rabbit antisound, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="112">
                    <text>C-term of CD40 at a 1:500 dilution, cannot is recognized in the immunoprecipitaiton with polyclonal anti-CD40 anti-rabbit antisound as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="113">
                    <text>C-term of CD40 at a 1:500 dilution, could be recognized in the immunoprecipitaiton with polyclonal anti-CD40 anti-rabbit antisound as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="114">
                    <text>C-term of CD40 at a 1:500 dilution, has been recognized in the immunoprecipitaiton with polyclonal anti-CD40 anti-rabbit antisound as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="115">
                    <text>C-term of CD40 at a 1:500 dilution, was not recognized in the immunoprecipitaiton with polyclonal anti-CD40 anti-rabbit antisound as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="116">
                    <text>C-term of CD40 at a 1:500 dilution, will be recognized in the immunoprecipitaiton with polyclonal anti-CD40 anti-rabbit antisound as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="117">
                    <text>D1 anti-64kD human autoantigen also binds to these 727 sites but, unlike NarP, also recognized polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="118">
                    <text>D1 anti-64kD human autoantigen also binds to these sites 7-2-7, but, unlike NarP, it also recognized polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle .</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="119">
                    <text>D1 anti-64kD human autoantigen also binds to these sites 7-2-7, but, unlike NarP, it also recognized polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="120">
                    <text>D1 anti-64kD human autoantigen are able to recognize polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle in regulated promoters.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="121">
                    <text>D1 anti-64kD human autoantigen binds to these 727 sites but, unlike NarP, will also recognize polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="122">
                    <text>D1 anti-64kD human autoantigen binds to these sites 7-2-7, but, unlike NarP, it also recognizes polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle .</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="123">
                    <text>D1 anti-64kD human autoantigen can recognize polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle in regulated promoters.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="124">
                    <text>D1 anti-64kD human autoantigen has also joined these 727 sites but, unlike NarP, has also recognized polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="125">
                    <text>D1 anti-64kD human autoantigen is able to recognize polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle in regulated promoters.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="126">
                    <text>D1 anti-64kD human autoantigen recognized polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle in regulated promoters.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="127">
                    <text>D1 anti-64kD human autoantigen recognized polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle in the regulated promoters.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="128">
                    <text>D1 anti-64kD human autoantigen recognized polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="129">
                    <text>D1 anti-64kD human autoantigen specifically recognized polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="130">
                    <text>D1 anti-64kD human autoantigen that has recognized polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="131">
                    <text>D1 anti-64kD human autoantigen that recognized polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="132">
                    <text>D1 anti-64kD human autoantigen that recognizes polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="133">
                    <text>D1 anti-64kD human autoantigen that recognizes polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="134">
                    <text>D1 anti-64kD human autoantigen will recognize polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle in regulated promoters.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="135">
                    <text>D1 antibody of anti-64kD human autoantigen also binds to these 727 sites but, unlike NarP, also recognized a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="136">
                    <text>D1 antibody of anti-64kD human autoantigen also binds to these sites 7-2-7, but, unlike NarP, it also recognized a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle .</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="137">
                    <text>D1 antibody of anti-64kD human autoantigen also binds to these sites 7-2-7, but, unlike NarP, it also recognized a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="138">
                    <text>D1 antibody of anti-64kD human autoantigen are able to recognize a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle in regulated promoters.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="139">
                    <text>D1 antibody of anti-64kD human autoantigen binds to these 727 sites but, unlike NarP, will also recognize a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="140">
                    <text>D1 antibody of anti-64kD human autoantigen binds to these sites 7-2-7, but, unlike NarP, it also recognizes a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle .</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="141">
                    <text>D1 antibody of anti-64kD human autoantigen can recognize a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle in regulated promoters.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="142">
                    <text>D1 antibody of anti-64kD human autoantigen recognized a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle in regulated promoters.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="143">
                    <text>D1 antibody of anti-64kD human autoantigen recognized a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle in the regulated promoters.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="144">
                    <text>D1 antibody of anti-64kD human autoantigen recognized a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="145">
                    <text>D1 antibody of anti-64kD human autoantigen recognizes a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="146">
                    <text>D1 antibody of anti-64kD human autoantigen that recognized a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="147">
                    <text>D1 antibody of anti-64kD human autoantigen that recognizes a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="148">
                    <text>D1 antibody of anti-64kD human autoantigen that recognizes a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="149">
                    <text>D1 antibody of anti-64kD human autoantigen will recognize a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle in regulated promoters.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="150">
                    <text>D1 antibody of human autoantigen anti-64kD also binds to these 727 sites but, unlike NarP, also recognized polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="151">
                    <text>D1 antibody of human autoantigen anti-64kD also binds to these sites 7-2-7, but, unlike NarP, it also recognized polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle .</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="152">
                    <text>D1 antibody of human autoantigen anti-64kD also binds to these sites 7-2-7, but, unlike NarP, it also recognized polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="153">
                    <text>D1 antibody of human autoantigen anti-64kD are able to recognize polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle in regulated promoters.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="154">
                    <text>D1 antibody of human autoantigen anti-64kD binds to these 727 sites but, unlike NarP, will also recognize polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="155">
                    <text>D1 antibody of human autoantigen anti-64kD binds to these sites 7-2-7, but, unlike NarP, it also recognizes polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle .</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="156">
                    <text>D1 antibody of human autoantigen anti-64kD can recognize polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle in regulated promoters.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="157">
                    <text>D1 antibody of human autoantigen anti-64kD has also joined these 727 sites but, unlike NarP, has also recognized polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="158">
                    <text>D1 antibody of human autoantigen anti-64kD is able to recognize polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle in regulated promoters.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="159">
                    <text>D1 antibody of human autoantigen anti-64kD recognized polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle in regulated promoters.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="160">
                    <text>D1 antibody of human autoantigen anti-64kD recognized polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle in the regulated promoters.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="161">
                    <text>D1 antibody of human autoantigen anti-64kD recognized polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="162">
                    <text>D1 antibody of human autoantigen anti-64kD recognizes polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="163">
                    <text>D1 antibody of human autoantigen anti-64kD specifically recognized polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="164">
                    <text>D1 antibody of human autoantigen anti-64kD that has recognized polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="165">
                    <text>D1 antibody of human autoantigen anti-64kD that recognized polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="166">
                    <text>D1 antibody of human autoantigen anti-64kD that recognizes polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="167">
                    <text>D1 antibody of human autoantigen anti-64kD will recognize polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle in regulated promoters.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="168">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that A monoclonal antibody can recognize STAT1 N-terminus.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="169">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that D1 anti-64kD human autoantigen can recognize polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="170">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that D1 antibody of anti-64kD human autoantigen can recognize a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="171">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that D1 antibody of human autoantigen anti-64kD can recognize polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="172">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that NarL protein can recognize heptameric in other arrangements.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="173">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that NarL protein can recognize heptamers in other arrangements.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="174">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that a monoclonal antibody can recognize STAT1 N-terminus.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="175">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that a monoclonal antibody can recognize the STAT1 N-terminal.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="176">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that activating complex cAMP-CRP can recognize two sites in tsx-p2.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="177">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that activating the cAMP-CRP complex can recognize two sites in tsx-p2.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="178">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that activator complex cAMP-CRP can recognize two sites in tsx-p2.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="179">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that anti-64kD antibodies of human autoantigen D1 can recognize a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="180">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that anti-64kD antibodies of human autoantigen D1 can recognize polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="181">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit can recognize term C of CD40 at a dilution 1:500.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="182">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that anti-LMP-1 anti-LMP-1 purified affinity can recognize epiptopes in the C-terminal of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="183">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that anti-LMP-1 anti-LMP-1 purified affinity can recognize epitopes in the terminal C of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="184">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that anti-LMP-1 antisembly purified can recognize epiptopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="185">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that anti-LMP-1 antisembly purified can recognize epitoped in the C-terminal of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="186">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that anti-LMP-1 purified affinity antiserum can recognize epiptopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="187">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that anti-Stat3 pAb can recognize the lowest form of Stat3, Stat3Beta.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="188">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that monoclonal antibody can recognize N-terminus STAT1.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="189">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that monoclonal antibody can recognize STAT1 N-terminal.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="190">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that monoclonal antibody can recognize STAT1 N-terminus.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="191">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that most of the regulators belonging to the AraC/XylS family can recognize multi-binding sites.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="192">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that most of the regulators belonging to the AraC/XylS family can recognize multiple connection site.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="193">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that most of the regulators belonging to the AraC/XylS family can recognize multiple linkage site.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="194">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that most of the regulators belonging to the AraC/XylS family can recognize multiple-link location.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="195">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that most regulators belonging to the AraC/XylS family can recognize multiple binding sites.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="196">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that polyclonal anti-CD40 anti-rabbit antisound can recognize C-term of CD40 at a 1:500 dilution.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="197">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that polyclonal anti-LMP-1 affinity antisumption can recognize epitopes in the C muscle of LMP-1 at a dilution of 1:200.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="198">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that proteins can recognize short reasons within the protected region.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="199">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that the activator complex cAMP-CRP can recognize two sites in tsx-p2.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="200">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that the upstream eukaryotic binding factor (UBF) can recognize the RNA ribosomal gene promoter.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="201">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that the upstream eukaryotic binding factor (UBF) can recognize the promoter of the RNA ribosomal gene.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="202">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that A monoclonal antibody has recognized STAT1 N-terminus.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="203">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that A monoclonal antibody recognized STAT1 N-terminus.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="204">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that D1 anti-64kD human autoantigen has recognized polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="205">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that D1 anti-64kD human autoantigen recognized polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="206">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that D1 antibody of anti-64kD human autoantigen has recognized a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="207">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that D1 antibody of human autoantigen anti-64kD has recognized polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="208">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that D1 antibody of human autoantigen anti-64kD recognized polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="209">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that NarL protein has recognized heptamers in other arrangements.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="210">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that NarL protein recognized heptameric in other arrangements.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="211">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that NarL protein recognized heptamers in other arrangements.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="212">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that a monoclonal antibody has recognized STAT1 N-terminus.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="213">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that a monoclonal antibody recognized STAT1 N-terminus.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="214">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that a monoclonal antibody recognized the STAT1 N-terminal.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="215">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that activating complex cAMP-CRP has recognized two sites in tsx-p2.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="216">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that activating complex cAMP-CRP recognized two sites in tsx-p2.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="217">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that activating the cAMP-CRP complex has recognized two sites in tsx-p2.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="218">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that activating the cAMP-CRP complex recognized two sites in tsx-p2.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="219">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that activator complex cAMP-CRP has recognized two sites in tsx-p2.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="220">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that activator complex cAMP-CRP recognized two sites in tsx-p2.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="221">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that anti-64kD antibodies of human autoantigen D1 has recognized a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="222">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that anti-64kD antibodies of human autoantigen D1 has recognized polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="223">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that anti-64kD antibodies of human autoantigen D1 recognized a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="224">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that anti-64kD antibodies of human autoantigen D1 recognized polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="225">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit recognized term C of CD40 at a dilution 1:500.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="226">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that anti-LMP-1 anti-LMP-1 purified affinity has recognized epiptopes in the C-terminal of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="227">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that anti-LMP-1 anti-LMP-1 purified affinity has recognized epitopes in the terminal C of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="228">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that anti-LMP-1 anti-LMP-1 purified affinity recognized epiptopes in the C-terminal of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="229">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that anti-LMP-1 anti-LMP-1 purified affinity recognized epitopes in the terminal C of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="230">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that anti-LMP-1 antisembly purified has recognized epiptopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="231">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that anti-LMP-1 antisembly purified recognized epiptopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="232">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that anti-LMP-1 antisembly purified recognized epitoped in the C-terminal of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="233">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that anti-LMP-1 purified affinity antiserum has recognized epictopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="234">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that anti-LMP-1 purified affinity antiserum has recognized epiptopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="235">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that anti-LMP-1 purified affinity antiserum recognized epictopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="236">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that anti-LMP-1 purified affinity antiserum recognized epiptopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="237">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that anti-Stat3 pAb has recognized the lowest form of Stat3, Stat3Beta.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="238">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that anti-Stat3 pAb recognized the lowest form of Stat3, Stat3Beta.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="239">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that monoclonal antibody has recognized STAT1 N-terminal.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="240">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that monoclonal antibody has recognized STAT1 N-terminus.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="241">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that monoclonal antibody recognized N-terminus STAT1.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="242">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that monoclonal antibody recognized STAT1 N-terminal.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="243">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that monoclonal antibody recognized STAT1 N-terminus.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="244">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that most of the regulators belonging to the AraC/XylS family has recognized multi-binding sites.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="245">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that most of the regulators belonging to the AraC/XylS family has recognized multiple connection site.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="246">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that most of the regulators belonging to the AraC/XylS family has recognized multiple linkage site.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="247">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that most of the regulators belonging to the AraC/XylS family has recognized multiple-link location.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="248">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that most of the regulators belonging to the AraC/XylS family recognized multiple connection site.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="249">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that most of the regulators belonging to the AraC/XylS family recognized multiple linkage site.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="250">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that most of the regulators belonging to the AraC/XylS family recognized multiple-link location.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="251">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that most regulators belonging to the AraC/XylS family has recognized multiple binding sites.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="252">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that most regulators belonging to the AraC/XylS family recognized multiple binding sites.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="253">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that polyclonal anti-CD40 anti-rabbit antisound recognized C-term of CD40 at a 1:500 dilution.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="254">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that polyclonal anti-LMP-1 affinity antisumption has recognized epitopes in the C muscle of LMP-1 at a dilution of 1:200.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="255">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that polyclonal anti-LMP-1 affinity antisumption recognized epitopes in the C muscle of LMP-1 at a dilution of 1:200.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="256">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that proteins has recognized short reasons within the protected region.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="257">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that proteins recognized short reasons within the protected region.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="258">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that the NarL protein has recognized heptamers in other arrangements.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="259">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that the NarL protein recognized heptamers in other arrangements.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="260">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that the activator complex cAMP-CRP has recognized two sites in tsx-p2.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="261">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that the activator complex cAMP-CRP recognized two sites in tsx-p2.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="262">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that the cAMP-CRP activator complex has recognized two sites in tsx-p2.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="263">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that the eukaryotic binding factor upstream (UBF) has recognized the promoter of the RNA ribosomal gene.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="264">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that the eukaryotic binding factor upstream (UBF) recognized the promoter of the RNA ribosomal gene.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="265">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that the upstream eukaryotic binding factor (UBF) has recognized the RNA ribosomal gene promoter.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="266">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that the upstream eukaryotic binding factor (UBF) has recognized the promoter of the RNA ribosomal gene.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="267">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that the upstream eukaryotic binding factor (UBF) recognized the RNA ribosomal gene promoter.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="268">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that the upstream eukaryotic binding factor (UBF) recognized the promoter of the RNA ribosomal gene.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="269">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where C-term of CD40 at a 1:500 dilution is recognized by polyclonal anti-CD40 anti-rabbit antisound.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="270">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where C-term of CD40 at a 1:500 dilution was recognized by polyclonal anti-CD40 anti-rabbit antisound.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="271">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where N-terminus STAT1 is recognized by monoclonal antibody.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="272">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where N-terminus STAT1 was recognized by monoclonal antibody.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="273">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where STAT1 N-terminal is recognized by monoclonal antibody.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="274">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where STAT1 N-terminal was recognized by monoclonal antibody.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="275">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where STAT1 N-terminus is recognized by A monoclonal antibody.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="276">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where STAT1 N-terminus is recognized by monoclonal antibody.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="277">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where STAT1 N-terminus was recognized by A monoclonal antibody.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="278">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle is recognized by D1 antibody of anti-64kD human autoantigen.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="279">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle was recognized by D1 antibody of anti-64kD human autoantigen.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="280">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle is recognized by anti-64kD antibodies of human autoantigen D1.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="281">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle was recognized by anti-64kD antibodies of human autoantigen D1.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="282">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where epictopes in the C-terminal of LMP-1 at a dilution 1:200 is recognized by anti-LMP-1 purified affinity antiserum.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="283">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where epictopes in the C-terminal of LMP-1 at a dilution 1:200 was recognized by anti-LMP-1 purified affinity antiserum.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="284">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where epiptopes in the C-terminal of LMP-1 at a 1:200 dilution is recognized by anti-LMP-1 anti-LMP-1 purified affinity.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="285">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where epiptopes in the C-terminal of LMP-1 at a 1:200 dilution was recognized by anti-LMP-1 anti-LMP-1 purified affinity.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="286">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where epiptopes in the C-terminal of LMP-1 at a dilution 1:200 is recognized by anti-LMP-1 purified affinity antiserum.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="287">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where epiptopes in the C-terminal of LMP-1 at a dilution 1:200 was recognized by anti-LMP-1 antisembly purified.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="288">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where epitoped in the C-terminal of LMP-1 in a 1:200 dilution is recognized by anti-LMP-1 antisembly purified.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="289">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where epitoped in the C-terminal of LMP-1 in a 1:200 dilution was recognized by anti-LMP-1 antisembly purified.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="290">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where epitopes in the C muscle of LMP-1 at a dilution of 1:200 is recognized by polyclonal anti-LMP-1 affinity antisumption.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="291">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where epitopes in the C muscle of LMP-1 at a dilution of 1:200 was recognized by polyclonal anti-LMP-1 affinity antisumption.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="292">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where epitopes in the terminal C of LMP-1 at a 1:200 dilution is recognized by anti-LMP-1 anti-LMP-1 purified affinity.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="293">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where epitopes in the terminal C of LMP-1 at a 1:200 dilution was recognized by anti-LMP-1 anti-LMP-1 purified affinity.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="294">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where heptameric in other arrangements is recognized by NarL protein.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="295">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where heptameric in other arrangements was recognized by NarL protein.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="296">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where heptamers in other arrangements is recognized by NarL protein.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="297">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where heptamers in other arrangements is recognized by the NarL protein.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="298">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where heptamers in other arrangements was recognized by the NarL protein.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="299">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where multi-binding sites is recognized by most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="300">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where multi-binding sites was recognized by most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="301">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where multiple binding sites is recognized by most regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="302">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where multiple binding sites was recognized by most regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="303">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where multiple connection site was recognized by most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="304">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where multiple linkage site is recognized by most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="305">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where multiple linkage site was recognized by most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="306">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where multiple-link location is recognized by most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="307">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where multiple-link location was recognized by most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="308">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle is recognized by D1 anti-64kD human autoantigen.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="309">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle is recognized by D1 antibody of human autoantigen anti-64kD.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="310">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle was recognized by D1 anti-64kD human autoantigen.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="311">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle was recognized by D1 antibody of human autoantigen anti-64kD.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="312">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where short motives within the protected region is recognized by proteins.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="313">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where short motives within the protected region was recognized by proteins.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="314">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where short reasons within the protected region was recognized by proteins.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="315">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where term C of CD40 at a dilution 1:500 was recognized by anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="316">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where the RNA ribosomal gene promoter was recognized by the upstream eukaryotic binding factor (UBF).</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="317">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where the STAT1 N-terminal is recognized by a monoclonal antibody.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="318">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where the STAT1 N-terminal was recognized by a monoclonal antibody.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="319">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where the lowest form of Stat3, Stat3Beta is recognized by anti-Stat3 pAb.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="320">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where the lowest form of Stat3, Stat3Beta was recognized by anti-Stat3 pAb.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="321">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where the promoter of the RNA ribosomal gene is recognized by the eukaryotic binding factor upstream (UBF).</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="322">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where the promoter of the RNA ribosomal gene is recognized by the upstream eukaryotic binding factor (UBF).</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="323">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where the promoter of the RNA ribosomal gene was recognized by the eukaryotic binding factor upstream (UBF).</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="324">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where the promoter of the RNA ribosomal gene was recognized by the upstream eukaryotic binding factor (UBF).</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="325">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where two sites in tsx-p2 is recognized by activating complex cAMP-CRP.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="326">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where two sites in tsx-p2 is recognized by activating the cAMP-CRP complex.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="327">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where two sites in tsx-p2 is recognized by activator complex cAMP-CRP.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="328">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where two sites in tsx-p2 is recognized by the activator complex cAMP-CRP.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="329">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where two sites in tsx-p2 is recognized by the cAMP-CRP activator complex.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="330">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where two sites in tsx-p2 was recognized by activating complex cAMP-CRP.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="331">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where two sites in tsx-p2 was recognized by activating the cAMP-CRP complex.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="332">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where two sites in tsx-p2 was recognized by activator complex cAMP-CRP.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="333">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where two sites in tsx-p2 was recognized by the cAMP-CRP activator complex.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="334">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with A monoclonal antibody which recognized STAT1 N-terminus and by the western inflorescence.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="335">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with A monoclonal antibody which recognized STAT1 N-terminus, and by Western blotting</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="336">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with A monoclonal antibody which recognizes STAT1 N-terminus, and by Western blotting</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="337">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with D1 anti-64kD human autoantigen which recognized polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle and by the western inflorescence.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="338">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with D1 anti-64kD human autoantigen which recognized polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle, and by Western blotting</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="339">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with D1 anti-64kD human autoantigen which recognizes polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle, and by Western blotting</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="340">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with D1 antibody of anti-64kD human autoantigen which recognized a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle and by the western inflorescence.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="341">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with D1 antibody of anti-64kD human autoantigen which recognized a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle, and by Western blotting</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="342">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with D1 antibody of anti-64kD human autoantigen which recognizes a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle, and by Western blotting</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="343">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with D1 antibody of human autoantigen anti-64kD which recognized polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle and by the western inflorescence.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="344">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with D1 antibody of human autoantigen anti-64kD which recognized polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle, and by Western blotting</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="345">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with D1 antibody of human autoantigen anti-64kD which recognizes polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle, and by Western blotting</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="346">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with NarL protein which recognized heptameric in other arrangements and by the western inflorescence.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="347">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with NarL protein which recognized heptameric in other arrangements, and by Western blotting</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="348">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with NarL protein which recognized heptamers in other arrangements and by the western inflorescence.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="349">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with NarL protein which recognizes heptameric in other arrangements, and by Western blotting</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="350">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with NarL protein which recognizes heptamers in other arrangements, and by Western blotting</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="351">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with a monoclonal antibody which recognized STAT1 N-terminus and by the western inflorescence.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="352">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with a monoclonal antibody which recognizes STAT1 N-terminus, and by Western blotting</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="353">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with activating complex cAMP-CRP which recognized two sites in tsx-p2 and by the western inflorescence.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="354">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with activating complex cAMP-CRP which recognized two sites in tsx-p2, and by Western blotting</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="355">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with activating complex cAMP-CRP which recognizes two sites in tsx-p2, and by Western blotting</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="356">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with activating the cAMP-CRP complex which recognized two sites in tsx-p2 and by the western inflorescence.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="357">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with activating the cAMP-CRP complex which recognizes two sites in tsx-p2, and by Western blotting</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="358">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with activator complex cAMP-CRP which recognized two sites in tsx-p2 and by the western inflorescence.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="359">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with activator complex cAMP-CRP which recognized two sites in tsx-p2, and by Western blotting</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="360">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with activator complex cAMP-CRP which recognizes two sites in tsx-p2, and by Western blotting</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="361">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with anti-64kD antibodies of human autoantigen D1 which recognized a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle and by the western inflorescence.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="362">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with anti-64kD antibodies of human autoantigen D1 which recognized a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle, and by Western blotting</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="363">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with anti-64kD antibodies of human autoantigen D1 which recognized polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle and by the western inflorescence.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="364">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with anti-64kD antibodies of human autoantigen D1 which recognized polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle, and by Western blotting</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="365">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with anti-64kD antibodies of human autoantigen D1 which recognizes a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle, and by Western blotting</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="366">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit which recognized term C of CD40 at a dilution 1:500 and by the western inflorescence.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="367">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit which recognized term C of CD40 at a dilution 1:500, and by Western blotting</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="368">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit which recognizes term C of CD40 at a dilution 1:500, and by Western blotting</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="369">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with anti-LMP-1 anti-LMP-1 purified affinity which recognized epiptopes in the C-terminal of LMP-1 at a 1:200 dilution and by the western inflorescence.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="370">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with anti-LMP-1 anti-LMP-1 purified affinity which recognized epiptopes in the C-terminal of LMP-1 at a 1:200 dilution, and by Western blotting</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="371">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with anti-LMP-1 anti-LMP-1 purified affinity which recognized epitopes in the terminal C of LMP-1 at a 1:200 dilution and by the western inflorescence.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="372">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with anti-LMP-1 anti-LMP-1 purified affinity which recognized epitopes in the terminal C of LMP-1 at a 1:200 dilution, and by Western blotting</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="373">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with anti-LMP-1 anti-LMP-1 purified affinity which recognizes epiptopes in the C-terminal of LMP-1 at a 1:200 dilution, and by Western blotting</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="374">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with anti-LMP-1 antisembly purified which recognized epiptopes in the C-terminal of LMP-1 at a dilution 1:200 and by the western inflorescence.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="375">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with anti-LMP-1 antisembly purified which recognized epiptopes in the C-terminal of LMP-1 at a dilution 1:200, and by Western blotting</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="376">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with anti-LMP-1 antisembly purified which recognized epitoped in the C-terminal of LMP-1 in a 1:200 dilution and by the western inflorescence.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="377">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with anti-LMP-1 antisembly purified which recognized epitoped in the C-terminal of LMP-1 in a 1:200 dilution, and by Western blotting</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="378">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with anti-LMP-1 antisembly purified which recognizes epiptopes in the C-terminal of LMP-1 at a dilution 1:200, and by Western blotting</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="379">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with anti-LMP-1 antisembly purified which recognizes epitoped in the C-terminal of LMP-1 in a 1:200 dilution, and by Western blotting</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="380">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with anti-LMP-1 purified affinity antiserum which recognized epictopes in the C-terminal of LMP-1 at a dilution 1:200 and by the western inflorescence.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="381">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with anti-LMP-1 purified affinity antiserum which recognized epictopes in the C-terminal of LMP-1 at a dilution 1:200, and by Western blotting</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="382">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with anti-LMP-1 purified affinity antiserum which recognized epiptopes in the C-terminal of LMP-1 at a dilution 1:200 and by the western inflorescence.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="383">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with anti-LMP-1 purified affinity antiserum which recognized epiptopes in the C-terminal of LMP-1 at a dilution 1:200, and by Western blotting</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="384">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with anti-LMP-1 purified affinity antiserum which recognizes epictopes in the C-terminal of LMP-1 at a dilution 1:200, and by Western blotting</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="385">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with anti-LMP-1 purified affinity antiserum which recognizes epiptopes in the C-terminal of LMP-1 at a dilution 1:200, and by Western blotting</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="386">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with anti-Stat3 pAb which recognized the lowest form of Stat3, Stat3Beta, and by Western blotting</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="387">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with anti-Stat3 pAb which recognizes the lowest form of Stat3, Stat3Beta, and by Western blotting</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="388">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with monoclonal antibody which recognized N-terminus STAT1, and by Western blotting</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="389">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with monoclonal antibody which recognized STAT1 N-terminal, and by Western blotting</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="390">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with monoclonal antibody which recognized STAT1 N-terminus and by the western inflorescence.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="391">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with monoclonal antibody which recognized STAT1 N-terminus, and by Western blotting</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="392">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with monoclonal antibody which recognizes N-terminus STAT1, and by Western blotting</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="393">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with monoclonal antibody which recognizes STAT1 N-terminal, and by Western blotting</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="394">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with monoclonal antibody which recognizes STAT1 N-terminus, and by Western blotting</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="395">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with most of the regulators belonging to the AraC/XylS family which recognized multi-binding sites and by the western inflorescence.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="396">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with most of the regulators belonging to the AraC/XylS family which recognized multi-binding sites, and by Western blotting</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="397">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with most of the regulators belonging to the AraC/XylS family which recognized multiple connection site, and by Western blotting</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="398">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with most of the regulators belonging to the AraC/XylS family which recognized multiple linkage site and by the western inflorescence.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="399">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with most of the regulators belonging to the AraC/XylS family which recognized multiple linkage site, and by Western blotting</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="400">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with most of the regulators belonging to the AraC/XylS family which recognized multiple-link location and by the western inflorescence.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="401">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with most of the regulators belonging to the AraC/XylS family which recognized multiple-link location, and by Western blotting</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="402">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with most of the regulators belonging to the AraC/XylS family which recognizes multi-binding sites, and by Western blotting</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="403">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with most of the regulators belonging to the AraC/XylS family which recognizes multiple connection site, and by Western blotting</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="404">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with most of the regulators belonging to the AraC/XylS family which recognizes multiple-link location, and by Western blotting</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="405">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with most regulators belonging to the AraC/XylS family which recognized multiple binding sites and by the western inflorescence.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="406">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with most regulators belonging to the AraC/XylS family which recognized multiple binding sites, and by Western blotting</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="407">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with most regulators belonging to the AraC/XylS family which recognizes multiple binding sites, and by Western blotting</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="408">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with polyclonal anti-CD40 anti-rabbit antisound which recognized C-term of CD40 at a 1:500 dilution, and by Western blotting</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="409">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with polyclonal anti-CD40 anti-rabbit antisound which recognizes C-term of CD40 at a 1:500 dilution, and by Western blotting</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="410">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with polyclonal anti-LMP-1 affinity antisumption which recognized epitopes in the C muscle of LMP-1 at a dilution of 1:200 and by the western inflorescence.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="411">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with polyclonal anti-LMP-1 affinity antisumption which recognized epitopes in the C muscle of LMP-1 at a dilution of 1:200, and by Western blotting</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="412">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with polyclonal anti-LMP-1 affinity antisumption which recognizes epitopes in the C muscle of LMP-1 at a dilution of 1:200, and by Western blotting</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="413">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with proteins which recognized short motives within the protected region and by the western inflorescence.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="414">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with proteins which recognized short motives within the protected region, and by Western blotting</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="415">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with proteins which recognized short reasons within the protected region and by the western inflorescence.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="416">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with the NarL protein which recognized heptamers in other arrangements and by the western inflorescence.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="417">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with the NarL protein which recognized heptamers in other arrangements, and by Western blotting</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="418">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with the NarL protein which recognizes heptamers in other arrangements, and by Western blotting</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="419">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with the activator complex cAMP-CRP which recognized two sites in tsx-p2, and by Western blotting</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="420">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with the cAMP-CRP activator complex which recognized two sites in tsx-p2 and by the western inflorescence.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="421">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with the cAMP-CRP activator complex which recognized two sites in tsx-p2, and by Western blotting</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="422">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with the cAMP-CRP activator complex which recognizes two sites in tsx-p2, and by Western blotting</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="423">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with the eukaryotic binding factor upstream (UBF) which recognized the promoter of the RNA ribosomal gene and by the western inflorescence.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="424">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with the eukaryotic binding factor upstream (UBF) which recognized the promoter of the RNA ribosomal gene, and by Western blotting</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="425">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with the upstream eukaryotic binding factor (UBF) which recognized the RNA ribosomal gene promoter and by the western inflorescence.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="426">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with the upstream eukaryotic binding factor (UBF) which recognized the RNA ribosomal gene promoter, and by Western blotting</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="427">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with the upstream eukaryotic binding factor (UBF) which recognized the promoter of the RNA ribosomal gene and by the western inflorescence.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="428">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with the upstream eukaryotic binding factor (UBF) which recognized the promoter of the RNA ribosomal gene, and by Western blotting</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="429">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with the upstream eukaryotic binding factor (UBF) which recognizes the RNA ribosomal gene promoter, and by Western blotting</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="430">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where C-term of CD40 at a 1:500 dilution was recognized by polyclonal anti-CD40 anti-rabbit antisound.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="431">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where N-terminus STAT1 was recognized by monoclonal antibody.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="432">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where STAT1 N-terminus was recognized by A monoclonal antibody.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="433">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where STAT1 N-terminus was recognized by monoclonal antibody.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="434">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle was recognized by D1 antibody of anti-64kD human autoantigen.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="435">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle was recognized by anti-64kD antibodies of human autoantigen D1.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="436">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where epictopes in the C-terminal of LMP-1 at a dilution 1:200 was recognized by anti-LMP-1 purified affinity antiserum.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="437">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where epiptopes in the C-terminal of LMP-1 at a 1:200 dilution was recognized by anti-LMP-1 anti-LMP-1 purified affinity.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="438">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where epiptopes in the C-terminal of LMP-1 at a dilution 1:200 was recognized by anti-LMP-1 antisembly purified.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="439">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where epitoped in the C-terminal of LMP-1 in a 1:200 dilution was recognized by anti-LMP-1 antisembly purified.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="440">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where epitopes in the C muscle of LMP-1 at a dilution of 1:200 was recognized by polyclonal anti-LMP-1 affinity antisumption.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="441">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where epitopes in the terminal C of LMP-1 at a 1:200 dilution was recognized by anti-LMP-1 anti-LMP-1 purified affinity.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="442">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where heptameric in other arrangements was recognized by NarL protein.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="443">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where heptamers in other arrangements was recognized by the NarL protein.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="444">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where multi-binding sites was recognized by most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="445">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where multiple binding sites was recognized by most regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="446">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where multiple connection site was recognized by most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="447">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where multiple linkage site was recognized by most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="448">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where multiple-link location was recognized by most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="449">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle was recognized by D1 anti-64kD human autoantigen.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="450">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle was recognized by D1 antibody of human autoantigen anti-64kD.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="451">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where term C of CD40 at a dilution 1:500 was recognized by anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="452">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where the RNA ribosomal gene promoter was recognized by the upstream eukaryotic binding factor (UBF).</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="453">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where the STAT1 N-terminal was recognized by a monoclonal antibody.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="454">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where the lowest form of Stat3, Stat3Beta was recognized by anti-Stat3 pAb.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="455">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where two sites in tsx-p2 was recognized by activating complex cAMP-CRP.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="456">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where two sites in tsx-p2 was recognized by activating the cAMP-CRP complex.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="457">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where two sites in tsx-p2 was recognized by activator complex cAMP-CRP.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="458">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where two sites in tsx-p2 was recognized by the activator complex cAMP-CRP.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="459">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where two sites in tsx-p2 was recognized by the cAMP-CRP activator complex.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="460">
                    <text>It is shown that A monoclonal antibody has recognized STAT1 N-terminus that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="461">
                    <text>It is shown that D1 antibody of anti-64kD human autoantigen has recognized a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="462">
                    <text>It is shown that D1 antibody of human autoantigen anti-64kD has recognized polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="463">
                    <text>It is shown that a monoclonal antibody has recognized STAT1 N-terminus that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="464">
                    <text>It is shown that a monoclonal antibody has recognized the STAT1 N-terminal that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="465">
                    <text>It is shown that activating complex cAMP-CRP has recognized two sites in tsx-p2 that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="466">
                    <text>It is shown that activating the cAMP-CRP complex has recognized two sites in tsx-p2 that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="467">
                    <text>It is shown that activator complex cAMP-CRP has recognized two sites in tsx-p2 that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="468">
                    <text>It is shown that anti-64kD antibodies of human autoantigen D1 has recognized a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="469">
                    <text>It is shown that anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit has recognized term C of CD40 at a dilution 1:500 that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="470">
                    <text>It is shown that anti-LMP-1 anti-LMP-1 purified affinity has recognized epiptopes in the C-terminal of LMP-1 at a 1:200 dilution that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="471">
                    <text>It is shown that anti-LMP-1 anti-LMP-1 purified affinity has recognized epitopes in the terminal C of LMP-1 at a 1:200 dilution that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="472">
                    <text>It is shown that anti-LMP-1 antisembly purified has recognized epitoped in the C-terminal of LMP-1 in a 1:200 dilution that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="473">
                    <text>It is shown that anti-LMP-1 purified affinity antiserum has recognized epictopes in the C-terminal of LMP-1 at a dilution 1:200 that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="474">
                    <text>It is shown that anti-Stat3 pAb has recognized the lowest form of Stat3, Stat3Beta that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="475">
                    <text>It is shown that monoclonal antibody has recognized N-terminus STAT1 that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="476">
                    <text>It is shown that monoclonal antibody has recognized STAT1 N-terminal that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="477">
                    <text>It is shown that monoclonal antibody has recognized STAT1 N-terminus that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="478">
                    <text>It is shown that most of the regulators belonging to the AraC/XylS family has recognized multi-binding sites that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="479">
                    <text>It is shown that most of the regulators belonging to the AraC/XylS family has recognized multiple connection site that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="480">
                    <text>It is shown that most of the regulators belonging to the AraC/XylS family has recognized multiple linkage site that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="481">
                    <text>It is shown that most of the regulators belonging to the AraC/XylS family has recognized multiple-link location that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="482">
                    <text>It is shown that most regulators belonging to the AraC/XylS family has recognized multiple binding sites that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="483">
                    <text>It is shown that polyclonal anti-CD40 anti-rabbit antisound has recognized C-term of CD40 at a 1:500 dilution that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="484">
                    <text>It is shown that polyclonal anti-LMP-1 affinity antisumption has recognized epitopes in the C muscle of LMP-1 at a dilution of 1:200 that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="485">
                    <text>It is shown that proteins has recognized short motives within the protected region that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="486">
                    <text>It is shown that proteins has recognized short reasons within the protected region that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="487">
                    <text>It is shown that the NarL protein has recognized heptamers in other arrangements that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="488">
                    <text>It is shown that the cAMP-CRP activator complex has recognized two sites in tsx-p2 that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="489">
                    <text>It is shown that the eukaryotic binding factor upstream (UBF) has recognized the promoter of the RNA ribosomal gene that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="490">
                    <text>It is shown that the upstream eukaryotic binding factor (UBF) has recognized the RNA ribosomal gene promoter that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="491">
                    <text>It is shown that the upstream eukaryotic binding factor (UBF) has recognized the promoter of the RNA ribosomal gene that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="492">
                    <text>N-terminus STAT1 are recognized by monoclonal antibody with which the threads were probed.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="493">
                    <text>N-terminus STAT1 are recognized by monoclonal antibody with which the wires were probed.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="494">
                    <text>N-terminus STAT1 could be recognized in immunoprecipitatio with monoclonal antibody, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="495">
                    <text>N-terminus STAT1 has been recognized by monoclonal antibody.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="496">
                    <text>N-terminus STAT1 is recognized by monoclonal antibody by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="497">
                    <text>N-terminus STAT1 is recognized by monoclonal antibody that the litters were probed.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="498">
                    <text>N-terminus STAT1 was recognized by monoclonal antibody by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="499">
                    <text>N-terminus STAT1 were recognized by monoclonal antibody.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="500">
                    <text>N-terminus STAT1 will be recognized by monoclonal antibody.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="501">
                    <text>N-terminus STAT1 will be recognized by the monoclonal antibody.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="502">
                    <text>N-terminus STAT1 will be recognized in immunoprecipitatio with monoclonal antibody, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="503">
                    <text>N-terminus STAT1, cannot is recognized in the immunoprecipitaiton with monoclonal antibody as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="504">
                    <text>N-terminus STAT1, could be recognized in the immunoprecipitaiton with monoclonal antibody as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="505">
                    <text>N-terminus STAT1, was not recognized in the immunoprecipitaiton with monoclonal antibody as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="506">
                    <text>N-terminus STAT1, was unrecognized in immunoprecipitatio with monoclonal antibody, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="507">
                    <text>N-terminus STAT1, will be recognized in the immunoprecipitaiton with monoclonal antibody as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="508">
                    <text>NarL protein also binds to these 727 sites but, unlike NarP, also recognized heptamers in other arrangements.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="509">
                    <text>NarL protein also binds to these sites 7-2-7, but, unlike NarP, it also recognized heptameric in other arrangements .</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="510">
                    <text>NarL protein also binds to these sites 7-2-7, but, unlike NarP, it also recognized heptamers in other arrangements.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="511">
                    <text>NarL protein are able to recognize heptameric in other arrangements in regulated promoters.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="512">
                    <text>NarL protein are able to recognize heptamers in other arrangements in regulated promoters.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="513">
                    <text>NarL protein binds to these 727 sites but, unlike NarP, will also recognize heptamers in other arrangements.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="514">
                    <text>NarL protein binds to these sites 7-2-7, but, unlike NarP, it also recognizes heptameric in other arrangements .</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="515">
                    <text>NarL protein can recognize heptamers in other arrangements in regulated promoters.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="516">
                    <text>NarL protein has also joined these 727 sites but, unlike NarP, has also recognized heptameric in other arrangements.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="517">
                    <text>NarL protein has also joined these 727 sites but, unlike NarP, has also recognized heptamers in other arrangements.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="518">
                    <text>NarL protein is able to recognize heptamers in other arrangements in regulated promoters.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="519">
                    <text>NarL protein recognized heptamers in other arrangements in regulated promoters.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="520">
                    <text>NarL protein recognized heptamers in other arrangements in the regulated promoters.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="521">
                    <text>NarL protein recognized heptamers in other arrangements.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="522">
                    <text>NarL protein recognizes heptameric in other arrangements.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="523">
                    <text>NarL protein recognizes heptamers in other arrangements.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="524">
                    <text>NarL protein specifically recognized heptameric in other arrangements.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="525">
                    <text>NarL protein specifically recognized heptamers in other arrangements.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="526">
                    <text>NarL protein that has recognized heptameric in other arrangements was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="527">
                    <text>NarL protein that has recognized heptamers in other arrangements was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="528">
                    <text>NarL protein that recognized heptamers in other arrangements was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="529">
                    <text>NarL protein that recognizes heptameric in other arrangements is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="530">
                    <text>NarL protein that recognizes heptameric in other arrangements is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="531">
                    <text>NarL protein that recognizes heptamers in other arrangements is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="532">
                    <text>NarL protein that recognizes heptamers in other arrangements is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="533">
                    <text>NarL protein will recognize heptameric in other arrangements in regulated promoters.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="534">
                    <text>NarL protein will recognize heptamers in other arrangements in regulated promoters.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="535">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that A monoclonal antibody are able to recognize STAT1 N-terminus.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="536">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that A monoclonal antibody can recognize STAT1 N-terminus.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="537">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that A monoclonal antibody has recognized STAT1 N-terminus.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="538">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that D1 anti-64kD human autoantigen are able to recognize polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="539">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that D1 anti-64kD human autoantigen can recognize polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="540">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that D1 anti-64kD human autoantigen has recognized polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="541">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that D1 anti-64kD human autoantigen recognized polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="542">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that D1 antibody of anti-64kD human autoantigen has recognized a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="543">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that D1 antibody of anti-64kD human autoantigen recognized a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="544">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that D1 antibody of human autoantigen anti-64kD are able to recognize polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="545">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that D1 antibody of human autoantigen anti-64kD can recognize polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="546">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that D1 antibody of human autoantigen anti-64kD has recognized polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="547">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that D1 antibody of human autoantigen anti-64kD recognized polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="548">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that NarL protein are able to recognize heptamers in other arrangements.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="549">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that NarL protein can recognize heptamers in other arrangements.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="550">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that NarL protein has recognized heptamers in other arrangements.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="551">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that NarL protein recognized heptameric in other arrangements.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="552">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that NarL protein recognized heptamers in other arrangements.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="553">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that a monoclonal antibody are able to recognize STAT1 N-terminus.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="554">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that a monoclonal antibody are able to recognize the STAT1 N-terminal.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="555">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that a monoclonal antibody can recognize STAT1 N-terminus.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="556">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that a monoclonal antibody has recognized the STAT1 N-terminal.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="557">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that a monoclonal antibody recognized STAT1 N-terminus.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="558">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that activating complex cAMP-CRP can recognize two sites in tsx-p2.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="559">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that activating complex cAMP-CRP recognized two sites in tsx-p2.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="560">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that activating the cAMP-CRP complex can recognize two sites in tsx-p2.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="561">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that activating the cAMP-CRP complex has recognized two sites in tsx-p2.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="562">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that activating the cAMP-CRP complex recognized two sites in tsx-p2.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="563">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that activator complex cAMP-CRP are able to recognize two sites in tsx-p2.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="564">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that activator complex cAMP-CRP can recognize two sites in tsx-p2.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="565">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that activator complex cAMP-CRP has recognized two sites in tsx-p2.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="566">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that activator complex cAMP-CRP recognized two sites in tsx-p2.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="567">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that anti-64kD antibodies of human autoantigen D1 are able to recognize a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="568">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that anti-64kD antibodies of human autoantigen D1 are able to recognize polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="569">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that anti-64kD antibodies of human autoantigen D1 can recognize a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="570">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that anti-64kD antibodies of human autoantigen D1 has recognized a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="571">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit are able to recognize term C of CD40 at a dilution 1:500.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="572">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit can recognize term C of CD40 at a dilution 1:500.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="573">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit has recognized term C of CD40 at a dilution 1:500.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="574">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit recognized term C of CD40 at a dilution 1:500.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="575">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that anti-LMP-1 anti-LMP-1 purified affinity are able to recognize epitopes in the terminal C of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="576">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that anti-LMP-1 anti-LMP-1 purified affinity can recognize epiptopes in the C-terminal of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="577">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that anti-LMP-1 anti-LMP-1 purified affinity can recognize epitopes in the terminal C of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="578">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that anti-LMP-1 anti-LMP-1 purified affinity has recognized epitopes in the terminal C of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="579">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that anti-LMP-1 anti-LMP-1 purified affinity recognized epiptopes in the C-terminal of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="580">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that anti-LMP-1 anti-LMP-1 purified affinity recognized epitopes in the terminal C of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="581">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that anti-LMP-1 antisembly purified are able to recognize epiptopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="582">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that anti-LMP-1 antisembly purified are able to recognize epitoped in the C-terminal of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="583">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that anti-LMP-1 antisembly purified can recognize epiptopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="584">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that anti-LMP-1 antisembly purified can recognize epitoped in the C-terminal of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="585">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that anti-LMP-1 antisembly purified has recognized epiptopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="586">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that anti-LMP-1 antisembly purified has recognized epitoped in the C-terminal of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="587">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that anti-LMP-1 antisembly purified recognized epiptopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="588">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that anti-LMP-1 antisembly purified recognized epitoped in the C-terminal of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="589">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that anti-LMP-1 purified affinity antiserum are able to recognize epictopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="590">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that anti-LMP-1 purified affinity antiserum are able to recognize epiptopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="591">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that anti-LMP-1 purified affinity antiserum can recognize epictopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="592">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that anti-LMP-1 purified affinity antiserum can recognize epiptopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="593">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that anti-LMP-1 purified affinity antiserum has recognized epictopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="594">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that anti-LMP-1 purified affinity antiserum has recognized epiptopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="595">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that anti-LMP-1 purified affinity antiserum recognized epictopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="596">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that anti-LMP-1 purified affinity antiserum recognized epiptopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="597">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that anti-Stat3 pAb are able to recognize the lowest form of Stat3, Stat3Beta.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="598">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that anti-Stat3 pAb can recognize the lowest form of Stat3, Stat3Beta.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="599">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that anti-Stat3 pAb has recognized the lowest form of Stat3, Stat3Beta.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="600">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that anti-Stat3 pAb recognized the lowest form of Stat3, Stat3Beta.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="601">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that monoclonal antibody are able to recognize STAT1 N-terminal.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="602">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that monoclonal antibody are able to recognize STAT1 N-terminus.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="603">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that monoclonal antibody can recognize N-terminus STAT1.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="604">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that monoclonal antibody can recognize STAT1 N-terminus.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="605">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that monoclonal antibody has recognized STAT1 N-terminal.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="606">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that monoclonal antibody has recognized STAT1 N-terminus.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="607">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that monoclonal antibody recognized N-terminus STAT1.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="608">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that monoclonal antibody recognized STAT1 N-terminus.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="609">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that most of the regulators belonging to the AraC/XylS family are able to recognize multi-binding sites.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="610">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that most of the regulators belonging to the AraC/XylS family are able to recognize multiple connection site.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="611">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that most of the regulators belonging to the AraC/XylS family are able to recognize multiple linkage site.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="612">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that most of the regulators belonging to the AraC/XylS family can recognize multi-binding sites.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="613">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that most of the regulators belonging to the AraC/XylS family has recognized multi-binding sites.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="614">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that most of the regulators belonging to the AraC/XylS family has recognized multiple connection site.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="615">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that most of the regulators belonging to the AraC/XylS family has recognized multiple linkage site.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="616">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that most of the regulators belonging to the AraC/XylS family has recognized multiple-link location.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="617">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that most of the regulators belonging to the AraC/XylS family recognized multi-binding sites.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="618">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that most of the regulators belonging to the AraC/XylS family recognized multiple connection site.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="619">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that most of the regulators belonging to the AraC/XylS family recognized multiple linkage site.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="620">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that most of the regulators belonging to the AraC/XylS family recognized multiple-link location.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="621">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that most regulators belonging to the AraC/XylS family are able to recognize multiple binding sites.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="622">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that most regulators belonging to the AraC/XylS family can recognize multiple binding sites.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="623">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that most regulators belonging to the AraC/XylS family has recognized multiple binding sites.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="624">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that most regulators belonging to the AraC/XylS family recognized multiple binding sites.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="625">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that polyclonal anti-CD40 anti-rabbit antisound are able to recognize C-term of CD40 at a 1:500 dilution.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="626">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that polyclonal anti-CD40 anti-rabbit antisound can recognize C-term of CD40 at a 1:500 dilution.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="627">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that polyclonal anti-CD40 anti-rabbit antisound has recognized C-term of CD40 at a 1:500 dilution.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="628">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that polyclonal anti-CD40 anti-rabbit antisound recognized C-term of CD40 at a 1:500 dilution.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="629">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that polyclonal anti-LMP-1 affinity antisumption are able to recognize epitopes in the C muscle of LMP-1 at a dilution of 1:200.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="630">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that polyclonal anti-LMP-1 affinity antisumption can recognize epitopes in the C muscle of LMP-1 at a dilution of 1:200.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="631">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that polyclonal anti-LMP-1 affinity antisumption has recognized epitopes in the C muscle of LMP-1 at a dilution of 1:200.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="632">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that polyclonal anti-LMP-1 affinity antisumption recognized epitopes in the C muscle of LMP-1 at a dilution of 1:200.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="633">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that proteins are able to recognize short motives within the protected region.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="634">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that proteins can recognize short motives within the protected region.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="635">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that proteins has recognized short motives within the protected region.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="636">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that proteins recognized short motives within the protected region.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="637">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that the NarL protein are able to recognize heptamers in other arrangements.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="638">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that the NarL protein can recognize heptamers in other arrangements.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="639">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that the NarL protein recognized heptamers in other arrangements.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="640">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that the activator complex cAMP-CRP are able to recognize two sites in tsx-p2.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="641">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that the activator complex cAMP-CRP can recognize two sites in tsx-p2.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="642">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that the activator complex cAMP-CRP has recognized two sites in tsx-p2.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="643">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that the activator complex cAMP-CRP recognized two sites in tsx-p2.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="644">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that the cAMP-CRP activator complex has recognized two sites in tsx-p2.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="645">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that the cAMP-CRP activator complex recognized two sites in tsx-p2.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="646">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that the eukaryotic binding factor upstream (UBF) are able to recognize the promoter of the RNA ribosomal gene.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="647">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that the eukaryotic binding factor upstream (UBF) can recognize the promoter of the RNA ribosomal gene.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="648">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that the eukaryotic binding factor upstream (UBF) has recognized the promoter of the RNA ribosomal gene.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="649">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that the eukaryotic binding factor upstream (UBF) recognized the promoter of the RNA ribosomal gene.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="650">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that the upstream eukaryotic binding factor (UBF) are able to recognize the RNA ribosomal gene promoter.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="651">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that the upstream eukaryotic binding factor (UBF) are able to recognize the promoter of the RNA ribosomal gene.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="652">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that the upstream eukaryotic binding factor (UBF) can recognize the RNA ribosomal gene promoter.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="653">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that the upstream eukaryotic binding factor (UBF) can recognize the promoter of the RNA ribosomal gene.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="654">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that the upstream eukaryotic binding factor (UBF) has recognized the RNA ribosomal gene promoter.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="655">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that the upstream eukaryotic binding factor (UBF) has recognized the promoter of the RNA ribosomal gene.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="656">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that the upstream eukaryotic binding factor (UBF) recognized the RNA ribosomal gene promoter.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="657">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that the upstream eukaryotic binding factor (UBF) recognized the promoter of the RNA ribosomal gene.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="658">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that A monoclonal antibody are able to recognize STAT1 N-terminus.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="659">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that D1 anti-64kD human autoantigen are able to recognize polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="660">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that D1 antibody of anti-64kD human autoantigen are able to recognize a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="661">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that D1 antibody of human autoantigen anti-64kD are able to recognize polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="662">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that NarL protein are able to recognize heptameric in other arrangements.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="663">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that NarL protein are able to recognize heptamers in other arrangements.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="664">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that a monoclonal antibody are able to recognize STAT1 N-terminus.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="665">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that a monoclonal antibody are able to recognize the STAT1 N-terminal.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="666">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that activating complex cAMP-CRP are able to recognize two sites in tsx-p2.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="667">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that activating the cAMP-CRP complex are able to recognize two sites in tsx-p2.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="668">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that activator complex cAMP-CRP are able to recognize two sites in tsx-p2.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="669">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit are able to recognize term C of CD40 at a dilution 1:500.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="670">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that anti-LMP-1 anti-LMP-1 purified affinity are able to recognize epiptopes in the C-terminal of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="671">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that anti-LMP-1 anti-LMP-1 purified affinity are able to recognize epitopes in the terminal C of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="672">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that anti-LMP-1 antisembly purified are able to recognize epiptopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="673">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that anti-Stat3 pAb are able to recognize the lowest form of Stat3, Stat3Beta.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="674">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that monoclonal antibody are able to recognize N-terminus STAT1.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="675">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that monoclonal antibody are able to recognize STAT1 N-terminal.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="676">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that monoclonal antibody are able to recognize STAT1 N-terminus.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="677">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that most of the regulators belonging to the AraC/XylS family are able to recognize multi-binding sites.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="678">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that most of the regulators belonging to the AraC/XylS family are able to recognize multiple connection site.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="679">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that most of the regulators belonging to the AraC/XylS family are able to recognize multiple linkage site.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="680">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that most of the regulators belonging to the AraC/XylS family are able to recognize multiple-link location.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="681">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that most regulators belonging to the AraC/XylS family are able to recognize multiple binding sites.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="682">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that polyclonal anti-CD40 anti-rabbit antisound are able to recognize C-term of CD40 at a 1:500 dilution.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="683">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that proteins are able to recognize short motives within the protected region.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="684">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that the NarL protein are able to recognize heptamers in other arrangements.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="685">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that the activator complex cAMP-CRP are able to recognize two sites in tsx-p2.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="686">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that the cAMP-CRP activator complex are able to recognize two sites in tsx-p2.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="687">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that the eukaryotic binding factor upstream (UBF) are able to recognize the promoter of the RNA ribosomal gene.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="688">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that the upstream eukaryotic binding factor (UBF) are able to recognize the RNA ribosomal gene promoter.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="689">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that the upstream eukaryotic binding factor (UBF) are able to recognize the promoter of the RNA ribosomal gene.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="690">
                    <text>STAT1 N-terminal are recognized by monoclonal antibody with which the threads were probed.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="691">
                    <text>STAT1 N-terminal are recognized by monoclonal antibody.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="692">
                    <text>STAT1 N-terminal could be recognized in immunoprecipitatio with monoclonal antibody, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="693">
                    <text>STAT1 N-terminal has been recognized by monoclonal antibody.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="694">
                    <text>STAT1 N-terminal is recognized by monoclonal antibody by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="695">
                    <text>STAT1 N-terminal is recognized by monoclonal antibody by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="696">
                    <text>STAT1 N-terminal is recognized by monoclonal antibody that the litters were probed.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="697">
                    <text>STAT1 N-terminal is recognized by monoclonal antibody.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="698">
                    <text>STAT1 N-terminal was recognized by monoclonal antibody by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="699">
                    <text>STAT1 N-terminal was recognized by monoclonal antibody.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="700">
                    <text>STAT1 N-terminal was recognized in the immunoprecipitatome with monoclonal antibody, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="701">
                    <text>STAT1 N-terminal will be recognized by monoclonal antibody.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="702">
                    <text>STAT1 N-terminal will be recognized by the monoclonal antibody.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="703">
                    <text>STAT1 N-terminal, cannot is recognized in the immunoprecipitaiton with monoclonal antibody as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="704">
                    <text>STAT1 N-terminal, could be recognized in the immunoprecipitaiton with monoclonal antibody as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="705">
                    <text>STAT1 N-terminal, has been recognized in the immunoprecipitaiton with monoclonal antibody as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="706">
                    <text>STAT1 N-terminal, was not recognized in the immunoprecipitaiton with monoclonal antibody as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="707">
                    <text>STAT1 N-terminal, was unrecognized in immunoprecipitatio with monoclonal antibody, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="708">
                    <text>STAT1 N-terminal, will be recognized in the immunoprecipitaiton with monoclonal antibody as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="709">
                    <text>STAT1 N-terminus are recognized by A monoclonal antibody with which the threads were probed.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="710">
                    <text>STAT1 N-terminus are recognized by A monoclonal antibody with which the wires were probed.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="711">
                    <text>STAT1 N-terminus are recognized by A monoclonal antibody.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="712">
                    <text>STAT1 N-terminus are recognized by a monoclonal antibody.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="713">
                    <text>STAT1 N-terminus are recognized by monoclonal antibody with which the wires were probed.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="714">
                    <text>STAT1 N-terminus are recognized by monoclonal antibody.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="715">
                    <text>STAT1 N-terminus could be recognized in immunoprecipitatio with A monoclonal antibody, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="716">
                    <text>STAT1 N-terminus could be recognized in immunoprecipitatio with a monoclonal antibody, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="717">
                    <text>STAT1 N-terminus could be recognized in immunoprecipitatio with monoclonal antibody, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="718">
                    <text>STAT1 N-terminus has been recognized by A monoclonal antibody.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="719">
                    <text>STAT1 N-terminus has been recognized by a monoclonal antibody.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="720">
                    <text>STAT1 N-terminus has been recognized by monoclonal antibody.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="721">
                    <text>STAT1 N-terminus is recognized by A monoclonal antibody by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="722">
                    <text>STAT1 N-terminus is recognized by A monoclonal antibody that the litters were probed.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="723">
                    <text>STAT1 N-terminus is recognized by A monoclonal antibody.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="724">
                    <text>STAT1 N-terminus is recognized by a monoclonal antibody by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="725">
                    <text>STAT1 N-terminus is recognized by a monoclonal antibody.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="726">
                    <text>STAT1 N-terminus is recognized by monoclonal antibody by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="727">
                    <text>STAT1 N-terminus is recognized by monoclonal antibody.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="728">
                    <text>STAT1 N-terminus was recognized by a monoclonal antibody by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="729">
                    <text>STAT1 N-terminus was recognized by a monoclonal antibody.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="730">
                    <text>STAT1 N-terminus was recognized by monoclonal antibody by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="731">
                    <text>STAT1 N-terminus was recognized in the immunoprecipitatome with A monoclonal antibody, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="732">
                    <text>STAT1 N-terminus were recognized by A monoclonal antibody.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="733">
                    <text>STAT1 N-terminus were recognized by a monoclonal antibody.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="734">
                    <text>STAT1 N-terminus will be recognized by a monoclonal antibody.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="735">
                    <text>STAT1 N-terminus will be recognized by the a monoclonal antibody.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="736">
                    <text>STAT1 N-terminus will be recognized by the monoclonal antibody.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="737">
                    <text>STAT1 N-terminus will be recognized in immunoprecipitatio with A monoclonal antibody, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="738">
                    <text>STAT1 N-terminus will be recognized in immunoprecipitatio with a monoclonal antibody, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="739">
                    <text>STAT1 N-terminus, cannot is recognized in immunoprecipitatio with A monoclonal antibody, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="740">
                    <text>STAT1 N-terminus, cannot is recognized in immunoprecipitatio with a monoclonal antibody, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="741">
                    <text>STAT1 N-terminus, cannot is recognized in immunoprecipitatio with monoclonal antibody, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="742">
                    <text>STAT1 N-terminus, cannot is recognized in the immunoprecipitaiton with a monoclonal antibody as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="743">
                    <text>STAT1 N-terminus, cannot is recognized in the immunoprecipitaiton with monoclonal antibody as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="744">
                    <text>STAT1 N-terminus, could be recognized in the immunoprecipitaiton with A monoclonal antibody as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="745">
                    <text>STAT1 N-terminus, could be recognized in the immunoprecipitaiton with a monoclonal antibody as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="746">
                    <text>STAT1 N-terminus, has been recognized in the immunoprecipitaiton with A monoclonal antibody as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="747">
                    <text>STAT1 N-terminus, has been recognized in the immunoprecipitaiton with monoclonal antibody as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="748">
                    <text>STAT1 N-terminus, was not recognized in the immunoprecipitaiton with A monoclonal antibody as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="749">
                    <text>STAT1 N-terminus, was not recognized in the immunoprecipitaiton with a monoclonal antibody as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="750">
                    <text>STAT1 N-terminus, was not recognized in the immunoprecipitaiton with monoclonal antibody as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="751">
                    <text>STAT1 N-terminus, was unrecognized in immunoprecipitatio with A monoclonal antibody, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="752">
                    <text>STAT1 N-terminus, was unrecognized in immunoprecipitatio with a monoclonal antibody, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="753">
                    <text>STAT1 N-terminus, was unrecognized in immunoprecipitatio with monoclonal antibody, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="754">
                    <text>STAT1 N-terminus, will be recognized in the immunoprecipitaiton with A monoclonal antibody as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="755">
                    <text>STAT1 N-terminus, will be recognized in the immunoprecipitaiton with a monoclonal antibody as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="756">
                    <text>STAT1 N-terminus, will be recognized in the immunoprecipitaiton with monoclonal antibody as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="757">
                    <text>The C-term of CD40 at a 1:500 dilution is recognized by the polyclonal anti-CD40 anti-rabbit antisound that the garbage was surveyed.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="758">
                    <text>The C-term of CD40 at a 1:500 dilution was recognized by the polyclonal anti-CD40 anti-rabbit antisound acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="759">
                    <text>The C-term of CD40 at a 1:500 dilution was recognized by the polyclonal anti-CD40 anti-rabbit antisound.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="760">
                    <text>The N-terminus STAT1 is recognized by the monoclonal antibody that the garbage was surveyed.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="761">
                    <text>The N-terminus STAT1 was recognized by the monoclonal antibody acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="762">
                    <text>The N-terminus STAT1 was recognized by the monoclonal antibody.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="763">
                    <text>The STAT1 N-terminal is recognized by the monoclonal antibody that the garbage was surveyed.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="764">
                    <text>The STAT1 N-terminal was recognized by the monoclonal antibody.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="765">
                    <text>The STAT1 N-terminus is recognized by the A monoclonal antibody that the garbage was surveyed.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="766">
                    <text>The STAT1 N-terminus is recognized by the a monoclonal antibody that the garbage was surveyed.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="767">
                    <text>The STAT1 N-terminus is recognized by the monoclonal antibody that the garbage was surveyed.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="768">
                    <text>The STAT1 N-terminus was recognized by the A monoclonal antibody acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="769">
                    <text>The STAT1 N-terminus was recognized by the A monoclonal antibody.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="770">
                    <text>The STAT1 N-terminus was recognized by the a monoclonal antibody acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="771">
                    <text>The STAT1 N-terminus was recognized by the a monoclonal antibody.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="772">
                    <text>The STAT1 N-terminus was recognized by the monoclonal antibody.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="773">
                    <text>The a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle is recognized by the D1 antibody of anti-64kD human autoantigen that the garbage was surveyed.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="774">
                    <text>The a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle was recognized by the D1 antibody of anti-64kD human autoantigen acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="775">
                    <text>The a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle is recognized by the anti-64kD antibodies of human autoantigen D1 that the garbage was surveyed.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="776">
                    <text>The a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle was recognized by the anti-64kD antibodies of human autoantigen D1 acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="777">
                    <text>The a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle was recognized by the anti-64kD antibodies of human autoantigen D1.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="778">
                    <text>The blots were investigated with A monoclonal antibody that recognized STAT1 N-terminus.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="779">
                    <text>The blots were investigated with D1 anti-64kD human autoantigen that recognized polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="780">
                    <text>The blots were investigated with D1 antibody of anti-64kD human autoantigen that recognized a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="781">
                    <text>The blots were investigated with D1 antibody of human autoantigen anti-64kD that recognized polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="782">
                    <text>The blots were investigated with NarL protein that recognized heptameric in other arrangements.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="783">
                    <text>The blots were investigated with NarL protein that recognized heptamers in other arrangements.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="784">
                    <text>The blots were investigated with a monoclonal antibody that recognized STAT1 N-terminus.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="785">
                    <text>The blots were investigated with a monoclonal antibody that recognized the STAT1 N-terminal.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="786">
                    <text>The blots were investigated with activating complex cAMP-CRP that recognized two sites in tsx-p2.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="787">
                    <text>The blots were investigated with activating the cAMP-CRP complex that recognized two sites in tsx-p2.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="788">
                    <text>The blots were investigated with activator complex cAMP-CRP that recognized two sites in tsx-p2.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="789">
                    <text>The blots were investigated with anti-64kD antibodies of human autoantigen D1 that recognized a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="790">
                    <text>The blots were investigated with anti-64kD antibodies of human autoantigen D1 that recognized polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="791">
                    <text>The blots were investigated with anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit that recognized term C of CD40 at a dilution 1:500.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="792">
                    <text>The blots were investigated with anti-LMP-1 anti-LMP-1 purified affinity that recognized epitopes in the terminal C of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="793">
                    <text>The blots were investigated with anti-LMP-1 antisembly purified that recognized epiptopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="794">
                    <text>The blots were investigated with anti-LMP-1 antisembly purified that recognized epitoped in the C-terminal of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="795">
                    <text>The blots were investigated with anti-LMP-1 purified affinity antiserum that recognized epictopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="796">
                    <text>The blots were investigated with anti-LMP-1 purified affinity antiserum that recognized epiptopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="797">
                    <text>The blots were investigated with anti-Stat3 pAb that recognized the lowest form of Stat3, Stat3Beta.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="798">
                    <text>The blots were investigated with monoclonal antibody that recognized N-terminus STAT1.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="799">
                    <text>The blots were investigated with monoclonal antibody that recognized STAT1 N-terminal.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="800">
                    <text>The blots were investigated with most of the regulators belonging to the AraC/XylS family that recognized multi-binding sites.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="801">
                    <text>The blots were investigated with most of the regulators belonging to the AraC/XylS family that recognized multiple connection site.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="802">
                    <text>The blots were investigated with most of the regulators belonging to the AraC/XylS family that recognized multiple linkage site.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="803">
                    <text>The blots were investigated with most of the regulators belonging to the AraC/XylS family that recognized multiple-link location.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="804">
                    <text>The blots were investigated with most regulators belonging to the AraC/XylS family that recognized multiple binding sites.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="805">
                    <text>The blots were investigated with polyclonal anti-CD40 anti-rabbit antisound that recognized C-term of CD40 at a 1:500 dilution.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="806">
                    <text>The blots were investigated with polyclonal anti-LMP-1 affinity antisumption that recognized epitopes in the C muscle of LMP-1 at a dilution of 1:200.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="807">
                    <text>The blots were investigated with proteins that recognized short motives within the protected region.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="808">
                    <text>The blots were investigated with proteins that recognized short reasons within the protected region.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="809">
                    <text>The blots were investigated with the activator complex cAMP-CRP that recognized two sites in tsx-p2.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="810">
                    <text>The blots were investigated with the eukaryotic binding factor upstream (UBF) that recognized the promoter of the RNA ribosomal gene.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="811">
                    <text>The blots were investigated with the upstream eukaryotic binding factor (UBF) that recognized the promoter of the RNA ribosomal gene.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="812">
                    <text>The blots were probed with A monoclonal antibody that can recognize STAT1 N-terminus.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="813">
                    <text>The blots were probed with D1 anti-64kD human autoantigen that can recognize polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="814">
                    <text>The blots were probed with D1 antibody of anti-64kD human autoantigen that can recognize a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="815">
                    <text>The blots were probed with NarL protein that can recognize heptameric in other arrangements.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="816">
                    <text>The blots were probed with NarL protein that can recognize heptamers in other arrangements.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="817">
                    <text>The blots were probed with a monoclonal antibody that can recognize STAT1 N-terminus.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="818">
                    <text>The blots were probed with a monoclonal antibody that can recognize the STAT1 N-terminal.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="819">
                    <text>The blots were probed with activating complex cAMP-CRP that can recognize two sites in tsx-p2.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="820">
                    <text>The blots were probed with activator complex cAMP-CRP that can recognize two sites in tsx-p2.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="821">
                    <text>The blots were probed with anti-64kD antibodies of human autoantigen D1 that can recognize a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="822">
                    <text>The blots were probed with anti-64kD antibodies of human autoantigen D1 that can recognize polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="823">
                    <text>The blots were probed with anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit that can recognize term C of CD40 at a dilution 1:500.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="824">
                    <text>The blots were probed with anti-LMP-1 anti-LMP-1 purified affinity that can recognize epiptopes in the C-terminal of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="825">
                    <text>The blots were probed with anti-LMP-1 antisembly purified that can recognize epiptopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="826">
                    <text>The blots were probed with anti-LMP-1 antisembly purified that can recognize epitoped in the C-terminal of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="827">
                    <text>The blots were probed with anti-LMP-1 antisumption of affinity recognizing A1 (epitopes in the C muscle of LMP-1 in 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 antisumption of affinity</arg>
                </example>
                <example src="PERMUTATE" no="828">
                    <text>The blots were probed with anti-LMP-1 antisumption of affinity that can recognize A1 (epitopes in the C muscle of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 antisumption of affinity</arg>
                </example>
                <example src="PERMUTATE" no="829">
                    <text>The blots were probed with anti-LMP-1 antisumption of affinity that recognized A1 (epitopes in the C muscle of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 antisumption of affinity</arg>
                </example>
                <example src="PERMUTATE" no="830">
                    <text>The blots were probed with anti-LMP-1 purified affinity antiserum that can recognize epictopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="831">
                    <text>The blots were probed with anti-LMP-1 purified affinity antiserum that can recognize epiptopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="832">
                    <text>The blots were probed with anti-Stat3 pAb that can recognize the lowest form of Stat3, Stat3Beta.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="833">
                    <text>The blots were probed with four different specific antibodies that can recognize A1 (epitopes in the C muscle of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">four different specific antibodies</arg>
                </example>
                <example src="PERMUTATE" no="834">
                    <text>The blots were probed with monoclonal antibody that can recognize N-terminus STAT1.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="835">
                    <text>The blots were probed with monoclonal antibody that can recognize STAT1 N-terminal.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="836">
                    <text>The blots were probed with monoclonal antibody that can recognize STAT1 N-terminus.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="837">
                    <text>The blots were probed with most of the regulators belonging to the AraC/XylS family that can recognize multi-binding sites.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="838">
                    <text>The blots were probed with most of the regulators belonging to the AraC/XylS family that can recognize multiple connection site.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="839">
                    <text>The blots were probed with most of the regulators belonging to the AraC/XylS family that can recognize multiple linkage site.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="840">
                    <text>The blots were probed with most regulators belonging to the AraC/XylS family that can recognize multiple binding sites.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="841">
                    <text>The blots were probed with polyclonal anti-CD40 anti-rabbit antisound that can recognize C-term of CD40 at a 1:500 dilution.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="842">
                    <text>The blots were probed with polyclonal anti-LMP-1 affinity antiserum that can recognize A1 (epitopes in the C muscle of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antiserum</arg>
                </example>
                <example src="PERMUTATE" no="843">
                    <text>The blots were probed with polyclonal anti-LMP-1 affinity antiserum that recognized A1 (epitopes in the C muscle of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antiserum</arg>
                </example>
                <example src="PERMUTATE" no="844">
                    <text>The blots were probed with polyclonal anti-LMP-1 affinity antisumption that can recognize epitopes in the C muscle of LMP-1 at a dilution of 1:200.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="845">
                    <text>The blots were probed with polyclonal anti-LMP-1 purified affinity antiserum recognizing A1 (epitopes in the C muscle of LMP-1 in 1:200 dilution.</text>
                    <arg n="0">polyclonal anti-LMP-1 purified affinity antiserum</arg>
                </example>
                <example src="PERMUTATE" no="846">
                    <text>The blots were probed with proteins that can recognize short motives within the protected region.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="847">
                    <text>The blots were probed with proteins that can recognize short reasons within the protected region.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="848">
                    <text>The blots were probed with the NarL protein that can recognize heptamers in other arrangements.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="849">
                    <text>The blots were probed with the activator complex cAMP-CRP that can recognize two sites in tsx-p2.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="850">
                    <text>The blots were probed with the cAMP-CRP activator complex that can recognize two sites in tsx-p2.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="851">
                    <text>The blots were probed with the upstream eukaryotic binding factor (UBF) that can recognize the RNA ribosomal gene promoter.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="852">
                    <text>The blots were probed with this antibody in PKR+/+MEFs recognizing A1 (epitopes in the C muscle of LMP-1 in 1:200 dilution.</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                </example>
                <example src="PERMUTATE" no="853">
                    <text>The blots were probed with this antibody in PKR+/+MEFs that can recognize A1 (epitopes in the C muscle of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                </example>
                <example src="PERMUTATE" no="854">
                    <text>The epictopes in the C-terminal of LMP-1 at a dilution 1:200 was recognized by the anti-LMP-1 purified affinity antiserum acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="855">
                    <text>The epictopes in the C-terminal of LMP-1 at a dilution 1:200 was recognized by the anti-LMP-1 purified affinity antiserum.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="856">
                    <text>The epiptopes in the C-terminal of LMP-1 at a 1:200 dilution was recognized by the anti-LMP-1 anti-LMP-1 purified affinity acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="857">
                    <text>The epiptopes in the C-terminal of LMP-1 at a 1:200 dilution was recognized by the anti-LMP-1 anti-LMP-1 purified affinity.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="858">
                    <text>The epiptopes in the C-terminal of LMP-1 at a dilution 1:200 is recognized by the anti-LMP-1 antisembly purified that the garbage was surveyed.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="859">
                    <text>The epiptopes in the C-terminal of LMP-1 at a dilution 1:200 is recognized by the anti-LMP-1 purified affinity antiserum that the garbage was surveyed.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="860">
                    <text>The epiptopes in the C-terminal of LMP-1 at a dilution 1:200 was recognized by the anti-LMP-1 antisembly purified.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="861">
                    <text>The epiptopes in the C-terminal of LMP-1 at a dilution 1:200 was recognized by the anti-LMP-1 purified affinity antiserum acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="862">
                    <text>The epiptopes in the C-terminal of LMP-1 at a dilution 1:200 was recognized by the anti-LMP-1 purified affinity antiserum.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="863">
                    <text>The epitoped in the C-terminal of LMP-1 in a 1:200 dilution is recognized by the anti-LMP-1 antisembly purified that the garbage was surveyed.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="864">
                    <text>The epitoped in the C-terminal of LMP-1 in a 1:200 dilution was recognized by the anti-LMP-1 antisembly purified acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="865">
                    <text>The epitoped in the C-terminal of LMP-1 in a 1:200 dilution was recognized by the anti-LMP-1 antisembly purified.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="866">
                    <text>The epitopes in the C muscle of LMP-1 at a dilution of 1:200 is recognized by the polyclonal anti-LMP-1 affinity antisumption that the garbage was surveyed.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="867">
                    <text>The epitopes in the C muscle of LMP-1 at a dilution of 1:200 was recognized by the polyclonal anti-LMP-1 affinity antisumption acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="868">
                    <text>The epitopes in the C muscle of LMP-1 at a dilution of 1:200 was recognized by the polyclonal anti-LMP-1 affinity antisumption.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="869">
                    <text>The epitopes in the terminal C of LMP-1 at a 1:200 dilution is recognized by the anti-LMP-1 anti-LMP-1 purified affinity that the garbage was surveyed.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="870">
                    <text>The epitopes in the terminal C of LMP-1 at a 1:200 dilution was recognized by the anti-LMP-1 anti-LMP-1 purified affinity acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="871">
                    <text>The epitopes in the terminal C of LMP-1 at a 1:200 dilution was recognized by the anti-LMP-1 anti-LMP-1 purified affinity.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="872">
                    <text>The heptameric in other arrangements is recognized by the NarL protein that the garbage was surveyed.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="873">
                    <text>The heptameric in other arrangements was recognized by the NarL protein acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="874">
                    <text>The heptameric in other arrangements was recognized by the NarL protein.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="875">
                    <text>The heptamers in other arrangements is recognized by the NarL protein that the garbage was surveyed.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="876">
                    <text>The heptamers in other arrangements was recognized by the NarL protein acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="877">
                    <text>The heptamers in other arrangements was recognized by the the NarL protein acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="878">
                    <text>The heptamers in other arrangements was recognized by the the NarL protein.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="879">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with D1 anti-64kD human autoantigen that recognizes polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle and by western blotting.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="880">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with D1 antibody of anti-64kD human autoantigen that recognizes a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle and by western blotting.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="881">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with D1 antibody of human autoantigen anti-64kD that recognizes polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle and by western blotting.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="882">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with NarL protein that recognizes heptameric in other arrangements and by western blotting.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="883">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with NarL protein that recognizes heptamers in other arrangements and by western blotting.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="884">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with a monoclonal antibody that recognizes STAT1 N-terminus and by western blotting.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="885">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with a monoclonal antibody that recognizes the STAT1 N-terminal and by western blotting.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="886">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with activating complex cAMP-CRP that recognizes two sites in tsx-p2 and by western blotting.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="887">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with activating the cAMP-CRP complex that recognizes two sites in tsx-p2 and by western blotting.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="888">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with activator complex cAMP-CRP that recognizes two sites in tsx-p2 and by western blotting.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="889">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with anti-64kD antibodies of human autoantigen D1 that recognizes a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle and by western blotting.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="890">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with anti-64kD antibodies of human autoantigen D1 that recognizes polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle and by western blotting.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="891">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit that recognizes term C of CD40 at a dilution 1:500 and by western blotting.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="892">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with anti-LMP-1 anti-LMP-1 purified affinity that recognizes epiptopes in the C-terminal of LMP-1 at a 1:200 dilution and by western blotting.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="893">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with anti-LMP-1 anti-LMP-1 purified affinity that recognizes epitopes in the terminal C of LMP-1 at a 1:200 dilution and by western blotting.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="894">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with anti-LMP-1 antisembly purified that recognizes epitoped in the C-terminal of LMP-1 in a 1:200 dilution and by western blotting.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="895">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with anti-LMP-1 purified affinity antiserum that recognizes epictopes in the C-terminal of LMP-1 at a dilution 1:200 and by western blotting.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="896">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with anti-LMP-1 purified affinity antiserum that recognizes epiptopes in the C-terminal of LMP-1 at a dilution 1:200 and by western blotting.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="897">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with monoclonal antibody that recognizes N-terminus STAT1 and by western blotting.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="898">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with most of the regulators belonging to the AraC/XylS family that recognizes multi-binding sites and by western blotting.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="899">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with most of the regulators belonging to the AraC/XylS family that recognizes multiple connection site and by western blotting.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="900">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with most of the regulators belonging to the AraC/XylS family that recognizes multiple linkage site and by western blotting.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="901">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with most of the regulators belonging to the AraC/XylS family that recognizes multiple-link location and by western blotting.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="902">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with most regulators belonging to the AraC/XylS family that recognizes multiple binding sites and by western blotting.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="903">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with polyclonal anti-CD40 anti-rabbit antisound that recognizes C-term of CD40 at a 1:500 dilution and by western blotting.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="904">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with polyclonal anti-LMP-1 affinity antisumption that recognizes epitopes in the C muscle of LMP-1 at a dilution of 1:200 and by western blotting.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="905">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with proteins that recognizes short motives within the protected region and by western blotting.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="906">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with proteins that recognizes short reasons within the protected region and by western blotting.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="907">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with the NarL protein that recognizes heptamers in other arrangements and by western blotting.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="908">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with the activator complex cAMP-CRP that recognizes two sites in tsx-p2 and by western blotting.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="909">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with the cAMP-CRP activator complex that recognizes two sites in tsx-p2 and by western blotting.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="910">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with the eukaryotic binding factor upstream (UBF) that recognizes the promoter of the RNA ribosomal gene and by western blotting.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="911">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with the upstream eukaryotic binding factor (UBF) that recognizes the RNA ribosomal gene promoter and by western blotting.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="912">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with the upstream eukaryotic binding factor (UBF) that recognizes the promoter of the RNA ribosomal gene and by western blotting.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="913">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where STAT1 N-terminal is recognized by monoclonal antibody.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="914">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where STAT1 N-terminus is recognized by A monoclonal antibody.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="915">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where STAT1 N-terminus is recognized by a monoclonal antibody.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="916">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle is recognized by D1 antibody of anti-64kD human autoantigen.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="917">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle is recognized by anti-64kD antibodies of human autoantigen D1.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="918">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where epictopes in the C-terminal of LMP-1 at a dilution 1:200 is recognized by anti-LMP-1 purified affinity antiserum.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="919">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where epiptopes in the C-terminal of LMP-1 at a 1:200 dilution is recognized by anti-LMP-1 anti-LMP-1 purified affinity.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="920">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where epiptopes in the C-terminal of LMP-1 at a dilution 1:200 is recognized by anti-LMP-1 purified affinity antiserum.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="921">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where epitoped in the C-terminal of LMP-1 in a 1:200 dilution is recognized by anti-LMP-1 antisembly purified.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="922">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where epitopes in the C muscle of LMP-1 at a dilution of 1:200 is recognized by polyclonal anti-LMP-1 affinity antisumption.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="923">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where epitopes in the terminal C of LMP-1 at a 1:200 dilution is recognized by anti-LMP-1 anti-LMP-1 purified affinity.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="924">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where heptameric in other arrangements is recognized by NarL protein.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="925">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where heptamers in other arrangements is recognized by NarL protein.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="926">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where heptamers in other arrangements is recognized by the NarL protein.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="927">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where multi-binding sites is recognized by most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="928">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where multiple binding sites is recognized by most regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="929">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where multiple connection site is recognized by most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="930">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where multiple-link location is recognized by most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="931">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle is recognized by D1 anti-64kD human autoantigen.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="932">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle is recognized by D1 antibody of human autoantigen anti-64kD.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="933">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle is recognized by anti-64kD antibodies of human autoantigen D1.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="934">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where term C of CD40 at a dilution 1:500 is recognized by anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="935">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where the STAT1 N-terminal is recognized by a monoclonal antibody.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="936">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where the lowest form of Stat3, Stat3Beta is recognized by anti-Stat3 pAb.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="937">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where the promoter of the RNA ribosomal gene is recognized by the eukaryotic binding factor upstream (UBF).</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="938">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where the promoter of the RNA ribosomal gene is recognized by the upstream eukaryotic binding factor (UBF).</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="939">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where two sites in tsx-p2 is recognized by activating complex cAMP-CRP.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="940">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where two sites in tsx-p2 is recognized by activating the cAMP-CRP complex.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="941">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where two sites in tsx-p2 is recognized by activator complex cAMP-CRP.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="942">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where two sites in tsx-p2 is recognized by the activator complex cAMP-CRP.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="943">
                    <text>The multi-binding sites is recognized by the most of the regulators belonging to the AraC/XylS family that the garbage was surveyed.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="944">
                    <text>The multi-binding sites was recognized by the most of the regulators belonging to the AraC/XylS family acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="945">
                    <text>The multi-binding sites was recognized by the most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="946">
                    <text>The multiple binding sites was recognized by the most regulators belonging to the AraC/XylS family acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="947">
                    <text>The multiple binding sites was recognized by the most regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="948">
                    <text>The multiple connection site is recognized by the most of the regulators belonging to the AraC/XylS family that the garbage was surveyed.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="949">
                    <text>The multiple connection site was recognized by the most of the regulators belonging to the AraC/XylS family acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="950">
                    <text>The multiple linkage site is recognized by the most of the regulators belonging to the AraC/XylS family that the garbage was surveyed.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="951">
                    <text>The multiple linkage site was recognized by the most of the regulators belonging to the AraC/XylS family acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="952">
                    <text>The multiple linkage site was recognized by the most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="953">
                    <text>The multiple-link location is recognized by the most of the regulators belonging to the AraC/XylS family that the garbage was surveyed.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="954">
                    <text>The multiple-link location was recognized by the most of the regulators belonging to the AraC/XylS family acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="955">
                    <text>The polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle is recognized by the D1 anti-64kD human autoantigen that the garbage was surveyed.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="956">
                    <text>The polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle is recognized by the D1 antibody of human autoantigen anti-64kD that the garbage was surveyed.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="957">
                    <text>The polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle was recognized by the D1 anti-64kD human autoantigen acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="958">
                    <text>The polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle was recognized by the D1 anti-64kD human autoantigen.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="959">
                    <text>The polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle was recognized by the D1 antibody of human autoantigen anti-64kD.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="960">
                    <text>The polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle is recognized by the anti-64kD antibodies of human autoantigen D1 that the garbage was surveyed.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="961">
                    <text>The polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle was recognized by the anti-64kD antibodies of human autoantigen D1 acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="962">
                    <text>The sequence (YPYDVPDYA) in a 1:500 dilution is recognized by the A0 (a monoclonal anti-HA RAT antibody (Boehringer-Ingelheim) with which the rostes were sounded.</text>
                    <arg n="1">sequence (YPYDVPDYA) in a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="963">
                    <text>The short motives within the protected region is recognized by the proteins that the garbage was surveyed.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="964">
                    <text>The short motives within the protected region was recognized by the proteins acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="965">
                    <text>The short motives within the protected region was recognized by the proteins.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="966">
                    <text>The short reasons within the protected region is recognized by the proteins that the garbage was surveyed.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="967">
                    <text>The short reasons within the protected region was recognized by the proteins acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="968">
                    <text>The term C of CD40 at a dilution 1:500 was recognized by the anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="969">
                    <text>The term C of CD40 at a dilution 1:500 was recognized by the anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="970">
                    <text>The the RNA ribosomal gene promoter is recognized by the the upstream eukaryotic binding factor (UBF) that the garbage was surveyed.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="971">
                    <text>The the RNA ribosomal gene promoter was recognized by the the upstream eukaryotic binding factor (UBF) acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="972">
                    <text>The the RNA ribosomal gene promoter was recognized by the the upstream eukaryotic binding factor (UBF).</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="973">
                    <text>The the STAT1 N-terminal is recognized by the a monoclonal antibody that the garbage was surveyed.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="974">
                    <text>The the STAT1 N-terminal was recognized by the a monoclonal antibody.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="975">
                    <text>The the lowest form of Stat3, Stat3Beta was recognized by the anti-Stat3 pAb acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="976">
                    <text>The the lowest form of Stat3, Stat3Beta was recognized by the anti-Stat3 pAb.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="977">
                    <text>The the promoter of the RNA ribosomal gene is recognized by the A0 (a monoclonal anti-HA RAT antibody (Boehringer-Ingelheim) with which the rostes were sounded.</text>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="978">
                    <text>The the promoter of the RNA ribosomal gene is recognized by the the eukaryotic binding factor upstream (UBF) that the garbage was surveyed.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="979">
                    <text>The the promoter of the RNA ribosomal gene is recognized by the the upstream eukaryotic binding factor (UBF) that the garbage was surveyed.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="980">
                    <text>The the promoter of the RNA ribosomal gene was recognized by the the eukaryotic binding factor upstream (UBF) acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="981">
                    <text>The the promoter of the RNA ribosomal gene was recognized by the the eukaryotic binding factor upstream (UBF).</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="982">
                    <text>The the promoter of the RNA ribosomal gene was recognized by the the upstream eukaryotic binding factor (UBF) acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="983">
                    <text>The the promoter of the RNA ribosomal gene was recognized by the the upstream eukaryotic binding factor (UBF).</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="984">
                    <text>The the ribosomal RNA promoter is recognized by the A0 (a monoclonal anti-HA RAT antibody (Boehringer-Ingelheim) with which the rostes were sounded.</text>
                    <arg n="1">the ribosomal RNA promoter</arg>
                </example>
                <example src="PERMUTATE" no="985">
                    <text>The two sites in tsx-p2 is recognized by the activating complex cAMP-CRP that the garbage was surveyed.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="986">
                    <text>The two sites in tsx-p2 is recognized by the activating the cAMP-CRP complex that the garbage was surveyed.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="987">
                    <text>The two sites in tsx-p2 is recognized by the activator complex cAMP-CRP that the garbage was surveyed.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="988">
                    <text>The two sites in tsx-p2 is recognized by the the activator complex cAMP-CRP that the garbage was surveyed.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="989">
                    <text>The two sites in tsx-p2 is recognized by the the cAMP-CRP activator complex that the garbage was surveyed.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="990">
                    <text>The two sites in tsx-p2 was recognized by the activating complex cAMP-CRP acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="991">
                    <text>The two sites in tsx-p2 was recognized by the activating complex cAMP-CRP.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="992">
                    <text>The two sites in tsx-p2 was recognized by the activating the cAMP-CRP complex acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="993">
                    <text>The two sites in tsx-p2 was recognized by the activating the cAMP-CRP complex.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="994">
                    <text>The two sites in tsx-p2 was recognized by the the activator complex cAMP-CRP acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="995">
                    <text>The two sites in tsx-p2 was recognized by the the cAMP-CRP activator complex acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="996">
                    <text>The two sites in tsx-p2 was recognized by the the cAMP-CRP activator complex.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="997">
                    <text>These bands can be detected with anti-LMP-1 antisumption of affinity that recognize A1 (the different non-muscle heavy chain isoforms of myosin (A and B)</text>
                    <arg n="0">anti-LMP-1 antisumption of affinity</arg>
                </example>
                <example src="PERMUTATE" no="998">
                    <text>These bands can be detected with anti-LMP-1 antisumption of affinity that recognized A1 (the different non-muscle heavy chain isoforms of myosin (A and B)</text>
                    <arg n="0">anti-LMP-1 antisumption of affinity</arg>
                </example>
                <example src="PERMUTATE" no="999">
                    <text>These bands can be detected with anti-LMP-1 antisumption of affinity that recognized A1 (the different non-muscular myosin heavy chain isoforms (A and B)</text>
                    <arg n="0">anti-LMP-1 antisumption of affinity</arg>
                </example>
                <example src="PERMUTATE" no="1000">
                    <text>These bands can be detected with polyclonal anti-LMP-1 affinity antiserum that recognize A1 (the different non-muscle heavy chain isoforms of myosin (A and B)</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antiserum</arg>
                </example>
                <example src="PERMUTATE" no="1001">
                    <text>These bands can be detected with polyclonal anti-LMP-1 affinity antiserum that recognized A1 (the different non-muscle heavy chain isoforms of myosin (A and B)</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antiserum</arg>
                </example>
                <example src="PERMUTATE" no="1002">
                    <text>These bands can be detected with polyclonal anti-LMP-1 affinity antiserum that recognized A1 (the different non-muscular myosin heavy chain isoforms (A and B)</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antiserum</arg>
                </example>
                <example src="PERMUTATE" no="1003">
                    <text>These bands can be detected with polyclonal anti-LMP-1 purified affinity antiserum that recognize A1 (the different non-muscle heavy chain isoforms of myosin (A and B)</text>
                    <arg n="0">polyclonal anti-LMP-1 purified affinity antiserum</arg>
                </example>
                <example src="PERMUTATE" no="1004">
                    <text>These bands can be detected with polyclonal anti-LMP-1 purified affinity antiserum that recognized A1 (the different non-muscle heavy chain isoforms of myosin (A and B)</text>
                    <arg n="0">polyclonal anti-LMP-1 purified affinity antiserum</arg>
                </example>
                <example src="PERMUTATE" no="1005">
                    <text>These bands can be detected with polyclonal anti-LMP-1 purified affinity antiserum that recognized A1 (the different non-muscular myosin heavy chain isoforms (A and B)</text>
                    <arg n="0">polyclonal anti-LMP-1 purified affinity antiserum</arg>
                </example>
                <example src="PERMUTATE" no="1006">
                    <text>These bands can be detected with this antibody in PKR+/+MEFs that recognize A1 (the different non-muscle heavy chain isoforms of myosin (A and B)</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                </example>
                <example src="PERMUTATE" no="1007">
                    <text>These bands can be detected with this antibody in PKR+/+MEFs that recognized A1 (the different non-muscle heavy chain isoforms of myosin (A and B)</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                </example>
                <example src="PERMUTATE" no="1008">
                    <text>These bands can be detected with this antibody in PKR+/+MEFs that recognized A1 (the different non-muscular myosin heavy chain isoforms (A and B)</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                </example>
                <example src="PERMUTATE" no="1009">
                    <text>We show that A monoclonal antibody recognized STAT1 N-terminus that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="1010">
                    <text>We show that A monoclonal antibody recognized STAT1 N-terminus that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="1011">
                    <text>We show that A monoclonal antibody recognized STAT1 N-terminus that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="1012">
                    <text>We show that A monoclonal antibody will recognize STAT1 N-terminus that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">A monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="1013">
                    <text>We show that D1 anti-64kD human autoantigen recognized polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1014">
                    <text>We show that D1 anti-64kD human autoantigen recognized polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1015">
                    <text>We show that D1 anti-64kD human autoantigen will recognize polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1016">
                    <text>We show that D1 antibody of anti-64kD human autoantigen recognized a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1017">
                    <text>We show that D1 antibody of anti-64kD human autoantigen recognized a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1018">
                    <text>We show that D1 antibody of anti-64kD human autoantigen recognized a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1019">
                    <text>We show that D1 antibody of anti-64kD human autoantigen will recognize a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1020">
                    <text>We show that D1 antibody of anti-64kD human autoantigen will recognize a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1021">
                    <text>We show that D1 antibody of human autoantigen anti-64kD recognized polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1022">
                    <text>We show that D1 antibody of human autoantigen anti-64kD recognized polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1023">
                    <text>We show that D1 antibody of human autoantigen anti-64kD recognized polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1024">
                    <text>We show that D1 antibody of human autoantigen anti-64kD will recognize polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1025">
                    <text>We show that D1 antibody of human autoantigen anti-64kD will recognize polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1026">
                    <text>We show that NarL protein recognized heptameric in other arrangements that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1027">
                    <text>We show that NarL protein recognized heptameric in other arrangements that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1028">
                    <text>We show that NarL protein recognized heptameric in other arrangements that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1029">
                    <text>We show that NarL protein recognized heptamers in other arrangements that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1030">
                    <text>We show that NarL protein recognized heptamers in other arrangements that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1031">
                    <text>We show that NarL protein will recognize heptameric in other arrangements that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1032">
                    <text>We show that NarL protein will recognize heptamers in other arrangements that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1033">
                    <text>We show that NarL protein will recognize heptamers in other arrangements that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1034">
                    <text>We show that a monoclonal antibody recognized STAT1 N-terminus that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="1035">
                    <text>We show that a monoclonal antibody recognized STAT1 N-terminus that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="1036">
                    <text>We show that a monoclonal antibody recognized STAT1 N-terminus that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="1037">
                    <text>We show that a monoclonal antibody recognized the STAT1 N-terminal that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="1038">
                    <text>We show that a monoclonal antibody recognized the STAT1 N-terminal that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="1039">
                    <text>We show that a monoclonal antibody recognized the STAT1 N-terminal that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="1040">
                    <text>We show that a monoclonal antibody will recognize STAT1 N-terminus that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="1041">
                    <text>We show that a monoclonal antibody will recognize the STAT1 N-terminal that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="1042">
                    <text>We show that a monoclonal antibody will recognize the STAT1 N-terminal that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="1043">
                    <text>We show that activating complex cAMP-CRP recognized two sites in tsx-p2 that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1044">
                    <text>We show that activating complex cAMP-CRP will recognize two sites in tsx-p2 that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1045">
                    <text>We show that activating complex cAMP-CRP will recognize two sites in tsx-p2 that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1046">
                    <text>We show that activating the cAMP-CRP complex recognized two sites in tsx-p2 that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1047">
                    <text>We show that activating the cAMP-CRP complex recognized two sites in tsx-p2 that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1048">
                    <text>We show that activating the cAMP-CRP complex recognized two sites in tsx-p2 that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1049">
                    <text>We show that activating the cAMP-CRP complex will recognize two sites in tsx-p2 that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1050">
                    <text>We show that activating the cAMP-CRP complex will recognize two sites in tsx-p2 that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1051">
                    <text>We show that activator complex cAMP-CRP recognized two sites in tsx-p2 that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1052">
                    <text>We show that activator complex cAMP-CRP recognized two sites in tsx-p2 that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1053">
                    <text>We show that anti-64kD antibodies of human autoantigen D1 recognized a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1054">
                    <text>We show that anti-64kD antibodies of human autoantigen D1 recognized a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1055">
                    <text>We show that anti-64kD antibodies of human autoantigen D1 recognized a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1056">
                    <text>We show that anti-64kD antibodies of human autoantigen D1 recognized polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1057">
                    <text>We show that anti-64kD antibodies of human autoantigen D1 will recognize a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1058">
                    <text>We show that anti-64kD antibodies of human autoantigen D1 will recognize polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1059">
                    <text>We show that anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit will recognize term C of CD40 at a dilution 1:500 that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="1060">
                    <text>We show that anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit will recognize term C of CD40 at a dilution 1:500 that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="1061">
                    <text>We show that anti-LMP-1 anti-LMP-1 purified affinity recognized epiptopes in the C-terminal of LMP-1 at a 1:200 dilution that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1062">
                    <text>We show that anti-LMP-1 anti-LMP-1 purified affinity recognized epiptopes in the C-terminal of LMP-1 at a 1:200 dilution that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1063">
                    <text>We show that anti-LMP-1 anti-LMP-1 purified affinity recognized epitopes in the terminal C of LMP-1 at a 1:200 dilution that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1064">
                    <text>We show that anti-LMP-1 anti-LMP-1 purified affinity recognized epitopes in the terminal C of LMP-1 at a 1:200 dilution that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1065">
                    <text>We show that anti-LMP-1 anti-LMP-1 purified affinity recognized epitopes in the terminal C of LMP-1 at a 1:200 dilution that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1066">
                    <text>We show that anti-LMP-1 anti-LMP-1 purified affinity will recognize epiptopes in the C-terminal of LMP-1 at a 1:200 dilution that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1067">
                    <text>We show that anti-LMP-1 anti-LMP-1 purified affinity will recognize epiptopes in the C-terminal of LMP-1 at a 1:200 dilution that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1068">
                    <text>We show that anti-LMP-1 anti-LMP-1 purified affinity will recognize epitopes in the terminal C of LMP-1 at a 1:200 dilution that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1069">
                    <text>We show that anti-LMP-1 anti-LMP-1 purified affinity will recognize epitopes in the terminal C of LMP-1 at a 1:200 dilution that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1070">
                    <text>We show that anti-LMP-1 antisembly purified recognized epiptopes in the C-terminal of LMP-1 at a dilution 1:200 that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1071">
                    <text>We show that anti-LMP-1 antisembly purified recognized epiptopes in the C-terminal of LMP-1 at a dilution 1:200 that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1072">
                    <text>We show that anti-LMP-1 antisembly purified recognized epiptopes in the C-terminal of LMP-1 at a dilution 1:200 that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1073">
                    <text>We show that anti-LMP-1 antisembly purified recognized epitoped in the C-terminal of LMP-1 in a 1:200 dilution that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1074">
                    <text>We show that anti-LMP-1 antisembly purified recognized epitoped in the C-terminal of LMP-1 in a 1:200 dilution that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1075">
                    <text>We show that anti-LMP-1 antisembly purified recognized epitoped in the C-terminal of LMP-1 in a 1:200 dilution that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1076">
                    <text>We show that anti-LMP-1 antisembly purified will recognize epiptopes in the C-terminal of LMP-1 at a dilution 1:200 that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1077">
                    <text>We show that anti-LMP-1 antisembly purified will recognize epitoped in the C-terminal of LMP-1 in a 1:200 dilution that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1078">
                    <text>We show that anti-LMP-1 antisembly purified will recognize epitoped in the C-terminal of LMP-1 in a 1:200 dilution that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1079">
                    <text>We show that anti-LMP-1 purified affinity antiserum recognized epictopes in the C-terminal of LMP-1 at a dilution 1:200 that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1080">
                    <text>We show that anti-LMP-1 purified affinity antiserum recognized epictopes in the C-terminal of LMP-1 at a dilution 1:200 that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1081">
                    <text>We show that anti-LMP-1 purified affinity antiserum recognized epictopes in the C-terminal of LMP-1 at a dilution 1:200 that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1082">
                    <text>We show that anti-LMP-1 purified affinity antiserum recognized epiptopes in the C-terminal of LMP-1 at a dilution 1:200 that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1083">
                    <text>We show that anti-LMP-1 purified affinity antiserum recognized epiptopes in the C-terminal of LMP-1 at a dilution 1:200 that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1084">
                    <text>We show that anti-LMP-1 purified affinity antiserum recognized epiptopes in the C-terminal of LMP-1 at a dilution 1:200 that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1085">
                    <text>We show that anti-LMP-1 purified affinity antiserum will recognize epictopes in the C-terminal of LMP-1 at a dilution 1:200 that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1086">
                    <text>We show that anti-LMP-1 purified affinity antiserum will recognize epictopes in the C-terminal of LMP-1 at a dilution 1:200 that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1087">
                    <text>We show that anti-LMP-1 purified affinity antiserum will recognize epiptopes in the C-terminal of LMP-1 at a dilution 1:200 that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1088">
                    <text>We show that anti-LMP-1 purified affinity antiserum will recognize epiptopes in the C-terminal of LMP-1 at a dilution 1:200 that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1089">
                    <text>We show that anti-Stat3 pAb recognized the lowest form of Stat3, Stat3Beta that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="1090">
                    <text>We show that anti-Stat3 pAb recognized the lowest form of Stat3, Stat3Beta that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="1091">
                    <text>We show that anti-Stat3 pAb recognized the lowest form of Stat3, Stat3Beta that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="1092">
                    <text>We show that anti-Stat3 pAb will recognize the lowest form of Stat3, Stat3Beta that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="1093">
                    <text>We show that anti-Stat3 pAb will recognize the lowest form of Stat3, Stat3Beta that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="1094">
                    <text>We show that monoclonal antibody recognized N-terminus STAT1 that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="1095">
                    <text>We show that monoclonal antibody recognized N-terminus STAT1 that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="1096">
                    <text>We show that monoclonal antibody recognized N-terminus STAT1 that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="1097">
                    <text>We show that monoclonal antibody recognized STAT1 N-terminal that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="1098">
                    <text>We show that monoclonal antibody recognized STAT1 N-terminal that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="1099">
                    <text>We show that monoclonal antibody recognized STAT1 N-terminal that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="1100">
                    <text>We show that monoclonal antibody recognized STAT1 N-terminus that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="1101">
                    <text>We show that monoclonal antibody recognized STAT1 N-terminus that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="1102">
                    <text>We show that monoclonal antibody will recognize N-terminus STAT1 that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="1103">
                    <text>We show that monoclonal antibody will recognize N-terminus STAT1 that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="1104">
                    <text>We show that monoclonal antibody will recognize STAT1 N-terminal that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="1105">
                    <text>We show that monoclonal antibody will recognize STAT1 N-terminus that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="1106">
                    <text>We show that monoclonal antibody will recognize STAT1 N-terminus that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="1107">
                    <text>We show that most of the regulators belonging to the AraC/XylS family recognized multi-binding sites that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1108">
                    <text>We show that most of the regulators belonging to the AraC/XylS family recognized multi-binding sites that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1109">
                    <text>We show that most of the regulators belonging to the AraC/XylS family recognized multiple connection site that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="1110">
                    <text>We show that most of the regulators belonging to the AraC/XylS family recognized multiple linkage site that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="1111">
                    <text>We show that most of the regulators belonging to the AraC/XylS family recognized multiple linkage site that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="1112">
                    <text>We show that most of the regulators belonging to the AraC/XylS family recognized multiple-link location that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="1113">
                    <text>We show that most of the regulators belonging to the AraC/XylS family recognized multiple-link location that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="1114">
                    <text>We show that most of the regulators belonging to the AraC/XylS family will recognize multi-binding sites that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1115">
                    <text>We show that most of the regulators belonging to the AraC/XylS family will recognize multi-binding sites that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1116">
                    <text>We show that most of the regulators belonging to the AraC/XylS family will recognize multiple connection site that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="1117">
                    <text>We show that most of the regulators belonging to the AraC/XylS family will recognize multiple connection site that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="1118">
                    <text>We show that most of the regulators belonging to the AraC/XylS family will recognize multiple linkage site that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="1119">
                    <text>We show that most of the regulators belonging to the AraC/XylS family will recognize multiple linkage site that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="1120">
                    <text>We show that most regulators belonging to the AraC/XylS family recognized multiple binding sites that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1121">
                    <text>We show that most regulators belonging to the AraC/XylS family recognized multiple binding sites that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1122">
                    <text>We show that most regulators belonging to the AraC/XylS family recognized multiple binding sites that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1123">
                    <text>We show that most regulators belonging to the AraC/XylS family will recognize multiple binding sites that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1124">
                    <text>We show that most regulators belonging to the AraC/XylS family will recognize multiple binding sites that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1125">
                    <text>We show that polyclonal anti-CD40 anti-rabbit antisound recognized C-term of CD40 at a 1:500 dilution that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1126">
                    <text>We show that polyclonal anti-CD40 anti-rabbit antisound recognized C-term of CD40 at a 1:500 dilution that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1127">
                    <text>We show that polyclonal anti-CD40 anti-rabbit antisound recognized C-term of CD40 at a 1:500 dilution that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1128">
                    <text>We show that polyclonal anti-CD40 anti-rabbit antisound will recognize C-term of CD40 at a 1:500 dilution that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1129">
                    <text>We show that polyclonal anti-CD40 anti-rabbit antisound will recognize C-term of CD40 at a 1:500 dilution that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1130">
                    <text>We show that polyclonal anti-LMP-1 affinity antisumption recognized epitopes in the C muscle of LMP-1 at a dilution of 1:200 that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1131">
                    <text>We show that polyclonal anti-LMP-1 affinity antisumption recognized epitopes in the C muscle of LMP-1 at a dilution of 1:200 that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1132">
                    <text>We show that polyclonal anti-LMP-1 affinity antisumption recognized epitopes in the C muscle of LMP-1 at a dilution of 1:200 that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1133">
                    <text>We show that polyclonal anti-LMP-1 affinity antisumption will recognize epitopes in the C muscle of LMP-1 at a dilution of 1:200 that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1134">
                    <text>We show that proteins recognized short motives within the protected region that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1135">
                    <text>We show that proteins recognized short motives within the protected region that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1136">
                    <text>We show that proteins recognized short reasons within the protected region that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1137">
                    <text>We show that proteins recognized short reasons within the protected region that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1138">
                    <text>We show that proteins recognized short reasons within the protected region that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1139">
                    <text>We show that proteins will recognize short motives within the protected region that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1140">
                    <text>We show that proteins will recognize short reasons within the protected region that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1141">
                    <text>We show that the NarL protein recognized heptamers in other arrangements that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1142">
                    <text>We show that the NarL protein recognized heptamers in other arrangements that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1143">
                    <text>We show that the NarL protein recognized heptamers in other arrangements that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1144">
                    <text>We show that the NarL protein will recognize heptamers in other arrangements that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1145">
                    <text>We show that the activator complex cAMP-CRP recognized two sites in tsx-p2 that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1146">
                    <text>We show that the activator complex cAMP-CRP recognized two sites in tsx-p2 that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1147">
                    <text>We show that the activator complex cAMP-CRP recognized two sites in tsx-p2 that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1148">
                    <text>We show that the activator complex cAMP-CRP will recognize two sites in tsx-p2 that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1149">
                    <text>We show that the activator complex cAMP-CRP will recognize two sites in tsx-p2 that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1150">
                    <text>We show that the cAMP-CRP activator complex recognized two sites in tsx-p2 that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1151">
                    <text>We show that the cAMP-CRP activator complex recognized two sites in tsx-p2 that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1152">
                    <text>We show that the cAMP-CRP activator complex will recognize two sites in tsx-p2 that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1153">
                    <text>We show that the cAMP-CRP activator complex will recognize two sites in tsx-p2 that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1154">
                    <text>We show that the eukaryotic binding factor upstream (UBF) recognized the promoter of the RNA ribosomal gene that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="1155">
                    <text>We show that the eukaryotic binding factor upstream (UBF) recognized the promoter of the RNA ribosomal gene that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="1156">
                    <text>We show that the eukaryotic binding factor upstream (UBF) will recognize the promoter of the RNA ribosomal gene that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="1157">
                    <text>We show that the eukaryotic binding factor upstream (UBF) will recognize the promoter of the RNA ribosomal gene that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="1158">
                    <text>We show that the upstream eukaryotic binding factor (UBF) recognized the RNA ribosomal gene promoter that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="1159">
                    <text>We show that the upstream eukaryotic binding factor (UBF) recognized the RNA ribosomal gene promoter that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="1160">
                    <text>We show that the upstream eukaryotic binding factor (UBF) recognized the RNA ribosomal gene promoter that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="1161">
                    <text>We show that the upstream eukaryotic binding factor (UBF) recognized the promoter of the RNA ribosomal gene that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="1162">
                    <text>We show that the upstream eukaryotic binding factor (UBF) recognized the promoter of the RNA ribosomal gene that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="1163">
                    <text>We show that the upstream eukaryotic binding factor (UBF) recognized the promoter of the RNA ribosomal gene that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="1164">
                    <text>We show that the upstream eukaryotic binding factor (UBF) will recognize the RNA ribosomal gene promoter that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="1165">
                    <text>We show that the upstream eukaryotic binding factor (UBF) will recognize the RNA ribosomal gene promoter that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="1166">
                    <text>We show that the upstream eukaryotic binding factor (UBF) will recognize the promoter of the RNA ribosomal gene that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="1167">
                    <text>a monoclonal antibody also binds to these 727 sites but, unlike NarP, also recognized STAT1 N-terminus.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="1168">
                    <text>a monoclonal antibody also binds to these sites 7-2-7, but, unlike NarP, it also recognized STAT1 N-terminus .</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="1169">
                    <text>a monoclonal antibody also binds to these sites 7-2-7, but, unlike NarP, it also recognized STAT1 N-terminus.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="1170">
                    <text>a monoclonal antibody also binds to these sites 7-2-7, but, unlike NarP, it also recognized the STAT1 N-terminal .</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="1171">
                    <text>a monoclonal antibody also binds to these sites 7-2-7, but, unlike NarP, it also recognized the STAT1 N-terminal.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="1172">
                    <text>a monoclonal antibody are able to recognize STAT1 N-terminus in regulated promoters.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="1173">
                    <text>a monoclonal antibody are able to recognize the STAT1 N-terminal in regulated promoters.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="1174">
                    <text>a monoclonal antibody binds to these 727 sites but, unlike NarP, will also recognize STAT1 N-terminus.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="1175">
                    <text>a monoclonal antibody binds to these 727 sites but, unlike NarP, will also recognize the STAT1 N-terminal.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="1176">
                    <text>a monoclonal antibody binds to these sites 7-2-7, but, unlike NarP, it also recognizes STAT1 N-terminus .</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="1177">
                    <text>a monoclonal antibody binds to these sites 7-2-7, but, unlike NarP, it also recognizes the STAT1 N-terminal .</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="1178">
                    <text>a monoclonal antibody can recognize STAT1 N-terminus in regulated promoters.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="1179">
                    <text>a monoclonal antibody can recognize the STAT1 N-terminal in regulated promoters.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="1180">
                    <text>a monoclonal antibody has also joined these 727 sites but, unlike NarP, has also recognized STAT1 N-terminus.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="1181">
                    <text>a monoclonal antibody has also joined these 727 sites but, unlike NarP, has also recognized the STAT1 N-terminal.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="1182">
                    <text>a monoclonal antibody is able to recognize STAT1 N-terminus in regulated promoters.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="1183">
                    <text>a monoclonal antibody recognized STAT1 N-terminus in regulated promoters.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="1184">
                    <text>a monoclonal antibody recognized STAT1 N-terminus in the regulated promoters.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="1185">
                    <text>a monoclonal antibody recognized STAT1 N-terminus.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="1186">
                    <text>a monoclonal antibody recognized the STAT1 N-terminal in regulated promoters.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="1187">
                    <text>a monoclonal antibody recognized the STAT1 N-terminal in the regulated promoters.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="1188">
                    <text>a monoclonal antibody recognized the STAT1 N-terminal.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="1189">
                    <text>a monoclonal antibody recognizes STAT1 N-terminus.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="1190">
                    <text>a monoclonal antibody recognizes the STAT1 N-terminal.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="1191">
                    <text>a monoclonal antibody specifically recognized STAT1 N-terminus.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="1192">
                    <text>a monoclonal antibody specifically recognized the STAT1 N-terminal.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="1193">
                    <text>a monoclonal antibody that has recognized the STAT1 N-terminal was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="1194">
                    <text>a monoclonal antibody that recognized STAT1 N-terminus was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="1195">
                    <text>a monoclonal antibody that recognized the STAT1 N-terminal was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="1196">
                    <text>a monoclonal antibody that recognizes STAT1 N-terminus is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="1197">
                    <text>a monoclonal antibody that recognizes STAT1 N-terminus is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="1198">
                    <text>a monoclonal antibody that recognizes the STAT1 N-terminal is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="1199">
                    <text>a monoclonal antibody will recognize STAT1 N-terminus in regulated promoters.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="1200">
                    <text>a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle are recognized by D1 antibody of anti-64kD human autoantigen with which the threads were probed.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1201">
                    <text>a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle are recognized by D1 antibody of anti-64kD human autoantigen with which the wires were probed.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1202">
                    <text>a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle could be recognized in immunoprecipitatio with D1 antibody of anti-64kD human autoantigen, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1203">
                    <text>a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle is recognized by D1 antibody of anti-64kD human autoantigen by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1204">
                    <text>a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle is recognized by D1 antibody of anti-64kD human autoantigen by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1205">
                    <text>a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle is recognized by D1 antibody of anti-64kD human autoantigen that the litters were probed.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1206">
                    <text>a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle was recognized by D1 antibody of anti-64kD human autoantigen by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1207">
                    <text>a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle was recognized by D1 antibody of anti-64kD human autoantigen.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1208">
                    <text>a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle was recognized in the immunoprecipitatome with D1 antibody of anti-64kD human autoantigen, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1209">
                    <text>a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle were recognized by D1 antibody of anti-64kD human autoantigen.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1210">
                    <text>a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle will be recognized by D1 antibody of anti-64kD human autoantigen.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1211">
                    <text>a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle, cannot is recognized in the immunoprecipitaiton with D1 antibody of anti-64kD human autoantigen as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1212">
                    <text>a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle, could be recognized in the immunoprecipitaiton with D1 antibody of anti-64kD human autoantigen as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1213">
                    <text>a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle, has been recognized in the immunoprecipitaiton with D1 antibody of anti-64kD human autoantigen as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1214">
                    <text>a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle, was not recognized in the immunoprecipitaiton with D1 antibody of anti-64kD human autoantigen as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1215">
                    <text>a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle, was unrecognized in immunoprecipitatio with D1 antibody of anti-64kD human autoantigen, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">D1 antibody of anti-64kD human autoantigen</arg>
                    <arg n="1">a polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1216">
                    <text>a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle are recognized by anti-64kD antibodies of human autoantigen D1 with which the threads were probed.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1217">
                    <text>a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle are recognized by anti-64kD antibodies of human autoantigen D1 with which the wires were probed.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1218">
                    <text>a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle are recognized by anti-64kD antibodies of human autoantigen D1.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1219">
                    <text>a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle could be recognized in immunoprecipitatio with anti-64kD antibodies of human autoantigen D1, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1220">
                    <text>a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle has been recognized by anti-64kD antibodies of human autoantigen D1.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1221">
                    <text>a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle is recognized by anti-64kD antibodies of human autoantigen D1 by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1222">
                    <text>a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle is recognized by anti-64kD antibodies of human autoantigen D1 by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1223">
                    <text>a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle is recognized by anti-64kD antibodies of human autoantigen D1.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1224">
                    <text>a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle was recognized by anti-64kD antibodies of human autoantigen D1 by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1225">
                    <text>a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle was recognized by anti-64kD antibodies of human autoantigen D1.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1226">
                    <text>a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle was recognized in the immunoprecipitatome with anti-64kD antibodies of human autoantigen D1, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1227">
                    <text>a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle will be recognized in immunoprecipitatio with anti-64kD antibodies of human autoantigen D1, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1228">
                    <text>a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle, cannot is recognized in immunoprecipitatio with anti-64kD antibodies of human autoantigen D1, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1229">
                    <text>a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle, cannot is recognized in the immunoprecipitaiton with anti-64kD antibodies of human autoantigen D1 as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1230">
                    <text>a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle, could be recognized in the immunoprecipitaiton with anti-64kD antibodies of human autoantigen D1 as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1231">
                    <text>a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle, has been recognized in the immunoprecipitaiton with anti-64kD antibodies of human autoantigen D1 as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1232">
                    <text>a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle, was unrecognized in immunoprecipitatio with anti-64kD antibodies of human autoantigen D1, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1233">
                    <text>a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle, will be recognized in the immunoprecipitaiton with anti-64kD antibodies of human autoantigen D1 as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1234">
                    <text>activating complex cAMP-CRP also binds to these sites 7-2-7, but, unlike NarP, it also recognized two sites in tsx-p2 .</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1235">
                    <text>activating complex cAMP-CRP also binds to these sites 7-2-7, but, unlike NarP, it also recognized two sites in tsx-p2.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1236">
                    <text>activating complex cAMP-CRP are able to recognize two sites in tsx-p2 in regulated promoters.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1237">
                    <text>activating complex cAMP-CRP binds to these 727 sites but, unlike NarP, will also recognize two sites in tsx-p2.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1238">
                    <text>activating complex cAMP-CRP binds to these sites 7-2-7, but, unlike NarP, it also recognizes two sites in tsx-p2 .</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1239">
                    <text>activating complex cAMP-CRP can recognize two sites in tsx-p2 in regulated promoters.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1240">
                    <text>activating complex cAMP-CRP is able to recognize two sites in tsx-p2 in regulated promoters.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1241">
                    <text>activating complex cAMP-CRP recognized two sites in tsx-p2 in regulated promoters.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1242">
                    <text>activating complex cAMP-CRP recognized two sites in tsx-p2 in the regulated promoters.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1243">
                    <text>activating complex cAMP-CRP recognized two sites in tsx-p2.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1244">
                    <text>activating complex cAMP-CRP recognizes two sites in tsx-p2.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1245">
                    <text>activating complex cAMP-CRP specifically recognized two sites in tsx-p2.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1246">
                    <text>activating complex cAMP-CRP that has recognized two sites in tsx-p2 was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1247">
                    <text>activating complex cAMP-CRP that recognized two sites in tsx-p2 was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1248">
                    <text>activating complex cAMP-CRP that recognizes two sites in tsx-p2 is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1249">
                    <text>activating complex cAMP-CRP that recognizes two sites in tsx-p2 is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1250">
                    <text>activating complex cAMP-CRP will recognize two sites in tsx-p2 in regulated promoters.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1251">
                    <text>activating the cAMP-CRP complex also binds to these sites 7-2-7, but, unlike NarP, it also recognized two sites in tsx-p2 .</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1252">
                    <text>activating the cAMP-CRP complex also binds to these sites 7-2-7, but, unlike NarP, it also recognized two sites in tsx-p2.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1253">
                    <text>activating the cAMP-CRP complex are able to recognize two sites in tsx-p2 in regulated promoters.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1254">
                    <text>activating the cAMP-CRP complex binds to these 727 sites but, unlike NarP, will also recognize two sites in tsx-p2.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1255">
                    <text>activating the cAMP-CRP complex binds to these sites 7-2-7, but, unlike NarP, it also recognizes two sites in tsx-p2 .</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1256">
                    <text>activating the cAMP-CRP complex has also joined these 727 sites but, unlike NarP, has also recognized two sites in tsx-p2.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1257">
                    <text>activating the cAMP-CRP complex recognized two sites in tsx-p2 in regulated promoters.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1258">
                    <text>activating the cAMP-CRP complex recognized two sites in tsx-p2 in the regulated promoters.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1259">
                    <text>activating the cAMP-CRP complex recognized two sites in tsx-p2.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1260">
                    <text>activating the cAMP-CRP complex recognizes two sites in tsx-p2.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1261">
                    <text>activating the cAMP-CRP complex specifically recognized two sites in tsx-p2.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1262">
                    <text>activating the cAMP-CRP complex that has recognized two sites in tsx-p2 was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1263">
                    <text>activating the cAMP-CRP complex that recognizes two sites in tsx-p2 is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1264">
                    <text>activating the cAMP-CRP complex that recognizes two sites in tsx-p2 is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1265">
                    <text>activating the cAMP-CRP complex will recognize two sites in tsx-p2 in regulated promoters.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1266">
                    <text>activator complex cAMP-CRP also binds to these 727 sites but, unlike NarP, also recognized two sites in tsx-p2.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1267">
                    <text>activator complex cAMP-CRP also binds to these sites 7-2-7, but, unlike NarP, it also recognized two sites in tsx-p2 .</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1268">
                    <text>activator complex cAMP-CRP also binds to these sites 7-2-7, but, unlike NarP, it also recognized two sites in tsx-p2.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1269">
                    <text>activator complex cAMP-CRP binds to these sites 7-2-7, but, unlike NarP, it also recognizes two sites in tsx-p2 .</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1270">
                    <text>activator complex cAMP-CRP can recognize two sites in tsx-p2 in regulated promoters.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1271">
                    <text>activator complex cAMP-CRP has also joined these 727 sites but, unlike NarP, has also recognized two sites in tsx-p2.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1272">
                    <text>activator complex cAMP-CRP recognized two sites in tsx-p2 in regulated promoters.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1273">
                    <text>activator complex cAMP-CRP recognized two sites in tsx-p2 in the regulated promoters.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1274">
                    <text>activator complex cAMP-CRP recognized two sites in tsx-p2.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1275">
                    <text>activator complex cAMP-CRP recognizes two sites in tsx-p2.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1276">
                    <text>activator complex cAMP-CRP specifically recognized two sites in tsx-p2.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1277">
                    <text>activator complex cAMP-CRP that recognizes two sites in tsx-p2 is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1278">
                    <text>activator complex cAMP-CRP that recognizes two sites in tsx-p2 is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1279">
                    <text>activator complex cAMP-CRP will recognize two sites in tsx-p2 in regulated promoters.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="1280">
                    <text>anti-64kD antibodies of human autoantigen D1 also binds to these 727 sites but, unlike NarP, also recognized a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1281">
                    <text>anti-64kD antibodies of human autoantigen D1 also binds to these 727 sites but, unlike NarP, also recognized polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1282">
                    <text>anti-64kD antibodies of human autoantigen D1 also binds to these sites 7-2-7, but, unlike NarP, it also recognized a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle .</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1283">
                    <text>anti-64kD antibodies of human autoantigen D1 also binds to these sites 7-2-7, but, unlike NarP, it also recognized a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1284">
                    <text>anti-64kD antibodies of human autoantigen D1 also binds to these sites 7-2-7, but, unlike NarP, it also recognized polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1285">
                    <text>anti-64kD antibodies of human autoantigen D1 are able to recognize a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle in regulated promoters.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1286">
                    <text>anti-64kD antibodies of human autoantigen D1 are able to recognize polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle in regulated promoters.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1287">
                    <text>anti-64kD antibodies of human autoantigen D1 binds to these 727 sites but, unlike NarP, will also recognize a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1288">
                    <text>anti-64kD antibodies of human autoantigen D1 binds to these 727 sites but, unlike NarP, will also recognize polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1289">
                    <text>anti-64kD antibodies of human autoantigen D1 binds to these sites 7-2-7, but, unlike NarP, it also recognizes a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle .</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1290">
                    <text>anti-64kD antibodies of human autoantigen D1 can recognize polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle in regulated promoters.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1291">
                    <text>anti-64kD antibodies of human autoantigen D1 has also joined these 727 sites but, unlike NarP, has also recognized a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1292">
                    <text>anti-64kD antibodies of human autoantigen D1 is able to recognize a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle in regulated promoters.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1293">
                    <text>anti-64kD antibodies of human autoantigen D1 recognized a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle in regulated promoters.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1294">
                    <text>anti-64kD antibodies of human autoantigen D1 recognized a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1295">
                    <text>anti-64kD antibodies of human autoantigen D1 recognized polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle in regulated promoters.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1296">
                    <text>anti-64kD antibodies of human autoantigen D1 recognized polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle in the regulated promoters.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1297">
                    <text>anti-64kD antibodies of human autoantigen D1 recognized polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1298">
                    <text>anti-64kD antibodies of human autoantigen D1 recognizes a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1299">
                    <text>anti-64kD antibodies of human autoantigen D1 recognizes polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1300">
                    <text>anti-64kD antibodies of human autoantigen D1 that has recognized a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1301">
                    <text>anti-64kD antibodies of human autoantigen D1 that has recognized polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1302">
                    <text>anti-64kD antibodies of human autoantigen D1 that recognized a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1303">
                    <text>anti-64kD antibodies of human autoantigen D1 that recognized polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1304">
                    <text>anti-64kD antibodies of human autoantigen D1 that recognizes a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1305">
                    <text>anti-64kD antibodies of human autoantigen D1 that recognizes polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1306">
                    <text>anti-64kD antibodies of human autoantigen D1 that recognizes polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1307">
                    <text>anti-64kD antibodies of human autoantigen D1 will recognize a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle in regulated promoters.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">a polypeptide approximately 70kD in western blots of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1308">
                    <text>anti-64kD antibodies of human autoantigen D1 will recognize polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle in regulated promoters.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1309">
                    <text>anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit also binds to these 727 sites but, unlike NarP, also recognized term C of CD40 at a dilution 1:500.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="1310">
                    <text>anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit also binds to these sites 7-2-7, but, unlike NarP, it also recognized term C of CD40 at a dilution 1:500 .</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="1311">
                    <text>anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit also binds to these sites 7-2-7, but, unlike NarP, it also recognized term C of CD40 at a dilution 1:500.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="1312">
                    <text>anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit are able to recognize term C of CD40 at a dilution 1:500 in regulated promoters.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="1313">
                    <text>anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit binds to these 727 sites but, unlike NarP, will also recognize term C of CD40 at a dilution 1:500.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="1314">
                    <text>anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit can recognize term C of CD40 at a dilution 1:500 in regulated promoters.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="1315">
                    <text>anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit recognized term C of CD40 at a dilution 1:500.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="1316">
                    <text>anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit recognizes term C of CD40 at a dilution 1:500.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="1317">
                    <text>anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit specifically recognized term C of CD40 at a dilution 1:500.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="1318">
                    <text>anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit that has recognized term C of CD40 at a dilution 1:500 was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="1319">
                    <text>anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit that recognized term C of CD40 at a dilution 1:500 was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="1320">
                    <text>anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit that recognizes term C of CD40 at a dilution 1:500 is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="1321">
                    <text>anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit will recognize term C of CD40 at a dilution 1:500 in regulated promoters.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="1322">
                    <text>anti-LMP-1 anti-LMP-1 purified affinity also binds to these 727 sites but, unlike NarP, also recognized epiptopes in the C-terminal of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1323">
                    <text>anti-LMP-1 anti-LMP-1 purified affinity also binds to these 727 sites but, unlike NarP, also recognized epitopes in the terminal C of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1324">
                    <text>anti-LMP-1 anti-LMP-1 purified affinity also binds to these sites 7-2-7, but, unlike NarP, it also recognized epiptopes in the C-terminal of LMP-1 at a 1:200 dilution .</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1325">
                    <text>anti-LMP-1 anti-LMP-1 purified affinity also binds to these sites 7-2-7, but, unlike NarP, it also recognized epiptopes in the C-terminal of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1326">
                    <text>anti-LMP-1 anti-LMP-1 purified affinity also binds to these sites 7-2-7, but, unlike NarP, it also recognized epitopes in the terminal C of LMP-1 at a 1:200 dilution .</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1327">
                    <text>anti-LMP-1 anti-LMP-1 purified affinity also binds to these sites 7-2-7, but, unlike NarP, it also recognized epitopes in the terminal C of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1328">
                    <text>anti-LMP-1 anti-LMP-1 purified affinity are able to recognize epiptopes in the C-terminal of LMP-1 at a 1:200 dilution in regulated promoters.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1329">
                    <text>anti-LMP-1 anti-LMP-1 purified affinity are able to recognize epitopes in the terminal C of LMP-1 at a 1:200 dilution in regulated promoters.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1330">
                    <text>anti-LMP-1 anti-LMP-1 purified affinity binds to these 727 sites but, unlike NarP, will also recognize epitopes in the terminal C of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1331">
                    <text>anti-LMP-1 anti-LMP-1 purified affinity binds to these sites 7-2-7, but, unlike NarP, it also recognizes epiptopes in the C-terminal of LMP-1 at a 1:200 dilution .</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1332">
                    <text>anti-LMP-1 anti-LMP-1 purified affinity binds to these sites 7-2-7, but, unlike NarP, it also recognizes epitopes in the terminal C of LMP-1 at a 1:200 dilution .</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1333">
                    <text>anti-LMP-1 anti-LMP-1 purified affinity can recognize epitopes in the terminal C of LMP-1 at a 1:200 dilution in regulated promoters.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1334">
                    <text>anti-LMP-1 anti-LMP-1 purified affinity has also joined these 727 sites but, unlike NarP, has also recognized epiptopes in the C-terminal of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1335">
                    <text>anti-LMP-1 anti-LMP-1 purified affinity has also joined these 727 sites but, unlike NarP, has also recognized epitopes in the terminal C of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1336">
                    <text>anti-LMP-1 anti-LMP-1 purified affinity is able to recognize epiptopes in the C-terminal of LMP-1 at a 1:200 dilution in regulated promoters.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1337">
                    <text>anti-LMP-1 anti-LMP-1 purified affinity recognized epiptopes in the C-terminal of LMP-1 at a 1:200 dilution in regulated promoters.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1338">
                    <text>anti-LMP-1 anti-LMP-1 purified affinity recognized epiptopes in the C-terminal of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1339">
                    <text>anti-LMP-1 anti-LMP-1 purified affinity recognized epitopes in the terminal C of LMP-1 at a 1:200 dilution in regulated promoters.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1340">
                    <text>anti-LMP-1 anti-LMP-1 purified affinity recognized epitopes in the terminal C of LMP-1 at a 1:200 dilution in the regulated promoters.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1341">
                    <text>anti-LMP-1 anti-LMP-1 purified affinity recognized epitopes in the terminal C of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1342">
                    <text>anti-LMP-1 anti-LMP-1 purified affinity recognizes epiptopes in the C-terminal of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1343">
                    <text>anti-LMP-1 anti-LMP-1 purified affinity recognizes epitopes in the terminal C of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1344">
                    <text>anti-LMP-1 anti-LMP-1 purified affinity specifically recognized epiptopes in the C-terminal of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1345">
                    <text>anti-LMP-1 anti-LMP-1 purified affinity specifically recognized epitopes in the terminal C of LMP-1 at a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1346">
                    <text>anti-LMP-1 anti-LMP-1 purified affinity that has recognized epiptopes in the C-terminal of LMP-1 at a 1:200 dilution was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1347">
                    <text>anti-LMP-1 anti-LMP-1 purified affinity that has recognized epitopes in the terminal C of LMP-1 at a 1:200 dilution was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1348">
                    <text>anti-LMP-1 anti-LMP-1 purified affinity that recognized epiptopes in the C-terminal of LMP-1 at a 1:200 dilution was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1349">
                    <text>anti-LMP-1 anti-LMP-1 purified affinity that recognized epitopes in the terminal C of LMP-1 at a 1:200 dilution was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1350">
                    <text>anti-LMP-1 anti-LMP-1 purified affinity that recognizes epiptopes in the C-terminal of LMP-1 at a 1:200 dilution is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1351">
                    <text>anti-LMP-1 anti-LMP-1 purified affinity that recognizes epiptopes in the C-terminal of LMP-1 at a 1:200 dilution is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1352">
                    <text>anti-LMP-1 anti-LMP-1 purified affinity that recognizes epitopes in the terminal C of LMP-1 at a 1:200 dilution is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1353">
                    <text>anti-LMP-1 anti-LMP-1 purified affinity that recognizes epitopes in the terminal C of LMP-1 at a 1:200 dilution is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1354">
                    <text>anti-LMP-1 anti-LMP-1 purified affinity will recognize epiptopes in the C-terminal of LMP-1 at a 1:200 dilution in regulated promoters.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1355">
                    <text>anti-LMP-1 anti-LMP-1 purified affinity will recognize epitopes in the terminal C of LMP-1 at a 1:200 dilution in regulated promoters.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1356">
                    <text>anti-LMP-1 antisembly purified also binds to these 727 sites but, unlike NarP, also recognized epiptopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1357">
                    <text>anti-LMP-1 antisembly purified also binds to these 727 sites but, unlike NarP, also recognized epitoped in the C-terminal of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1358">
                    <text>anti-LMP-1 antisembly purified also binds to these sites 7-2-7, but, unlike NarP, it also recognized epiptopes in the C-terminal of LMP-1 at a dilution 1:200 .</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1359">
                    <text>anti-LMP-1 antisembly purified also binds to these sites 7-2-7, but, unlike NarP, it also recognized epitoped in the C-terminal of LMP-1 in a 1:200 dilution .</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1360">
                    <text>anti-LMP-1 antisembly purified also binds to these sites 7-2-7, but, unlike NarP, it also recognized epitoped in the C-terminal of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1361">
                    <text>anti-LMP-1 antisembly purified are able to recognize epiptopes in the C-terminal of LMP-1 at a dilution 1:200 in regulated promoters.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1362">
                    <text>anti-LMP-1 antisembly purified are able to recognize epitoped in the C-terminal of LMP-1 in a 1:200 dilution in regulated promoters.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1363">
                    <text>anti-LMP-1 antisembly purified binds to these 727 sites but, unlike NarP, will also recognize epiptopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1364">
                    <text>anti-LMP-1 antisembly purified binds to these 727 sites but, unlike NarP, will also recognize epitoped in the C-terminal of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1365">
                    <text>anti-LMP-1 antisembly purified binds to these sites 7-2-7, but, unlike NarP, it also recognizes epitoped in the C-terminal of LMP-1 in a 1:200 dilution .</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1366">
                    <text>anti-LMP-1 antisembly purified can recognize epiptopes in the C-terminal of LMP-1 at a dilution 1:200 in regulated promoters.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1367">
                    <text>anti-LMP-1 antisembly purified can recognize epitoped in the C-terminal of LMP-1 in a 1:200 dilution in regulated promoters.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1368">
                    <text>anti-LMP-1 antisembly purified has also joined these 727 sites but, unlike NarP, has also recognized epiptopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1369">
                    <text>anti-LMP-1 antisembly purified has also joined these 727 sites but, unlike NarP, has also recognized epitoped in the C-terminal of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1370">
                    <text>anti-LMP-1 antisembly purified is able to recognize epiptopes in the C-terminal of LMP-1 at a dilution 1:200 in regulated promoters.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1371">
                    <text>anti-LMP-1 antisembly purified is able to recognize epitoped in the C-terminal of LMP-1 in a 1:200 dilution in regulated promoters.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1372">
                    <text>anti-LMP-1 antisembly purified recognized epiptopes in the C-terminal of LMP-1 at a dilution 1:200 in regulated promoters.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1373">
                    <text>anti-LMP-1 antisembly purified recognized epiptopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1374">
                    <text>anti-LMP-1 antisembly purified recognized epitoped in the C-terminal of LMP-1 in a 1:200 dilution in regulated promoters.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1375">
                    <text>anti-LMP-1 antisembly purified recognized epitoped in the C-terminal of LMP-1 in a 1:200 dilution in the regulated promoters.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1376">
                    <text>anti-LMP-1 antisembly purified recognized epitoped in the C-terminal of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1377">
                    <text>anti-LMP-1 antisembly purified recognizes epiptopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1378">
                    <text>anti-LMP-1 antisembly purified recognizes epitoped in the C-terminal of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1379">
                    <text>anti-LMP-1 antisembly purified specifically recognized epiptopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1380">
                    <text>anti-LMP-1 antisembly purified specifically recognized epitoped in the C-terminal of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1381">
                    <text>anti-LMP-1 antisembly purified that has recognized epiptopes in the C-terminal of LMP-1 at a dilution 1:200 was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1382">
                    <text>anti-LMP-1 antisembly purified that recognized epiptopes in the C-terminal of LMP-1 at a dilution 1:200 was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1383">
                    <text>anti-LMP-1 antisembly purified that recognized epitoped in the C-terminal of LMP-1 in a 1:200 dilution was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1384">
                    <text>anti-LMP-1 antisembly purified that recognizes epitoped in the C-terminal of LMP-1 in a 1:200 dilution is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1385">
                    <text>anti-LMP-1 antisembly purified will recognize epiptopes in the C-terminal of LMP-1 at a dilution 1:200 in regulated promoters.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1386">
                    <text>anti-LMP-1 antisembly purified will recognize epitoped in the C-terminal of LMP-1 in a 1:200 dilution in regulated promoters.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1387">
                    <text>anti-LMP-1 purified affinity antiserum also binds to these 727 sites but, unlike NarP, also recognized epictopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1388">
                    <text>anti-LMP-1 purified affinity antiserum also binds to these 727 sites but, unlike NarP, also recognized epiptopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1389">
                    <text>anti-LMP-1 purified affinity antiserum also binds to these sites 7-2-7, but, unlike NarP, it also recognized epictopes in the C-terminal of LMP-1 at a dilution 1:200 .</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1390">
                    <text>anti-LMP-1 purified affinity antiserum also binds to these sites 7-2-7, but, unlike NarP, it also recognized epictopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1391">
                    <text>anti-LMP-1 purified affinity antiserum also binds to these sites 7-2-7, but, unlike NarP, it also recognized epiptopes in the C-terminal of LMP-1 at a dilution 1:200 .</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1392">
                    <text>anti-LMP-1 purified affinity antiserum also binds to these sites 7-2-7, but, unlike NarP, it also recognized epiptopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1393">
                    <text>anti-LMP-1 purified affinity antiserum are able to recognize epictopes in the C-terminal of LMP-1 at a dilution 1:200 in regulated promoters.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1394">
                    <text>anti-LMP-1 purified affinity antiserum binds to these 727 sites but, unlike NarP, will also recognize epictopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1395">
                    <text>anti-LMP-1 purified affinity antiserum binds to these 727 sites but, unlike NarP, will also recognize epiptopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1396">
                    <text>anti-LMP-1 purified affinity antiserum binds to these sites 7-2-7, but, unlike NarP, it also recognizes epictopes in the C-terminal of LMP-1 at a dilution 1:200 .</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1397">
                    <text>anti-LMP-1 purified affinity antiserum binds to these sites 7-2-7, but, unlike NarP, it also recognizes epiptopes in the C-terminal of LMP-1 at a dilution 1:200 .</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1398">
                    <text>anti-LMP-1 purified affinity antiserum can recognize epictopes in the C-terminal of LMP-1 at a dilution 1:200 in regulated promoters.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1399">
                    <text>anti-LMP-1 purified affinity antiserum can recognize epiptopes in the C-terminal of LMP-1 at a dilution 1:200 in regulated promoters.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1400">
                    <text>anti-LMP-1 purified affinity antiserum has also joined these 727 sites but, unlike NarP, has also recognized epictopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1401">
                    <text>anti-LMP-1 purified affinity antiserum has also joined these 727 sites but, unlike NarP, has also recognized epiptopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1402">
                    <text>anti-LMP-1 purified affinity antiserum is able to recognize epictopes in the C-terminal of LMP-1 at a dilution 1:200 in regulated promoters.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1403">
                    <text>anti-LMP-1 purified affinity antiserum recognized epictopes in the C-terminal of LMP-1 at a dilution 1:200 in regulated promoters.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1404">
                    <text>anti-LMP-1 purified affinity antiserum recognized epictopes in the C-terminal of LMP-1 at a dilution 1:200 in the regulated promoters.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1405">
                    <text>anti-LMP-1 purified affinity antiserum recognized epiptopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1406">
                    <text>anti-LMP-1 purified affinity antiserum recognizes epictopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1407">
                    <text>anti-LMP-1 purified affinity antiserum specifically recognized epictopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1408">
                    <text>anti-LMP-1 purified affinity antiserum specifically recognized epiptopes in the C-terminal of LMP-1 at a dilution 1:200.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1409">
                    <text>anti-LMP-1 purified affinity antiserum that has recognized epictopes in the C-terminal of LMP-1 at a dilution 1:200 was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1410">
                    <text>anti-LMP-1 purified affinity antiserum that has recognized epiptopes in the C-terminal of LMP-1 at a dilution 1:200 was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1411">
                    <text>anti-LMP-1 purified affinity antiserum that recognized epiptopes in the C-terminal of LMP-1 at a dilution 1:200 was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1412">
                    <text>anti-LMP-1 purified affinity antiserum that recognizes epictopes in the C-terminal of LMP-1 at a dilution 1:200 is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1413">
                    <text>anti-LMP-1 purified affinity antiserum that recognizes epictopes in the C-terminal of LMP-1 at a dilution 1:200 is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1414">
                    <text>anti-LMP-1 purified affinity antiserum that recognizes epiptopes in the C-terminal of LMP-1 at a dilution 1:200 is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1415">
                    <text>anti-LMP-1 purified affinity antiserum that recognizes epiptopes in the C-terminal of LMP-1 at a dilution 1:200 is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1416">
                    <text>anti-LMP-1 purified affinity antiserum will recognize epiptopes in the C-terminal of LMP-1 at a dilution 1:200 in regulated promoters.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1417">
                    <text>anti-Stat3 pAb also binds to these 727 sites but, unlike NarP, also recognized the lowest form of Stat3, Stat3Beta.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="1418">
                    <text>anti-Stat3 pAb also binds to these sites 7-2-7, but, unlike NarP, it also recognized the lowest form of Stat3, Stat3Beta .</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="1419">
                    <text>anti-Stat3 pAb also binds to these sites 7-2-7, but, unlike NarP, it also recognized the lowest form of Stat3, Stat3Beta.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="1420">
                    <text>anti-Stat3 pAb are able to recognize the lowest form of Stat3, Stat3Beta in regulated promoters.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="1421">
                    <text>anti-Stat3 pAb binds to these 727 sites but, unlike NarP, will also recognize the lowest form of Stat3, Stat3Beta.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="1422">
                    <text>anti-Stat3 pAb binds to these sites 7-2-7, but, unlike NarP, it also recognizes the lowest form of Stat3, Stat3Beta .</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="1423">
                    <text>anti-Stat3 pAb can recognize the lowest form of Stat3, Stat3Beta in regulated promoters.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="1424">
                    <text>anti-Stat3 pAb has also joined these 727 sites but, unlike NarP, has also recognized the lowest form of Stat3, Stat3Beta.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="1425">
                    <text>anti-Stat3 pAb is able to recognize the lowest form of Stat3, Stat3Beta in regulated promoters.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="1426">
                    <text>anti-Stat3 pAb recognized the lowest form of Stat3, Stat3Beta in regulated promoters.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="1427">
                    <text>anti-Stat3 pAb recognized the lowest form of Stat3, Stat3Beta in the regulated promoters.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="1428">
                    <text>anti-Stat3 pAb recognizes the lowest form of Stat3, Stat3Beta.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="1429">
                    <text>anti-Stat3 pAb specifically recognized the lowest form of Stat3, Stat3Beta.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="1430">
                    <text>anti-Stat3 pAb that has recognized the lowest form of Stat3, Stat3Beta was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="1431">
                    <text>anti-Stat3 pAb that recognized the lowest form of Stat3, Stat3Beta was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="1432">
                    <text>anti-Stat3 pAb that recognizes the lowest form of Stat3, Stat3Beta is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="1433">
                    <text>anti-Stat3 pAb that recognizes the lowest form of Stat3, Stat3Beta is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="1434">
                    <text>anti-Stat3 pAb will recognize the lowest form of Stat3, Stat3Beta in regulated promoters.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="1435">
                    <text>epictopes in the C-terminal of LMP-1 at a dilution 1:200 are recognized by anti-LMP-1 purified affinity antiserum with which the threads were probed.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1436">
                    <text>epictopes in the C-terminal of LMP-1 at a dilution 1:200 are recognized by anti-LMP-1 purified affinity antiserum with which the wires were probed.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1437">
                    <text>epictopes in the C-terminal of LMP-1 at a dilution 1:200 are recognized by anti-LMP-1 purified affinity antiserum.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1438">
                    <text>epictopes in the C-terminal of LMP-1 at a dilution 1:200 could be recognized in immunoprecipitatio with anti-LMP-1 purified affinity antiserum, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1439">
                    <text>epictopes in the C-terminal of LMP-1 at a dilution 1:200 has been recognized by anti-LMP-1 purified affinity antiserum.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1440">
                    <text>epictopes in the C-terminal of LMP-1 at a dilution 1:200 is recognized by anti-LMP-1 purified affinity antiserum by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1441">
                    <text>epictopes in the C-terminal of LMP-1 at a dilution 1:200 is recognized by anti-LMP-1 purified affinity antiserum by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1442">
                    <text>epictopes in the C-terminal of LMP-1 at a dilution 1:200 is recognized by anti-LMP-1 purified affinity antiserum that the litters were probed.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1443">
                    <text>epictopes in the C-terminal of LMP-1 at a dilution 1:200 is recognized by anti-LMP-1 purified affinity antiserum.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1444">
                    <text>epictopes in the C-terminal of LMP-1 at a dilution 1:200 was recognized by anti-LMP-1 purified affinity antiserum by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1445">
                    <text>epictopes in the C-terminal of LMP-1 at a dilution 1:200 was recognized by anti-LMP-1 purified affinity antiserum.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1446">
                    <text>epictopes in the C-terminal of LMP-1 at a dilution 1:200 was recognized in the immunoprecipitatome with anti-LMP-1 purified affinity antiserum, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1447">
                    <text>epictopes in the C-terminal of LMP-1 at a dilution 1:200 were recognized by anti-LMP-1 purified affinity antiserum.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1448">
                    <text>epictopes in the C-terminal of LMP-1 at a dilution 1:200 will be recognized by anti-LMP-1 purified affinity antiserum.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1449">
                    <text>epictopes in the C-terminal of LMP-1 at a dilution 1:200 will be recognized by the anti-LMP-1 purified affinity antiserum.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1450">
                    <text>epictopes in the C-terminal of LMP-1 at a dilution 1:200 will be recognized in immunoprecipitatio with anti-LMP-1 purified affinity antiserum, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1451">
                    <text>epictopes in the C-terminal of LMP-1 at a dilution 1:200, cannot is recognized in immunoprecipitatio with anti-LMP-1 purified affinity antiserum, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1452">
                    <text>epictopes in the C-terminal of LMP-1 at a dilution 1:200, cannot is recognized in the immunoprecipitaiton with anti-LMP-1 purified affinity antiserum as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1453">
                    <text>epictopes in the C-terminal of LMP-1 at a dilution 1:200, could be recognized in the immunoprecipitaiton with anti-LMP-1 purified affinity antiserum as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1454">
                    <text>epictopes in the C-terminal of LMP-1 at a dilution 1:200, has been recognized in the immunoprecipitaiton with anti-LMP-1 purified affinity antiserum as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1455">
                    <text>epictopes in the C-terminal of LMP-1 at a dilution 1:200, will be recognized in the immunoprecipitaiton with anti-LMP-1 purified affinity antiserum as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epictopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1456">
                    <text>epiptopes in the C-terminal of LMP-1 at a 1:200 dilution are recognized by anti-LMP-1 anti-LMP-1 purified affinity with which the threads were probed.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1457">
                    <text>epiptopes in the C-terminal of LMP-1 at a 1:200 dilution are recognized by anti-LMP-1 anti-LMP-1 purified affinity with which the wires were probed.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1458">
                    <text>epiptopes in the C-terminal of LMP-1 at a 1:200 dilution are recognized by anti-LMP-1 anti-LMP-1 purified affinity.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1459">
                    <text>epiptopes in the C-terminal of LMP-1 at a 1:200 dilution could be recognized in immunoprecipitatio with anti-LMP-1 anti-LMP-1 purified affinity, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1460">
                    <text>epiptopes in the C-terminal of LMP-1 at a 1:200 dilution is recognized by anti-LMP-1 anti-LMP-1 purified affinity by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1461">
                    <text>epiptopes in the C-terminal of LMP-1 at a 1:200 dilution is recognized by anti-LMP-1 anti-LMP-1 purified affinity by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1462">
                    <text>epiptopes in the C-terminal of LMP-1 at a 1:200 dilution is recognized by anti-LMP-1 anti-LMP-1 purified affinity.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1463">
                    <text>epiptopes in the C-terminal of LMP-1 at a 1:200 dilution was recognized by anti-LMP-1 anti-LMP-1 purified affinity by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1464">
                    <text>epiptopes in the C-terminal of LMP-1 at a 1:200 dilution was recognized by anti-LMP-1 anti-LMP-1 purified affinity.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1465">
                    <text>epiptopes in the C-terminal of LMP-1 at a 1:200 dilution were recognized by anti-LMP-1 anti-LMP-1 purified affinity.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1466">
                    <text>epiptopes in the C-terminal of LMP-1 at a 1:200 dilution will be recognized by anti-LMP-1 anti-LMP-1 purified affinity.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1467">
                    <text>epiptopes in the C-terminal of LMP-1 at a 1:200 dilution will be recognized by the anti-LMP-1 anti-LMP-1 purified affinity.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1468">
                    <text>epiptopes in the C-terminal of LMP-1 at a 1:200 dilution will be recognized in immunoprecipitatio with anti-LMP-1 anti-LMP-1 purified affinity, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1469">
                    <text>epiptopes in the C-terminal of LMP-1 at a 1:200 dilution, cannot is recognized in immunoprecipitatio with anti-LMP-1 anti-LMP-1 purified affinity, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1470">
                    <text>epiptopes in the C-terminal of LMP-1 at a 1:200 dilution, cannot is recognized in the immunoprecipitaiton with anti-LMP-1 anti-LMP-1 purified affinity as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1471">
                    <text>epiptopes in the C-terminal of LMP-1 at a 1:200 dilution, could be recognized in the immunoprecipitaiton with anti-LMP-1 anti-LMP-1 purified affinity as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1472">
                    <text>epiptopes in the C-terminal of LMP-1 at a 1:200 dilution, has been recognized in the immunoprecipitaiton with anti-LMP-1 anti-LMP-1 purified affinity as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1473">
                    <text>epiptopes in the C-terminal of LMP-1 at a 1:200 dilution, was not recognized in the immunoprecipitaiton with anti-LMP-1 anti-LMP-1 purified affinity as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1474">
                    <text>epiptopes in the C-terminal of LMP-1 at a 1:200 dilution, was unrecognized in immunoprecipitatio with anti-LMP-1 anti-LMP-1 purified affinity, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1475">
                    <text>epiptopes in the C-terminal of LMP-1 at a 1:200 dilution, will be recognized in the immunoprecipitaiton with anti-LMP-1 anti-LMP-1 purified affinity as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1476">
                    <text>epiptopes in the C-terminal of LMP-1 at a dilution 1:200 are recognized by anti-LMP-1 antisembly purified with which the wires were probed.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1477">
                    <text>epiptopes in the C-terminal of LMP-1 at a dilution 1:200 are recognized by anti-LMP-1 purified affinity antiserum with which the threads were probed.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1478">
                    <text>epiptopes in the C-terminal of LMP-1 at a dilution 1:200 are recognized by anti-LMP-1 purified affinity antiserum with which the wires were probed.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1479">
                    <text>epiptopes in the C-terminal of LMP-1 at a dilution 1:200 could be recognized in immunoprecipitatio with anti-LMP-1 antisembly purified, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1480">
                    <text>epiptopes in the C-terminal of LMP-1 at a dilution 1:200 has been recognized by anti-LMP-1 antisembly purified.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1481">
                    <text>epiptopes in the C-terminal of LMP-1 at a dilution 1:200 has been recognized by anti-LMP-1 purified affinity antiserum.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1482">
                    <text>epiptopes in the C-terminal of LMP-1 at a dilution 1:200 is recognized by anti-LMP-1 antisembly purified by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1483">
                    <text>epiptopes in the C-terminal of LMP-1 at a dilution 1:200 is recognized by anti-LMP-1 antisembly purified that the litters were probed.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1484">
                    <text>epiptopes in the C-terminal of LMP-1 at a dilution 1:200 is recognized by anti-LMP-1 antisembly purified.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1485">
                    <text>epiptopes in the C-terminal of LMP-1 at a dilution 1:200 is recognized by anti-LMP-1 purified affinity antiserum by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1486">
                    <text>epiptopes in the C-terminal of LMP-1 at a dilution 1:200 is recognized by anti-LMP-1 purified affinity antiserum by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1487">
                    <text>epiptopes in the C-terminal of LMP-1 at a dilution 1:200 is recognized by anti-LMP-1 purified affinity antiserum that the litters were probed.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1488">
                    <text>epiptopes in the C-terminal of LMP-1 at a dilution 1:200 is recognized by anti-LMP-1 purified affinity antiserum.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1489">
                    <text>epiptopes in the C-terminal of LMP-1 at a dilution 1:200 was recognized by anti-LMP-1 antisembly purified by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1490">
                    <text>epiptopes in the C-terminal of LMP-1 at a dilution 1:200 was recognized by anti-LMP-1 purified affinity antiserum by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1491">
                    <text>epiptopes in the C-terminal of LMP-1 at a dilution 1:200 was recognized by anti-LMP-1 purified affinity antiserum.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1492">
                    <text>epiptopes in the C-terminal of LMP-1 at a dilution 1:200 was recognized in the immunoprecipitatome with anti-LMP-1 antisembly purified, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1493">
                    <text>epiptopes in the C-terminal of LMP-1 at a dilution 1:200 was recognized in the immunoprecipitatome with anti-LMP-1 purified affinity antiserum, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1494">
                    <text>epiptopes in the C-terminal of LMP-1 at a dilution 1:200 were recognized by anti-LMP-1 antisembly purified.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1495">
                    <text>epiptopes in the C-terminal of LMP-1 at a dilution 1:200 were recognized by anti-LMP-1 purified affinity antiserum.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1496">
                    <text>epiptopes in the C-terminal of LMP-1 at a dilution 1:200 will be recognized by anti-LMP-1 purified affinity antiserum.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1497">
                    <text>epiptopes in the C-terminal of LMP-1 at a dilution 1:200 will be recognized by the anti-LMP-1 antisembly purified.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1498">
                    <text>epiptopes in the C-terminal of LMP-1 at a dilution 1:200 will be recognized by the anti-LMP-1 purified affinity antiserum.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1499">
                    <text>epiptopes in the C-terminal of LMP-1 at a dilution 1:200 will be recognized in immunoprecipitatio with anti-LMP-1 antisembly purified, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1500">
                    <text>epiptopes in the C-terminal of LMP-1 at a dilution 1:200, cannot is recognized in immunoprecipitatio with anti-LMP-1 antisembly purified, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1501">
                    <text>epiptopes in the C-terminal of LMP-1 at a dilution 1:200, cannot is recognized in immunoprecipitatio with anti-LMP-1 purified affinity antiserum, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1502">
                    <text>epiptopes in the C-terminal of LMP-1 at a dilution 1:200, cannot is recognized in the immunoprecipitaiton with anti-LMP-1 antisembly purified as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1503">
                    <text>epiptopes in the C-terminal of LMP-1 at a dilution 1:200, cannot is recognized in the immunoprecipitaiton with anti-LMP-1 purified affinity antiserum as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1504">
                    <text>epiptopes in the C-terminal of LMP-1 at a dilution 1:200, could be recognized in the immunoprecipitaiton with anti-LMP-1 antisembly purified as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1505">
                    <text>epiptopes in the C-terminal of LMP-1 at a dilution 1:200, could be recognized in the immunoprecipitaiton with anti-LMP-1 purified affinity antiserum as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1506">
                    <text>epiptopes in the C-terminal of LMP-1 at a dilution 1:200, has been recognized in the immunoprecipitaiton with anti-LMP-1 antisembly purified as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1507">
                    <text>epiptopes in the C-terminal of LMP-1 at a dilution 1:200, was not recognized in the immunoprecipitaiton with anti-LMP-1 antisembly purified as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1508">
                    <text>epiptopes in the C-terminal of LMP-1 at a dilution 1:200, was unrecognized in immunoprecipitatio with anti-LMP-1 antisembly purified, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1509">
                    <text>epiptopes in the C-terminal of LMP-1 at a dilution 1:200, was unrecognized in immunoprecipitatio with anti-LMP-1 purified affinity antiserum, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 purified affinity antiserum</arg>
                    <arg n="1">epiptopes in the C-terminal of LMP-1 at a dilution 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1510">
                    <text>epitoped in the C-terminal of LMP-1 in a 1:200 dilution are recognized by anti-LMP-1 antisembly purified.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1511">
                    <text>epitoped in the C-terminal of LMP-1 in a 1:200 dilution could be recognized in immunoprecipitatio with anti-LMP-1 antisembly purified, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1512">
                    <text>epitoped in the C-terminal of LMP-1 in a 1:200 dilution has been recognized by anti-LMP-1 antisembly purified.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1513">
                    <text>epitoped in the C-terminal of LMP-1 in a 1:200 dilution is recognized by anti-LMP-1 antisembly purified by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1514">
                    <text>epitoped in the C-terminal of LMP-1 in a 1:200 dilution is recognized by anti-LMP-1 antisembly purified by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1515">
                    <text>epitoped in the C-terminal of LMP-1 in a 1:200 dilution is recognized by anti-LMP-1 antisembly purified that the litters were probed.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1516">
                    <text>epitoped in the C-terminal of LMP-1 in a 1:200 dilution is recognized by anti-LMP-1 antisembly purified.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1517">
                    <text>epitoped in the C-terminal of LMP-1 in a 1:200 dilution was recognized by anti-LMP-1 antisembly purified by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1518">
                    <text>epitoped in the C-terminal of LMP-1 in a 1:200 dilution was recognized by anti-LMP-1 antisembly purified.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1519">
                    <text>epitoped in the C-terminal of LMP-1 in a 1:200 dilution was recognized in the immunoprecipitatome with anti-LMP-1 antisembly purified, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1520">
                    <text>epitoped in the C-terminal of LMP-1 in a 1:200 dilution were recognized by anti-LMP-1 antisembly purified.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1521">
                    <text>epitoped in the C-terminal of LMP-1 in a 1:200 dilution will be recognized by anti-LMP-1 antisembly purified.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1522">
                    <text>epitoped in the C-terminal of LMP-1 in a 1:200 dilution will be recognized by the anti-LMP-1 antisembly purified.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1523">
                    <text>epitoped in the C-terminal of LMP-1 in a 1:200 dilution will be recognized in immunoprecipitatio with anti-LMP-1 antisembly purified, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1524">
                    <text>epitoped in the C-terminal of LMP-1 in a 1:200 dilution, cannot is recognized in immunoprecipitatio with anti-LMP-1 antisembly purified, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1525">
                    <text>epitoped in the C-terminal of LMP-1 in a 1:200 dilution, cannot is recognized in the immunoprecipitaiton with anti-LMP-1 antisembly purified as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1526">
                    <text>epitoped in the C-terminal of LMP-1 in a 1:200 dilution, could be recognized in the immunoprecipitaiton with anti-LMP-1 antisembly purified as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1527">
                    <text>epitoped in the C-terminal of LMP-1 in a 1:200 dilution, was not recognized in the immunoprecipitaiton with anti-LMP-1 antisembly purified as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1528">
                    <text>epitoped in the C-terminal of LMP-1 in a 1:200 dilution, was unrecognized in immunoprecipitatio with anti-LMP-1 antisembly purified, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1529">
                    <text>epitoped in the C-terminal of LMP-1 in a 1:200 dilution, will be recognized in the immunoprecipitaiton with anti-LMP-1 antisembly purified as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 antisembly purified</arg>
                    <arg n="1">epitoped in the C-terminal of LMP-1 in a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1530">
                    <text>epitopes in the C muscle of LMP-1 at a dilution of 1:200 are recognized by polyclonal anti-LMP-1 affinity antisumption with which the threads were probed.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1531">
                    <text>epitopes in the C muscle of LMP-1 at a dilution of 1:200 are recognized by polyclonal anti-LMP-1 affinity antisumption with which the wires were probed.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1532">
                    <text>epitopes in the C muscle of LMP-1 at a dilution of 1:200 are recognized by polyclonal anti-LMP-1 affinity antisumption.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1533">
                    <text>epitopes in the C muscle of LMP-1 at a dilution of 1:200 could be recognized in immunoprecipitatio with polyclonal anti-LMP-1 affinity antisumption, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1534">
                    <text>epitopes in the C muscle of LMP-1 at a dilution of 1:200 has been recognized by polyclonal anti-LMP-1 affinity antisumption.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1535">
                    <text>epitopes in the C muscle of LMP-1 at a dilution of 1:200 is recognized by polyclonal anti-LMP-1 affinity antisumption by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1536">
                    <text>epitopes in the C muscle of LMP-1 at a dilution of 1:200 is recognized by polyclonal anti-LMP-1 affinity antisumption by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1537">
                    <text>epitopes in the C muscle of LMP-1 at a dilution of 1:200 is recognized by polyclonal anti-LMP-1 affinity antisumption that the litters were probed.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1538">
                    <text>epitopes in the C muscle of LMP-1 at a dilution of 1:200 is recognized by polyclonal anti-LMP-1 affinity antisumption.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1539">
                    <text>epitopes in the C muscle of LMP-1 at a dilution of 1:200 was recognized by polyclonal anti-LMP-1 affinity antisumption by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1540">
                    <text>epitopes in the C muscle of LMP-1 at a dilution of 1:200 was recognized by polyclonal anti-LMP-1 affinity antisumption.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1541">
                    <text>epitopes in the C muscle of LMP-1 at a dilution of 1:200 was recognized in the immunoprecipitatome with polyclonal anti-LMP-1 affinity antisumption, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1542">
                    <text>epitopes in the C muscle of LMP-1 at a dilution of 1:200 were recognized by polyclonal anti-LMP-1 affinity antisumption.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1543">
                    <text>epitopes in the C muscle of LMP-1 at a dilution of 1:200 will be recognized by polyclonal anti-LMP-1 affinity antisumption.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1544">
                    <text>epitopes in the C muscle of LMP-1 at a dilution of 1:200 will be recognized by the polyclonal anti-LMP-1 affinity antisumption.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1545">
                    <text>epitopes in the C muscle of LMP-1 at a dilution of 1:200 will be recognized in immunoprecipitatio with polyclonal anti-LMP-1 affinity antisumption, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1546">
                    <text>epitopes in the C muscle of LMP-1 at a dilution of 1:200, cannot is recognized in immunoprecipitatio with polyclonal anti-LMP-1 affinity antisumption, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1547">
                    <text>epitopes in the C muscle of LMP-1 at a dilution of 1:200, cannot is recognized in the immunoprecipitaiton with polyclonal anti-LMP-1 affinity antisumption as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1548">
                    <text>epitopes in the C muscle of LMP-1 at a dilution of 1:200, could be recognized in the immunoprecipitaiton with polyclonal anti-LMP-1 affinity antisumption as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1549">
                    <text>epitopes in the C muscle of LMP-1 at a dilution of 1:200, has been recognized in the immunoprecipitaiton with polyclonal anti-LMP-1 affinity antisumption as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1550">
                    <text>epitopes in the C muscle of LMP-1 at a dilution of 1:200, was unrecognized in immunoprecipitatio with polyclonal anti-LMP-1 affinity antisumption, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1551">
                    <text>epitopes in the C muscle of LMP-1 at a dilution of 1:200, will be recognized in the immunoprecipitaiton with polyclonal anti-LMP-1 affinity antisumption as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1552">
                    <text>epitopes in the terminal C of LMP-1 at a 1:200 dilution are recognized by anti-LMP-1 anti-LMP-1 purified affinity with which the threads were probed.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1553">
                    <text>epitopes in the terminal C of LMP-1 at a 1:200 dilution are recognized by anti-LMP-1 anti-LMP-1 purified affinity with which the wires were probed.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1554">
                    <text>epitopes in the terminal C of LMP-1 at a 1:200 dilution are recognized by anti-LMP-1 anti-LMP-1 purified affinity.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1555">
                    <text>epitopes in the terminal C of LMP-1 at a 1:200 dilution could be recognized in immunoprecipitatio with anti-LMP-1 anti-LMP-1 purified affinity, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1556">
                    <text>epitopes in the terminal C of LMP-1 at a 1:200 dilution has been recognized by anti-LMP-1 anti-LMP-1 purified affinity.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1557">
                    <text>epitopes in the terminal C of LMP-1 at a 1:200 dilution is recognized by anti-LMP-1 anti-LMP-1 purified affinity by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1558">
                    <text>epitopes in the terminal C of LMP-1 at a 1:200 dilution is recognized by anti-LMP-1 anti-LMP-1 purified affinity by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1559">
                    <text>epitopes in the terminal C of LMP-1 at a 1:200 dilution is recognized by anti-LMP-1 anti-LMP-1 purified affinity that the litters were probed.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1560">
                    <text>epitopes in the terminal C of LMP-1 at a 1:200 dilution is recognized by anti-LMP-1 anti-LMP-1 purified affinity.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1561">
                    <text>epitopes in the terminal C of LMP-1 at a 1:200 dilution was recognized by anti-LMP-1 anti-LMP-1 purified affinity by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1562">
                    <text>epitopes in the terminal C of LMP-1 at a 1:200 dilution was recognized by anti-LMP-1 anti-LMP-1 purified affinity.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1563">
                    <text>epitopes in the terminal C of LMP-1 at a 1:200 dilution were recognized by anti-LMP-1 anti-LMP-1 purified affinity.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1564">
                    <text>epitopes in the terminal C of LMP-1 at a 1:200 dilution will be recognized by anti-LMP-1 anti-LMP-1 purified affinity.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1565">
                    <text>epitopes in the terminal C of LMP-1 at a 1:200 dilution will be recognized by the anti-LMP-1 anti-LMP-1 purified affinity.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1566">
                    <text>epitopes in the terminal C of LMP-1 at a 1:200 dilution will be recognized in immunoprecipitatio with anti-LMP-1 anti-LMP-1 purified affinity, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1567">
                    <text>epitopes in the terminal C of LMP-1 at a 1:200 dilution, cannot is recognized in the immunoprecipitaiton with anti-LMP-1 anti-LMP-1 purified affinity as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1568">
                    <text>epitopes in the terminal C of LMP-1 at a 1:200 dilution, could be recognized in the immunoprecipitaiton with anti-LMP-1 anti-LMP-1 purified affinity as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1569">
                    <text>epitopes in the terminal C of LMP-1 at a 1:200 dilution, has been recognized in the immunoprecipitaiton with anti-LMP-1 anti-LMP-1 purified affinity as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1570">
                    <text>epitopes in the terminal C of LMP-1 at a 1:200 dilution, was not recognized in the immunoprecipitaiton with anti-LMP-1 anti-LMP-1 purified affinity as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1571">
                    <text>epitopes in the terminal C of LMP-1 at a 1:200 dilution, was unrecognized in immunoprecipitatio with anti-LMP-1 anti-LMP-1 purified affinity, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1572">
                    <text>epitopes in the terminal C of LMP-1 at a 1:200 dilution, will be recognized in the immunoprecipitaiton with anti-LMP-1 anti-LMP-1 purified affinity as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-LMP-1 anti-LMP-1 purified affinity</arg>
                    <arg n="1">epitopes in the terminal C of LMP-1 at a 1:200 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1573">
                    <text>four different specific antibodies recognized A1 (epitopes in the C muscle of LMP-1 in dilution 1:200.</text>
                    <arg n="0">four different specific antibodies</arg>
                </example>
                <example src="PERMUTATE" no="1574">
                    <text>heptameric in other arrangements are recognized by NarL protein with which the threads were probed.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1575">
                    <text>heptameric in other arrangements are recognized by NarL protein with which the wires were probed.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1576">
                    <text>heptameric in other arrangements are recognized by NarL protein.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1577">
                    <text>heptameric in other arrangements has been recognized by NarL protein.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1578">
                    <text>heptameric in other arrangements is recognized by NarL protein by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1579">
                    <text>heptameric in other arrangements is recognized by NarL protein that the litters were probed.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1580">
                    <text>heptameric in other arrangements is recognized by NarL protein.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1581">
                    <text>heptameric in other arrangements was recognized by NarL protein by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1582">
                    <text>heptameric in other arrangements was recognized by NarL protein.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1583">
                    <text>heptameric in other arrangements was recognized in the immunoprecipitatome with NarL protein, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1584">
                    <text>heptameric in other arrangements were recognized by NarL protein.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1585">
                    <text>heptameric in other arrangements will be recognized by NarL protein.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1586">
                    <text>heptameric in other arrangements will be recognized by the NarL protein.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1587">
                    <text>heptameric in other arrangements will be recognized in immunoprecipitatio with NarL protein, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1588">
                    <text>heptameric in other arrangements, cannot is recognized in immunoprecipitatio with NarL protein, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1589">
                    <text>heptameric in other arrangements, cannot is recognized in the immunoprecipitaiton with NarL protein as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1590">
                    <text>heptameric in other arrangements, could be recognized in the immunoprecipitaiton with NarL protein as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1591">
                    <text>heptameric in other arrangements, has been recognized in the immunoprecipitaiton with NarL protein as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1592">
                    <text>heptameric in other arrangements, was unrecognized in immunoprecipitatio with NarL protein, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptameric in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1593">
                    <text>heptamers in other arrangements are recognized by NarL protein with which the threads were probed.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1594">
                    <text>heptamers in other arrangements are recognized by NarL protein with which the wires were probed.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1595">
                    <text>heptamers in other arrangements are recognized by NarL protein.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1596">
                    <text>heptamers in other arrangements are recognized by the NarL protein with which the threads were probed.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1597">
                    <text>heptamers in other arrangements are recognized by the NarL protein with which the wires were probed.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1598">
                    <text>heptamers in other arrangements are recognized by the NarL protein.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1599">
                    <text>heptamers in other arrangements could be recognized in immunoprecipitatio with NarL protein, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1600">
                    <text>heptamers in other arrangements could be recognized in immunoprecipitatio with the NarL protein, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1601">
                    <text>heptamers in other arrangements has been recognized by NarL protein.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1602">
                    <text>heptamers in other arrangements has been recognized by the NarL protein.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1603">
                    <text>heptamers in other arrangements is recognized by NarL protein by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1604">
                    <text>heptamers in other arrangements is recognized by NarL protein by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1605">
                    <text>heptamers in other arrangements is recognized by NarL protein that the litters were probed.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1606">
                    <text>heptamers in other arrangements is recognized by NarL protein.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1607">
                    <text>heptamers in other arrangements is recognized by the NarL protein by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1608">
                    <text>heptamers in other arrangements is recognized by the NarL protein that the litters were probed.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1609">
                    <text>heptamers in other arrangements is recognized by the NarL protein.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1610">
                    <text>heptamers in other arrangements was recognized by NarL protein by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1611">
                    <text>heptamers in other arrangements was recognized by NarL protein.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1612">
                    <text>heptamers in other arrangements was recognized by the NarL protein.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1613">
                    <text>heptamers in other arrangements was recognized in the immunoprecipitatome with NarL protein, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1614">
                    <text>heptamers in other arrangements was recognized in the immunoprecipitatome with the NarL protein, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1615">
                    <text>heptamers in other arrangements were recognized by the NarL protein.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1616">
                    <text>heptamers in other arrangements will be recognized by NarL protein.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1617">
                    <text>heptamers in other arrangements will be recognized by the NarL protein.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1618">
                    <text>heptamers in other arrangements will be recognized in immunoprecipitatio with NarL protein, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1619">
                    <text>heptamers in other arrangements will be recognized in immunoprecipitatio with the NarL protein, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1620">
                    <text>heptamers in other arrangements, cannot is recognized in immunoprecipitatio with NarL protein, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1621">
                    <text>heptamers in other arrangements, cannot is recognized in immunoprecipitatio with the NarL protein, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1622">
                    <text>heptamers in other arrangements, cannot is recognized in the immunoprecipitaiton with the NarL protein as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1623">
                    <text>heptamers in other arrangements, could be recognized in the immunoprecipitaiton with NarL protein as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1624">
                    <text>heptamers in other arrangements, could be recognized in the immunoprecipitaiton with the NarL protein as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1625">
                    <text>heptamers in other arrangements, has been recognized in the immunoprecipitaiton with NarL protein as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1626">
                    <text>heptamers in other arrangements, has been recognized in the immunoprecipitaiton with the NarL protein as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1627">
                    <text>heptamers in other arrangements, was not recognized in the immunoprecipitaiton with NarL protein as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1628">
                    <text>heptamers in other arrangements, was not recognized in the immunoprecipitaiton with the NarL protein as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1629">
                    <text>heptamers in other arrangements, was unrecognized in immunoprecipitatio with NarL protein, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1630">
                    <text>heptamers in other arrangements, was unrecognized in immunoprecipitatio with the NarL protein, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1631">
                    <text>heptamers in other arrangements, will be recognized in the immunoprecipitaiton with NarL protein as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1632">
                    <text>heptamers in other arrangements, will be recognized in the immunoprecipitaiton with the NarL protein as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="1633">
                    <text>monoclonal antibody also binds to these 727 sites but, unlike NarP, also recognized N-terminus STAT1.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="1634">
                    <text>monoclonal antibody also binds to these 727 sites but, unlike NarP, also recognized STAT1 N-terminal.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="1635">
                    <text>monoclonal antibody also binds to these 727 sites but, unlike NarP, also recognized STAT1 N-terminus.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="1636">
                    <text>monoclonal antibody also binds to these sites 7-2-7, but, unlike NarP, it also recognized N-terminus STAT1 .</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="1637">
                    <text>monoclonal antibody also binds to these sites 7-2-7, but, unlike NarP, it also recognized N-terminus STAT1.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="1638">
                    <text>monoclonal antibody also binds to these sites 7-2-7, but, unlike NarP, it also recognized STAT1 N-terminal.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="1639">
                    <text>monoclonal antibody also binds to these sites 7-2-7, but, unlike NarP, it also recognized STAT1 N-terminus .</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="1640">
                    <text>monoclonal antibody also binds to these sites 7-2-7, but, unlike NarP, it also recognized STAT1 N-terminus.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="1641">
                    <text>monoclonal antibody are able to recognize N-terminus STAT1 in regulated promoters.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="1642">
                    <text>monoclonal antibody are able to recognize STAT1 N-terminus in regulated promoters.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="1643">
                    <text>monoclonal antibody binds to these 727 sites but, unlike NarP, will also recognize N-terminus STAT1.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="1644">
                    <text>monoclonal antibody binds to these 727 sites but, unlike NarP, will also recognize STAT1 N-terminal.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="1645">
                    <text>monoclonal antibody binds to these sites 7-2-7, but, unlike NarP, it also recognizes N-terminus STAT1 .</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="1646">
                    <text>monoclonal antibody binds to these sites 7-2-7, but, unlike NarP, it also recognizes STAT1 N-terminal .</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="1647">
                    <text>monoclonal antibody binds to these sites 7-2-7, but, unlike NarP, it also recognizes STAT1 N-terminus .</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="1648">
                    <text>monoclonal antibody can recognize N-terminus STAT1 in regulated promoters.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="1649">
                    <text>monoclonal antibody can recognize STAT1 N-terminal in regulated promoters.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="1650">
                    <text>monoclonal antibody can recognize STAT1 N-terminus in regulated promoters.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="1651">
                    <text>monoclonal antibody has also joined these 727 sites but, unlike NarP, has also recognized STAT1 N-terminal.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="1652">
                    <text>monoclonal antibody has also joined these 727 sites but, unlike NarP, has also recognized STAT1 N-terminus.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="1653">
                    <text>monoclonal antibody is able to recognize STAT1 N-terminal in regulated promoters.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="1654">
                    <text>monoclonal antibody is able to recognize STAT1 N-terminus in regulated promoters.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="1655">
                    <text>monoclonal antibody recognized N-terminus STAT1 in regulated promoters.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="1656">
                    <text>monoclonal antibody recognized N-terminus STAT1 in the regulated promoters.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="1657">
                    <text>monoclonal antibody recognized N-terminus STAT1.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="1658">
                    <text>monoclonal antibody recognized STAT1 N-terminal in regulated promoters.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="1659">
                    <text>monoclonal antibody recognized STAT1 N-terminal in the regulated promoters.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="1660">
                    <text>monoclonal antibody recognized STAT1 N-terminal.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="1661">
                    <text>monoclonal antibody recognized STAT1 N-terminus in regulated promoters.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="1662">
                    <text>monoclonal antibody recognized STAT1 N-terminus in the regulated promoters.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="1663">
                    <text>monoclonal antibody recognized STAT1 N-terminus.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="1664">
                    <text>monoclonal antibody recognizes N-terminus STAT1.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="1665">
                    <text>monoclonal antibody recognizes STAT1 N-terminal.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="1666">
                    <text>monoclonal antibody recognizes STAT1 N-terminus.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="1667">
                    <text>monoclonal antibody specifically recognized N-terminus STAT1.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="1668">
                    <text>monoclonal antibody specifically recognized STAT1 N-terminal.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="1669">
                    <text>monoclonal antibody specifically recognized STAT1 N-terminus.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="1670">
                    <text>monoclonal antibody that has recognized STAT1 N-terminal was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="1671">
                    <text>monoclonal antibody that has recognized STAT1 N-terminus was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="1672">
                    <text>monoclonal antibody that recognized STAT1 N-terminal was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="1673">
                    <text>monoclonal antibody that recognized STAT1 N-terminus was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="1674">
                    <text>monoclonal antibody that recognizes STAT1 N-terminus is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="1675">
                    <text>monoclonal antibody that recognizes STAT1 N-terminus is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="1676">
                    <text>monoclonal antibody will recognize N-terminus STAT1 in regulated promoters.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">N-terminus STAT1</arg>
                </example>
                <example src="PERMUTATE" no="1677">
                    <text>monoclonal antibody will recognize STAT1 N-terminal in regulated promoters.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="1678">
                    <text>monoclonal antibody will recognize STAT1 N-terminus in regulated promoters.</text>
                    <arg n="0">monoclonal antibody</arg>
                    <arg n="1">STAT1 N-terminus</arg>
                </example>
                <example src="PERMUTATE" no="1679">
                    <text>most of the regulators belonging to the AraC/XylS family also binds to these 727 sites but, unlike NarP, also recognized multi-binding sites.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1680">
                    <text>most of the regulators belonging to the AraC/XylS family also binds to these 727 sites but, unlike NarP, also recognized multiple linkage site.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="1681">
                    <text>most of the regulators belonging to the AraC/XylS family also binds to these 727 sites but, unlike NarP, also recognized multiple-link location.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="1682">
                    <text>most of the regulators belonging to the AraC/XylS family also binds to these sites 7-2-7, but, unlike NarP, it also recognized multi-binding sites .</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1683">
                    <text>most of the regulators belonging to the AraC/XylS family also binds to these sites 7-2-7, but, unlike NarP, it also recognized multi-binding sites.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1684">
                    <text>most of the regulators belonging to the AraC/XylS family also binds to these sites 7-2-7, but, unlike NarP, it also recognized multiple connection site .</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="1685">
                    <text>most of the regulators belonging to the AraC/XylS family also binds to these sites 7-2-7, but, unlike NarP, it also recognized multiple connection site.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="1686">
                    <text>most of the regulators belonging to the AraC/XylS family also binds to these sites 7-2-7, but, unlike NarP, it also recognized multiple linkage site .</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="1687">
                    <text>most of the regulators belonging to the AraC/XylS family also binds to these sites 7-2-7, but, unlike NarP, it also recognized multiple linkage site.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="1688">
                    <text>most of the regulators belonging to the AraC/XylS family also binds to these sites 7-2-7, but, unlike NarP, it also recognized multiple-link location .</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="1689">
                    <text>most of the regulators belonging to the AraC/XylS family are able to recognize multiple connection site in regulated promoters.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="1690">
                    <text>most of the regulators belonging to the AraC/XylS family are able to recognize multiple linkage site in regulated promoters.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="1691">
                    <text>most of the regulators belonging to the AraC/XylS family are able to recognize multiple-link location in regulated promoters.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="1692">
                    <text>most of the regulators belonging to the AraC/XylS family binds to these 727 sites but, unlike NarP, will also recognize multi-binding sites.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1693">
                    <text>most of the regulators belonging to the AraC/XylS family binds to these 727 sites but, unlike NarP, will also recognize multiple connection site.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="1694">
                    <text>most of the regulators belonging to the AraC/XylS family binds to these sites 7-2-7, but, unlike NarP, it also recognizes multi-binding sites .</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1695">
                    <text>most of the regulators belonging to the AraC/XylS family binds to these sites 7-2-7, but, unlike NarP, it also recognizes multiple connection site .</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="1696">
                    <text>most of the regulators belonging to the AraC/XylS family can recognize multi-binding sites in regulated promoters.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1697">
                    <text>most of the regulators belonging to the AraC/XylS family can recognize multiple linkage site in regulated promoters.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="1698">
                    <text>most of the regulators belonging to the AraC/XylS family has also joined these 727 sites but, unlike NarP, has also recognized multi-binding sites.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1699">
                    <text>most of the regulators belonging to the AraC/XylS family has also joined these 727 sites but, unlike NarP, has also recognized multiple connection site.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="1700">
                    <text>most of the regulators belonging to the AraC/XylS family has also joined these 727 sites but, unlike NarP, has also recognized multiple linkage site.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="1701">
                    <text>most of the regulators belonging to the AraC/XylS family is able to recognize multi-binding sites in regulated promoters.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1702">
                    <text>most of the regulators belonging to the AraC/XylS family is able to recognize multiple linkage site in regulated promoters.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="1703">
                    <text>most of the regulators belonging to the AraC/XylS family is able to recognize multiple-link location in regulated promoters.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="1704">
                    <text>most of the regulators belonging to the AraC/XylS family recognized multi-binding sites in regulated promoters.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1705">
                    <text>most of the regulators belonging to the AraC/XylS family recognized multi-binding sites.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1706">
                    <text>most of the regulators belonging to the AraC/XylS family recognized multiple connection site in the regulated promoters.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="1707">
                    <text>most of the regulators belonging to the AraC/XylS family recognized multiple connection site.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="1708">
                    <text>most of the regulators belonging to the AraC/XylS family recognized multiple linkage site in the regulated promoters.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="1709">
                    <text>most of the regulators belonging to the AraC/XylS family recognized multiple linkage site.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="1710">
                    <text>most of the regulators belonging to the AraC/XylS family recognized multiple-link location in regulated promoters.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="1711">
                    <text>most of the regulators belonging to the AraC/XylS family recognized multiple-link location in the regulated promoters.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="1712">
                    <text>most of the regulators belonging to the AraC/XylS family recognized multiple-link location.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="1713">
                    <text>most of the regulators belonging to the AraC/XylS family recognizes multi-binding sites.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1714">
                    <text>most of the regulators belonging to the AraC/XylS family recognizes multiple linkage site.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="1715">
                    <text>most of the regulators belonging to the AraC/XylS family recognizes multiple-link location.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="1716">
                    <text>most of the regulators belonging to the AraC/XylS family specifically recognized multi-binding sites.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1717">
                    <text>most of the regulators belonging to the AraC/XylS family specifically recognized multiple connection site.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="1718">
                    <text>most of the regulators belonging to the AraC/XylS family specifically recognized multiple linkage site.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="1719">
                    <text>most of the regulators belonging to the AraC/XylS family specifically recognized multiple-link location.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="1720">
                    <text>most of the regulators belonging to the AraC/XylS family that has recognized multiple connection site was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="1721">
                    <text>most of the regulators belonging to the AraC/XylS family that has recognized multiple-link location was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="1722">
                    <text>most of the regulators belonging to the AraC/XylS family that recognized multi-binding sites was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1723">
                    <text>most of the regulators belonging to the AraC/XylS family that recognized multiple connection site was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="1724">
                    <text>most of the regulators belonging to the AraC/XylS family that recognized multiple linkage site was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="1725">
                    <text>most of the regulators belonging to the AraC/XylS family that recognized multiple-link location was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="1726">
                    <text>most of the regulators belonging to the AraC/XylS family that recognizes multi-binding sites is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1727">
                    <text>most of the regulators belonging to the AraC/XylS family that recognizes multi-binding sites is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1728">
                    <text>most of the regulators belonging to the AraC/XylS family that recognizes multiple connection site is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="1729">
                    <text>most of the regulators belonging to the AraC/XylS family that recognizes multiple linkage site is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="1730">
                    <text>most of the regulators belonging to the AraC/XylS family that recognizes multiple linkage site is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="1731">
                    <text>most of the regulators belonging to the AraC/XylS family that recognizes multiple-link location is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="1732">
                    <text>most of the regulators belonging to the AraC/XylS family will recognize multi-binding sites in regulated promoters.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1733">
                    <text>most of the regulators belonging to the AraC/XylS family will recognize multiple connection site in regulated promoters.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="1734">
                    <text>most of the regulators belonging to the AraC/XylS family will recognize multiple linkage site in regulated promoters.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="1735">
                    <text>most regulators belonging to the AraC/XylS family also binds to these 727 sites but, unlike NarP, also recognized multiple binding sites.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1736">
                    <text>most regulators belonging to the AraC/XylS family also binds to these sites 7-2-7, but, unlike NarP, it also recognized multiple binding sites .</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1737">
                    <text>most regulators belonging to the AraC/XylS family also binds to these sites 7-2-7, but, unlike NarP, it also recognized multiple binding sites.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1738">
                    <text>most regulators belonging to the AraC/XylS family binds to these 727 sites but, unlike NarP, will also recognize multiple binding sites.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1739">
                    <text>most regulators belonging to the AraC/XylS family binds to these sites 7-2-7, but, unlike NarP, it also recognizes multiple binding sites .</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1740">
                    <text>most regulators belonging to the AraC/XylS family can recognize multiple binding sites in regulated promoters.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1741">
                    <text>most regulators belonging to the AraC/XylS family has also joined these 727 sites but, unlike NarP, has also recognized multiple binding sites.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1742">
                    <text>most regulators belonging to the AraC/XylS family is able to recognize multiple binding sites in regulated promoters.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1743">
                    <text>most regulators belonging to the AraC/XylS family recognized multiple binding sites in regulated promoters.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1744">
                    <text>most regulators belonging to the AraC/XylS family recognized multiple binding sites in the regulated promoters.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1745">
                    <text>most regulators belonging to the AraC/XylS family recognized multiple binding sites.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1746">
                    <text>most regulators belonging to the AraC/XylS family recognizes multiple binding sites.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1747">
                    <text>most regulators belonging to the AraC/XylS family specifically recognized multiple binding sites.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1748">
                    <text>most regulators belonging to the AraC/XylS family that has recognized multiple binding sites was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1749">
                    <text>most regulators belonging to the AraC/XylS family that recognized multiple binding sites was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1750">
                    <text>most regulators belonging to the AraC/XylS family that recognizes multiple binding sites is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1751">
                    <text>most regulators belonging to the AraC/XylS family that recognizes multiple binding sites is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1752">
                    <text>multi-binding sites are recognized by most of the regulators belonging to the AraC/XylS family with which the threads were probed.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1753">
                    <text>multi-binding sites are recognized by most of the regulators belonging to the AraC/XylS family with which the wires were probed.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1754">
                    <text>multi-binding sites are recognized by most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1755">
                    <text>multi-binding sites could be recognized in immunoprecipitatio with most of the regulators belonging to the AraC/XylS family, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1756">
                    <text>multi-binding sites has been recognized by most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1757">
                    <text>multi-binding sites is recognized by most of the regulators belonging to the AraC/XylS family by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1758">
                    <text>multi-binding sites is recognized by most of the regulators belonging to the AraC/XylS family by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1759">
                    <text>multi-binding sites was recognized by most of the regulators belonging to the AraC/XylS family by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1760">
                    <text>multi-binding sites was recognized by most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1761">
                    <text>multi-binding sites was recognized in the immunoprecipitatome with most of the regulators belonging to the AraC/XylS family, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1762">
                    <text>multi-binding sites were recognized by most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1763">
                    <text>multi-binding sites will be recognized by most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1764">
                    <text>multi-binding sites will be recognized by the most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1765">
                    <text>multi-binding sites, cannot is recognized in the immunoprecipitaiton with most of the regulators belonging to the AraC/XylS family as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1766">
                    <text>multi-binding sites, could be recognized in the immunoprecipitaiton with most of the regulators belonging to the AraC/XylS family as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1767">
                    <text>multi-binding sites, has been recognized in the immunoprecipitaiton with most of the regulators belonging to the AraC/XylS family as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1768">
                    <text>multi-binding sites, was unrecognized in immunoprecipitatio with most of the regulators belonging to the AraC/XylS family, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multi-binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1769">
                    <text>multiple binding sites are recognized by most regulators belonging to the AraC/XylS family with which the threads were probed.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1770">
                    <text>multiple binding sites are recognized by most regulators belonging to the AraC/XylS family with which the wires were probed.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1771">
                    <text>multiple binding sites are recognized by most regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1772">
                    <text>multiple binding sites could be recognized in immunoprecipitatio with most regulators belonging to the AraC/XylS family, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1773">
                    <text>multiple binding sites has been recognized by most regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1774">
                    <text>multiple binding sites is recognized by most regulators belonging to the AraC/XylS family by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1775">
                    <text>multiple binding sites is recognized by most regulators belonging to the AraC/XylS family that the litters were probed.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1776">
                    <text>multiple binding sites was recognized by most regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1777">
                    <text>multiple binding sites was recognized in the immunoprecipitatome with most regulators belonging to the AraC/XylS family, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1778">
                    <text>multiple binding sites were recognized by most regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1779">
                    <text>multiple binding sites will be recognized by most regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1780">
                    <text>multiple binding sites will be recognized by the most regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1781">
                    <text>multiple binding sites will be recognized in immunoprecipitatio with most regulators belonging to the AraC/XylS family, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1782">
                    <text>multiple binding sites, cannot is recognized in the immunoprecipitaiton with most regulators belonging to the AraC/XylS family as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1783">
                    <text>multiple binding sites, has been recognized in the immunoprecipitaiton with most regulators belonging to the AraC/XylS family as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1784">
                    <text>multiple binding sites, was not recognized in the immunoprecipitaiton with most regulators belonging to the AraC/XylS family as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1785">
                    <text>multiple binding sites, will be recognized in the immunoprecipitaiton with most regulators belonging to the AraC/XylS family as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">most regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple binding sites</arg>
                </example>
                <example src="PERMUTATE" no="1786">
                    <text>multiple connection site are recognized by most of the regulators belonging to the AraC/XylS family with which the threads were probed.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="1787">
                    <text>multiple connection site are recognized by most of the regulators belonging to the AraC/XylS family with which the wires were probed.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="1788">
                    <text>multiple connection site are recognized by most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="1789">
                    <text>multiple connection site could be recognized in immunoprecipitatio with most of the regulators belonging to the AraC/XylS family, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="1790">
                    <text>multiple connection site has been recognized by most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="1791">
                    <text>multiple connection site is recognized by most of the regulators belonging to the AraC/XylS family by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="1792">
                    <text>multiple connection site is recognized by most of the regulators belonging to the AraC/XylS family by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="1793">
                    <text>multiple connection site is recognized by most of the regulators belonging to the AraC/XylS family that the litters were probed.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="1794">
                    <text>multiple connection site is recognized by most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="1795">
                    <text>multiple connection site was recognized by most of the regulators belonging to the AraC/XylS family by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="1796">
                    <text>multiple connection site was recognized by most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="1797">
                    <text>multiple connection site was recognized in the immunoprecipitatome with most of the regulators belonging to the AraC/XylS family, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="1798">
                    <text>multiple connection site were recognized by most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="1799">
                    <text>multiple connection site will be recognized by most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="1800">
                    <text>multiple connection site will be recognized by the most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="1801">
                    <text>multiple connection site will be recognized in immunoprecipitatio with most of the regulators belonging to the AraC/XylS family, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="1802">
                    <text>multiple connection site, cannot is recognized in immunoprecipitatio with most of the regulators belonging to the AraC/XylS family, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="1803">
                    <text>multiple connection site, cannot is recognized in the immunoprecipitaiton with most of the regulators belonging to the AraC/XylS family as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="1804">
                    <text>multiple connection site, could be recognized in the immunoprecipitaiton with most of the regulators belonging to the AraC/XylS family as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="1805">
                    <text>multiple connection site, has been recognized in the immunoprecipitaiton with most of the regulators belonging to the AraC/XylS family as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="1806">
                    <text>multiple connection site, was not recognized in the immunoprecipitaiton with most of the regulators belonging to the AraC/XylS family as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="1807">
                    <text>multiple connection site, was unrecognized in immunoprecipitatio with most of the regulators belonging to the AraC/XylS family, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="1808">
                    <text>multiple connection site, will be recognized in the immunoprecipitaiton with most of the regulators belonging to the AraC/XylS family as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple connection site</arg>
                </example>
                <example src="PERMUTATE" no="1809">
                    <text>multiple linkage site are recognized by most of the regulators belonging to the AraC/XylS family with which the threads were probed.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="1810">
                    <text>multiple linkage site are recognized by most of the regulators belonging to the AraC/XylS family with which the wires were probed.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="1811">
                    <text>multiple linkage site are recognized by most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="1812">
                    <text>multiple linkage site has been recognized by most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="1813">
                    <text>multiple linkage site is recognized by most of the regulators belonging to the AraC/XylS family by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="1814">
                    <text>multiple linkage site is recognized by most of the regulators belonging to the AraC/XylS family by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="1815">
                    <text>multiple linkage site is recognized by most of the regulators belonging to the AraC/XylS family that the litters were probed.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="1816">
                    <text>multiple linkage site is recognized by most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="1817">
                    <text>multiple linkage site was recognized by most of the regulators belonging to the AraC/XylS family by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="1818">
                    <text>multiple linkage site was recognized by most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="1819">
                    <text>multiple linkage site was recognized in the immunoprecipitatome with most of the regulators belonging to the AraC/XylS family, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="1820">
                    <text>multiple linkage site were recognized by most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="1821">
                    <text>multiple linkage site will be recognized by most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="1822">
                    <text>multiple linkage site will be recognized by the most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="1823">
                    <text>multiple linkage site, cannot is recognized in immunoprecipitatio with most of the regulators belonging to the AraC/XylS family, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="1824">
                    <text>multiple linkage site, cannot is recognized in the immunoprecipitaiton with most of the regulators belonging to the AraC/XylS family as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="1825">
                    <text>multiple linkage site, could be recognized in the immunoprecipitaiton with most of the regulators belonging to the AraC/XylS family as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="1826">
                    <text>multiple linkage site, has been recognized in the immunoprecipitaiton with most of the regulators belonging to the AraC/XylS family as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="1827">
                    <text>multiple linkage site, was not recognized in the immunoprecipitaiton with most of the regulators belonging to the AraC/XylS family as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="1828">
                    <text>multiple linkage site, was unrecognized in immunoprecipitatio with most of the regulators belonging to the AraC/XylS family, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="1829">
                    <text>multiple linkage site, will be recognized in the immunoprecipitaiton with most of the regulators belonging to the AraC/XylS family as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple linkage site</arg>
                </example>
                <example src="PERMUTATE" no="1830">
                    <text>multiple-link location are recognized by most of the regulators belonging to the AraC/XylS family with which the threads were probed.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="1831">
                    <text>multiple-link location are recognized by most of the regulators belonging to the AraC/XylS family with which the wires were probed.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="1832">
                    <text>multiple-link location are recognized by most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="1833">
                    <text>multiple-link location could be recognized in immunoprecipitatio with most of the regulators belonging to the AraC/XylS family, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="1834">
                    <text>multiple-link location has been recognized by most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="1835">
                    <text>multiple-link location is recognized by most of the regulators belonging to the AraC/XylS family by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="1836">
                    <text>multiple-link location is recognized by most of the regulators belonging to the AraC/XylS family by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="1837">
                    <text>multiple-link location is recognized by most of the regulators belonging to the AraC/XylS family that the litters were probed.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="1838">
                    <text>multiple-link location is recognized by most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="1839">
                    <text>multiple-link location was recognized by most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="1840">
                    <text>multiple-link location was recognized in the immunoprecipitatome with most of the regulators belonging to the AraC/XylS family, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="1841">
                    <text>multiple-link location were recognized by most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="1842">
                    <text>multiple-link location will be recognized by most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="1843">
                    <text>multiple-link location will be recognized by the most of the regulators belonging to the AraC/XylS family.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="1844">
                    <text>multiple-link location, cannot is recognized in the immunoprecipitaiton with most of the regulators belonging to the AraC/XylS family as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="1845">
                    <text>multiple-link location, could be recognized in the immunoprecipitaiton with most of the regulators belonging to the AraC/XylS family as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="1846">
                    <text>multiple-link location, has been recognized in the immunoprecipitaiton with most of the regulators belonging to the AraC/XylS family as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="1847">
                    <text>multiple-link location, was unrecognized in immunoprecipitatio with most of the regulators belonging to the AraC/XylS family, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="1848">
                    <text>multiple-link location, will be recognized in the immunoprecipitaiton with most of the regulators belonging to the AraC/XylS family as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">most of the regulators belonging to the AraC/XylS family</arg>
                    <arg n="1">multiple-link location</arg>
                </example>
                <example src="PERMUTATE" no="1849">
                    <text>polyclonal anti-CD40 anti-rabbit antisound also binds to these 727 sites but, unlike NarP, also recognized C-term of CD40 at a 1:500 dilution.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1850">
                    <text>polyclonal anti-CD40 anti-rabbit antisound also binds to these sites 7-2-7, but, unlike NarP, it also recognized C-term of CD40 at a 1:500 dilution.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1851">
                    <text>polyclonal anti-CD40 anti-rabbit antisound are able to recognize C-term of CD40 at a 1:500 dilution in regulated promoters.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1852">
                    <text>polyclonal anti-CD40 anti-rabbit antisound binds to these 727 sites but, unlike NarP, will also recognize C-term of CD40 at a 1:500 dilution.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1853">
                    <text>polyclonal anti-CD40 anti-rabbit antisound binds to these sites 7-2-7, but, unlike NarP, it also recognizes C-term of CD40 at a 1:500 dilution .</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1854">
                    <text>polyclonal anti-CD40 anti-rabbit antisound can recognize C-term of CD40 at a 1:500 dilution in regulated promoters.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1855">
                    <text>polyclonal anti-CD40 anti-rabbit antisound has also joined these 727 sites but, unlike NarP, has also recognized C-term of CD40 at a 1:500 dilution.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1856">
                    <text>polyclonal anti-CD40 anti-rabbit antisound is able to recognize C-term of CD40 at a 1:500 dilution in regulated promoters.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1857">
                    <text>polyclonal anti-CD40 anti-rabbit antisound recognized C-term of CD40 at a 1:500 dilution in regulated promoters.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1858">
                    <text>polyclonal anti-CD40 anti-rabbit antisound recognized C-term of CD40 at a 1:500 dilution in the regulated promoters.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1859">
                    <text>polyclonal anti-CD40 anti-rabbit antisound recognizes C-term of CD40 at a 1:500 dilution.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1860">
                    <text>polyclonal anti-CD40 anti-rabbit antisound specifically recognized C-term of CD40 at a 1:500 dilution.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1861">
                    <text>polyclonal anti-CD40 anti-rabbit antisound that recognizes C-term of CD40 at a 1:500 dilution is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1862">
                    <text>polyclonal anti-CD40 anti-rabbit antisound that recognizes C-term of CD40 at a 1:500 dilution is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1863">
                    <text>polyclonal anti-CD40 anti-rabbit antisound will recognize C-term of CD40 at a 1:500 dilution in regulated promoters.</text>
                    <arg n="0">polyclonal anti-CD40 anti-rabbit antisound</arg>
                    <arg n="1">C-term of CD40 at a 1:500 dilution</arg>
                </example>
                <example src="PERMUTATE" no="1864">
                    <text>polyclonal anti-LMP-1 affinity antiserum recognized A1 (epitopes in the C muscle of LMP-1 in dilution 1:200.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antiserum</arg>
                </example>
                <example src="PERMUTATE" no="1865">
                    <text>polyclonal anti-LMP-1 affinity antisumption also binds to these sites 7-2-7, but, unlike NarP, it also recognized epitopes in the C muscle of LMP-1 at a dilution of 1:200 .</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1866">
                    <text>polyclonal anti-LMP-1 affinity antisumption also binds to these sites 7-2-7, but, unlike NarP, it also recognized epitopes in the C muscle of LMP-1 at a dilution of 1:200.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1867">
                    <text>polyclonal anti-LMP-1 affinity antisumption binds to these 727 sites but, unlike NarP, will also recognize epitopes in the C muscle of LMP-1 at a dilution of 1:200.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1868">
                    <text>polyclonal anti-LMP-1 affinity antisumption binds to these sites 7-2-7, but, unlike NarP, it also recognizes epitopes in the C muscle of LMP-1 at a dilution of 1:200 .</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1869">
                    <text>polyclonal anti-LMP-1 affinity antisumption can recognize epitopes in the C muscle of LMP-1 at a dilution of 1:200 in regulated promoters.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1870">
                    <text>polyclonal anti-LMP-1 affinity antisumption has also joined these 727 sites but, unlike NarP, has also recognized epitopes in the C muscle of LMP-1 at a dilution of 1:200.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1871">
                    <text>polyclonal anti-LMP-1 affinity antisumption is able to recognize epitopes in the C muscle of LMP-1 at a dilution of 1:200 in regulated promoters.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1872">
                    <text>polyclonal anti-LMP-1 affinity antisumption recognized epitopes in the C muscle of LMP-1 at a dilution of 1:200 in regulated promoters.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1873">
                    <text>polyclonal anti-LMP-1 affinity antisumption recognized epitopes in the C muscle of LMP-1 at a dilution of 1:200 in the regulated promoters.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1874">
                    <text>polyclonal anti-LMP-1 affinity antisumption recognized epitopes in the C muscle of LMP-1 at a dilution of 1:200.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1875">
                    <text>polyclonal anti-LMP-1 affinity antisumption that has recognized epitopes in the C muscle of LMP-1 at a dilution of 1:200 was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1876">
                    <text>polyclonal anti-LMP-1 affinity antisumption that recognizes epitopes in the C muscle of LMP-1 at a dilution of 1:200 is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1877">
                    <text>polyclonal anti-LMP-1 affinity antisumption that recognizes epitopes in the C muscle of LMP-1 at a dilution of 1:200 is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1878">
                    <text>polyclonal anti-LMP-1 affinity antisumption will recognize epitopes in the C muscle of LMP-1 at a dilution of 1:200 in regulated promoters.</text>
                    <arg n="0">polyclonal anti-LMP-1 affinity antisumption</arg>
                    <arg n="1">epitopes in the C muscle of LMP-1 at a dilution of 1:200</arg>
                </example>
                <example src="PERMUTATE" no="1879">
                    <text>polyclonal anti-LMP-1 purified affinity antiserum recognized A1 (epitopes in the C muscle of LMP-1 in dilution 1:200.</text>
                    <arg n="0">polyclonal anti-LMP-1 purified affinity antiserum</arg>
                </example>
                <example src="PERMUTATE" no="1880">
                    <text>polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle are recognized by D1 anti-64kD human autoantigen with which the threads were probed.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1881">
                    <text>polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle are recognized by D1 anti-64kD human autoantigen with which the wires were probed.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1882">
                    <text>polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle are recognized by D1 anti-64kD human autoantigen.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1883">
                    <text>polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle are recognized by D1 antibody of human autoantigen anti-64kD with which the threads were probed.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1884">
                    <text>polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle are recognized by D1 antibody of human autoantigen anti-64kD with which the wires were probed.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1885">
                    <text>polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle are recognized by D1 antibody of human autoantigen anti-64kD.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1886">
                    <text>polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle could be recognized in immunoprecipitatio with D1 anti-64kD human autoantigen, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1887">
                    <text>polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle could be recognized in immunoprecipitatio with D1 antibody of human autoantigen anti-64kD, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1888">
                    <text>polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle has been recognized by D1 anti-64kD human autoantigen.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1889">
                    <text>polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle has been recognized by D1 antibody of human autoantigen anti-64kD.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1890">
                    <text>polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle is recognized by D1 anti-64kD human autoantigen by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1891">
                    <text>polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle is recognized by D1 anti-64kD human autoantigen by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1892">
                    <text>polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle is recognized by D1 antibody of human autoantigen anti-64kD by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1893">
                    <text>polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle is recognized by D1 antibody of human autoantigen anti-64kD that the litters were probed.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1894">
                    <text>polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle was recognized by D1 anti-64kD human autoantigen by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1895">
                    <text>polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle was recognized by D1 antibody of human autoantigen anti-64kD by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1896">
                    <text>polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle was recognized in the immunoprecipitatome with D1 anti-64kD human autoantigen, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1897">
                    <text>polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle was recognized in the immunoprecipitatome with D1 antibody of human autoantigen anti-64kD, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1898">
                    <text>polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle were recognized by D1 anti-64kD human autoantigen.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1899">
                    <text>polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle were recognized by D1 antibody of human autoantigen anti-64kD.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1900">
                    <text>polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle will be recognized by D1 anti-64kD human autoantigen.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1901">
                    <text>polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle will be recognized by the D1 antibody of human autoantigen anti-64kD.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1902">
                    <text>polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle will be recognized in immunoprecipitatio with D1 anti-64kD human autoantigen, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1903">
                    <text>polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle will be recognized in immunoprecipitatio with D1 antibody of human autoantigen anti-64kD, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1904">
                    <text>polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle, cannot is recognized in immunoprecipitatio with D1 anti-64kD human autoantigen, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1905">
                    <text>polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle, cannot is recognized in immunoprecipitatio with D1 antibody of human autoantigen anti-64kD, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1906">
                    <text>polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle, cannot is recognized in the immunoprecipitaiton with D1 anti-64kD human autoantigen as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1907">
                    <text>polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle, cannot is recognized in the immunoprecipitaiton with D1 antibody of human autoantigen anti-64kD as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1908">
                    <text>polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle, could be recognized in the immunoprecipitaiton with D1 antibody of human autoantigen anti-64kD as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1909">
                    <text>polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle, has been recognized in the immunoprecipitaiton with D1 anti-64kD human autoantigen as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1910">
                    <text>polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle, has been recognized in the immunoprecipitaiton with D1 antibody of human autoantigen anti-64kD as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1911">
                    <text>polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle, was not recognized in the immunoprecipitaiton with D1 anti-64kD human autoantigen as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1912">
                    <text>polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle, was not recognized in the immunoprecipitaiton with D1 antibody of human autoantigen anti-64kD as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1913">
                    <text>polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle, was unrecognized in immunoprecipitatio with D1 anti-64kD human autoantigen, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1914">
                    <text>polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle, was unrecognized in immunoprecipitatio with D1 antibody of human autoantigen anti-64kD, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1915">
                    <text>polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle, will be recognized in the immunoprecipitaiton with D1 anti-64kD human autoantigen as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">D1 anti-64kD human autoantigen</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1916">
                    <text>polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle, will be recognized in the immunoprecipitaiton with D1 antibody of human autoantigen anti-64kD as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">D1 antibody of human autoantigen anti-64kD</arg>
                    <arg n="1">polypeptide approximately 70kD in the western muscles of the extraocular muscle, sternotirio muscle and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1917">
                    <text>polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle are recognized by anti-64kD antibodies of human autoantigen D1 with which the threads were probed.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1918">
                    <text>polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle are recognized by anti-64kD antibodies of human autoantigen D1 with which the wires were probed.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1919">
                    <text>polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle are recognized by anti-64kD antibodies of human autoantigen D1.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1920">
                    <text>polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle is recognized by anti-64kD antibodies of human autoantigen D1 by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1921">
                    <text>polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle is recognized by anti-64kD antibodies of human autoantigen D1 that the litters were probed.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1922">
                    <text>polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle is recognized by anti-64kD antibodies of human autoantigen D1.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1923">
                    <text>polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle was recognized by anti-64kD antibodies of human autoantigen D1 by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1924">
                    <text>polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle was recognized by anti-64kD antibodies of human autoantigen D1.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1925">
                    <text>polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle were recognized by anti-64kD antibodies of human autoantigen D1.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1926">
                    <text>polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle will be recognized by anti-64kD antibodies of human autoantigen D1.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1927">
                    <text>polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle will be recognized by the anti-64kD antibodies of human autoantigen D1.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1928">
                    <text>polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle will be recognized in immunoprecipitatio with anti-64kD antibodies of human autoantigen D1, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1929">
                    <text>polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle, cannot is recognized in the immunoprecipitaiton with anti-64kD antibodies of human autoantigen D1 as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1930">
                    <text>polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle, has been recognized in the immunoprecipitaiton with anti-64kD antibodies of human autoantigen D1 as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1931">
                    <text>polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle, was unrecognized in immunoprecipitatio with anti-64kD antibodies of human autoantigen D1, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1932">
                    <text>polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle, will be recognized in the immunoprecipitaiton with anti-64kD antibodies of human autoantigen D1 as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-64kD antibodies of human autoantigen D1</arg>
                    <arg n="1">polypeptide approximately 70kD in western areas of extraocular muscle, sternotirio muscle, and smooth muscle</arg>
                </example>
                <example src="PERMUTATE" no="1933">
                    <text>proteins also binds to these sites 7-2-7, but, unlike NarP, it also recognized short motives within the protected region .</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1934">
                    <text>proteins also binds to these sites 7-2-7, but, unlike NarP, it also recognized short reasons within the protected region .</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1935">
                    <text>proteins also binds to these sites 7-2-7, but, unlike NarP, it also recognized short reasons within the protected region.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1936">
                    <text>proteins are able to recognize short reasons within the protected region in regulated promoters.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1937">
                    <text>proteins binds to these 727 sites but, unlike NarP, will also recognize short motives within the protected region.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1938">
                    <text>proteins binds to these 727 sites but, unlike NarP, will also recognize short reasons within the protected region.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1939">
                    <text>proteins binds to these sites 7-2-7, but, unlike NarP, it also recognizes short motives within the protected region .</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1940">
                    <text>proteins binds to these sites 7-2-7, but, unlike NarP, it also recognizes short reasons within the protected region .</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1941">
                    <text>proteins can recognize short motives within the protected region in regulated promoters.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1942">
                    <text>proteins can recognize short reasons within the protected region in regulated promoters.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1943">
                    <text>proteins has also joined these 727 sites but, unlike NarP, has also recognized short reasons within the protected region.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1944">
                    <text>proteins is able to recognize short motives within the protected region in regulated promoters.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1945">
                    <text>proteins is able to recognize short reasons within the protected region in regulated promoters.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1946">
                    <text>proteins recognized short motives within the protected region in regulated promoters.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1947">
                    <text>proteins recognized short motives within the protected region in the regulated promoters.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1948">
                    <text>proteins recognized short motives within the protected region.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1949">
                    <text>proteins recognized short reasons within the protected region in regulated promoters.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1950">
                    <text>proteins recognized short reasons within the protected region.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1951">
                    <text>proteins recognizes short motives within the protected region.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1952">
                    <text>proteins recognizes short reasons within the protected region.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1953">
                    <text>proteins specifically recognized short motives within the protected region.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1954">
                    <text>proteins specifically recognized short reasons within the protected region.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1955">
                    <text>proteins that has recognized short motives within the protected region was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1956">
                    <text>proteins that recognized short motives within the protected region was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1957">
                    <text>proteins that recognizes short motives within the protected region is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1958">
                    <text>proteins that recognizes short motives within the protected region is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1959">
                    <text>proteins that recognizes short reasons within the protected region is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1960">
                    <text>proteins that recognizes short reasons within the protected region is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1961">
                    <text>proteins will recognize short motives within the protected region in regulated promoters.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1962">
                    <text>proteins will recognize short reasons within the protected region in regulated promoters.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1963">
                    <text>sequence (YPYDVPDYA) at a dilution 1:500 is recognized by A0 (monoclonal anti-HA RAT antibody (Boehringer-Ingelheim) with which the screws were sound.</text>
                    <arg n="1">sequence (YPYDVPDYA) at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="1964">
                    <text>short motives within the protected region are recognized by proteins with which the threads were probed.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1965">
                    <text>short motives within the protected region are recognized by proteins.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1966">
                    <text>short motives within the protected region could be recognized in immunoprecipitatio with proteins, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1967">
                    <text>short motives within the protected region has been recognized by proteins.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1968">
                    <text>short motives within the protected region is recognized by proteins by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1969">
                    <text>short motives within the protected region is recognized by proteins that the litters were probed.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1970">
                    <text>short motives within the protected region is recognized by proteins.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1971">
                    <text>short motives within the protected region was recognized by proteins.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1972">
                    <text>short motives within the protected region were recognized by proteins.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1973">
                    <text>short motives within the protected region, cannot is recognized in the immunoprecipitaiton with proteins as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1974">
                    <text>short motives within the protected region, could be recognized in the immunoprecipitaiton with proteins as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1975">
                    <text>short motives within the protected region, was unrecognized in immunoprecipitatio with proteins, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1976">
                    <text>short motives within the protected region, will be recognized in the immunoprecipitaiton with proteins as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short motives within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1977">
                    <text>short reasons within the protected region are recognized by proteins with which the threads were probed.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1978">
                    <text>short reasons within the protected region are recognized by proteins with which the wires were probed.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1979">
                    <text>short reasons within the protected region are recognized by proteins.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1980">
                    <text>short reasons within the protected region could be recognized in immunoprecipitatio with proteins, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1981">
                    <text>short reasons within the protected region has been recognized by proteins.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1982">
                    <text>short reasons within the protected region is recognized by proteins by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1983">
                    <text>short reasons within the protected region is recognized by proteins by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1984">
                    <text>short reasons within the protected region is recognized by proteins that the litters were probed.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1985">
                    <text>short reasons within the protected region is recognized by proteins.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1986">
                    <text>short reasons within the protected region was recognized by proteins by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1987">
                    <text>short reasons within the protected region was recognized by proteins.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1988">
                    <text>short reasons within the protected region was recognized in the immunoprecipitatome with proteins, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1989">
                    <text>short reasons within the protected region will be recognized by proteins.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1990">
                    <text>short reasons within the protected region will be recognized by the proteins.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1991">
                    <text>short reasons within the protected region will be recognized in immunoprecipitatio with proteins, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1992">
                    <text>short reasons within the protected region, cannot is recognized in immunoprecipitatio with proteins, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1993">
                    <text>short reasons within the protected region, cannot is recognized in the immunoprecipitaiton with proteins as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1994">
                    <text>short reasons within the protected region, has been recognized in the immunoprecipitaiton with proteins as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1995">
                    <text>short reasons within the protected region, was not recognized in the immunoprecipitaiton with proteins as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1996">
                    <text>short reasons within the protected region, was unrecognized in immunoprecipitatio with proteins, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1997">
                    <text>short reasons within the protected region, will be recognized in the immunoprecipitaiton with proteins as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">proteins</arg>
                    <arg n="1">short reasons within the protected region</arg>
                </example>
                <example src="PERMUTATE" no="1998">
                    <text>term C of CD40 at a dilution 1:500 are recognized by anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit with which the threads were probed.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="1999">
                    <text>term C of CD40 at a dilution 1:500 are recognized by anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit with which the wires were probed.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="2000">
                    <text>term C of CD40 at a dilution 1:500 are recognized by anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="2001">
                    <text>term C of CD40 at a dilution 1:500 could be recognized in immunoprecipitatio with anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="2002">
                    <text>term C of CD40 at a dilution 1:500 has been recognized by anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="2003">
                    <text>term C of CD40 at a dilution 1:500 is recognized by anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="2004">
                    <text>term C of CD40 at a dilution 1:500 is recognized by anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="2005">
                    <text>term C of CD40 at a dilution 1:500 is recognized by anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit that the litters were probed.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="2006">
                    <text>term C of CD40 at a dilution 1:500 is recognized by anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="2007">
                    <text>term C of CD40 at a dilution 1:500 was recognized by anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="2008">
                    <text>term C of CD40 at a dilution 1:500 was recognized by anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="2009">
                    <text>term C of CD40 at a dilution 1:500 was recognized in the immunoprecipitatome with anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="2010">
                    <text>term C of CD40 at a dilution 1:500 were recognized by anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="2011">
                    <text>term C of CD40 at a dilution 1:500 will be recognized by anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="2012">
                    <text>term C of CD40 at a dilution 1:500 will be recognized by the anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="2013">
                    <text>term C of CD40 at a dilution 1:500 will be recognized in immunoprecipitatio with anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="2014">
                    <text>term C of CD40 at a dilution 1:500, cannot is recognized in immunoprecipitatio with anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="2015">
                    <text>term C of CD40 at a dilution 1:500, has been recognized in the immunoprecipitaiton with anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="2016">
                    <text>term C of CD40 at a dilution 1:500, was not recognized in the immunoprecipitaiton with anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="2017">
                    <text>term C of CD40 at a dilution 1:500, will be recognized in the immunoprecipitaiton with anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">anti-CD40 anti-rabbit polyclonal anti-CD40 anti-rabbit</arg>
                    <arg n="1">term C of CD40 at a dilution 1:500</arg>
                </example>
                <example src="PERMUTATE" no="2018">
                    <text>the NarL protein also binds to these sites 7-2-7, but, unlike NarP, it also recognized heptamers in other arrangements .</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="2019">
                    <text>the NarL protein also binds to these sites 7-2-7, but, unlike NarP, it also recognized heptamers in other arrangements.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="2020">
                    <text>the NarL protein are able to recognize heptamers in other arrangements in regulated promoters.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="2021">
                    <text>the NarL protein binds to these sites 7-2-7, but, unlike NarP, it also recognizes heptamers in other arrangements .</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="2022">
                    <text>the NarL protein can recognize heptamers in other arrangements in regulated promoters.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="2023">
                    <text>the NarL protein recognized heptamers in other arrangements in regulated promoters.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="2024">
                    <text>the NarL protein recognized heptamers in other arrangements in the regulated promoters.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="2025">
                    <text>the NarL protein recognized heptamers in other arrangements.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="2026">
                    <text>the NarL protein recognizes heptamers in other arrangements.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="2027">
                    <text>the NarL protein specifically recognized heptamers in other arrangements.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="2028">
                    <text>the NarL protein that has recognized heptamers in other arrangements was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="2029">
                    <text>the NarL protein that recognized heptamers in other arrangements was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="2030">
                    <text>the NarL protein that recognizes heptamers in other arrangements is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="2031">
                    <text>the NarL protein that recognizes heptamers in other arrangements is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="2032">
                    <text>the NarL protein will recognize heptamers in other arrangements in regulated promoters.</text>
                    <arg n="0">the NarL protein</arg>
                    <arg n="1">heptamers in other arrangements</arg>
                </example>
                <example src="PERMUTATE" no="2033">
                    <text>the RNA ribosomal gene promoter are recognized by the upstream eukaryotic binding factor (UBF) with which the threads were probed.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="2034">
                    <text>the RNA ribosomal gene promoter are recognized by the upstream eukaryotic binding factor (UBF).</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="2035">
                    <text>the RNA ribosomal gene promoter could be recognized in immunoprecipitatio with the upstream eukaryotic binding factor (UBF), since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="2036">
                    <text>the RNA ribosomal gene promoter has been recognized by the upstream eukaryotic binding factor (UBF).</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="2037">
                    <text>the RNA ribosomal gene promoter is recognized by the upstream eukaryotic binding factor (UBF) by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="2038">
                    <text>the RNA ribosomal gene promoter is recognized by the upstream eukaryotic binding factor (UBF) by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="2039">
                    <text>the RNA ribosomal gene promoter is recognized by the upstream eukaryotic binding factor (UBF) that the litters were probed.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="2040">
                    <text>the RNA ribosomal gene promoter was recognized by the upstream eukaryotic binding factor (UBF) by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="2041">
                    <text>the RNA ribosomal gene promoter was recognized by the upstream eukaryotic binding factor (UBF).</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="2042">
                    <text>the RNA ribosomal gene promoter was recognized in the immunoprecipitatome with the upstream eukaryotic binding factor (UBF), because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="2043">
                    <text>the RNA ribosomal gene promoter will be recognized by the the upstream eukaryotic binding factor (UBF).</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="2044">
                    <text>the RNA ribosomal gene promoter will be recognized by the upstream eukaryotic binding factor (UBF).</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="2045">
                    <text>the RNA ribosomal gene promoter will be recognized in immunoprecipitatio with the upstream eukaryotic binding factor (UBF), since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="2046">
                    <text>the RNA ribosomal gene promoter, cannot is recognized in immunoprecipitatio with the upstream eukaryotic binding factor (UBF), as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="2047">
                    <text>the RNA ribosomal gene promoter, cannot is recognized in the immunoprecipitaiton with the upstream eukaryotic binding factor (UBF) as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="2048">
                    <text>the RNA ribosomal gene promoter, could be recognized in the immunoprecipitaiton with the upstream eukaryotic binding factor (UBF) as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="2049">
                    <text>the RNA ribosomal gene promoter, has been recognized in the immunoprecipitaiton with the upstream eukaryotic binding factor (UBF) as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="2050">
                    <text>the RNA ribosomal gene promoter, will be recognized in the immunoprecipitaiton with the upstream eukaryotic binding factor (UBF) as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="2051">
                    <text>the STAT1 N-terminal are recognized by a monoclonal antibody with which the threads were probed.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="2052">
                    <text>the STAT1 N-terminal are recognized by a monoclonal antibody with which the wires were probed.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="2053">
                    <text>the STAT1 N-terminal are recognized by a monoclonal antibody.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="2054">
                    <text>the STAT1 N-terminal could be recognized in immunoprecipitatio with a monoclonal antibody, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="2055">
                    <text>the STAT1 N-terminal has been recognized by a monoclonal antibody.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="2056">
                    <text>the STAT1 N-terminal is recognized by a monoclonal antibody by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="2057">
                    <text>the STAT1 N-terminal is recognized by a monoclonal antibody that the litters were probed.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="2058">
                    <text>the STAT1 N-terminal was recognized by a monoclonal antibody by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="2059">
                    <text>the STAT1 N-terminal was recognized by a monoclonal antibody.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="2060">
                    <text>the STAT1 N-terminal was recognized in the immunoprecipitatome with a monoclonal antibody, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="2061">
                    <text>the STAT1 N-terminal were recognized by a monoclonal antibody.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="2062">
                    <text>the STAT1 N-terminal will be recognized by a monoclonal antibody.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="2063">
                    <text>the STAT1 N-terminal will be recognized by the a monoclonal antibody.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="2064">
                    <text>the STAT1 N-terminal will be recognized in immunoprecipitatio with a monoclonal antibody, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="2065">
                    <text>the STAT1 N-terminal, cannot is recognized in immunoprecipitatio with a monoclonal antibody, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="2066">
                    <text>the STAT1 N-terminal, cannot is recognized in the immunoprecipitaiton with a monoclonal antibody as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="2067">
                    <text>the STAT1 N-terminal, was not recognized in the immunoprecipitaiton with a monoclonal antibody as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="2068">
                    <text>the STAT1 N-terminal, will be recognized in the immunoprecipitaiton with a monoclonal antibody as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">a monoclonal antibody</arg>
                    <arg n="1">the STAT1 N-terminal</arg>
                </example>
                <example src="PERMUTATE" no="2069">
                    <text>the activator complex cAMP-CRP also binds to these 727 sites but, unlike NarP, also recognized two sites in tsx-p2.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2070">
                    <text>the activator complex cAMP-CRP also binds to these sites 7-2-7, but, unlike NarP, it also recognized two sites in tsx-p2.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2071">
                    <text>the activator complex cAMP-CRP are able to recognize two sites in tsx-p2 in regulated promoters.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2072">
                    <text>the activator complex cAMP-CRP binds to these 727 sites but, unlike NarP, will also recognize two sites in tsx-p2.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2073">
                    <text>the activator complex cAMP-CRP binds to these sites 7-2-7, but, unlike NarP, it also recognizes two sites in tsx-p2 .</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2074">
                    <text>the activator complex cAMP-CRP can recognize two sites in tsx-p2 in regulated promoters.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2075">
                    <text>the activator complex cAMP-CRP is able to recognize two sites in tsx-p2 in regulated promoters.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2076">
                    <text>the activator complex cAMP-CRP recognized two sites in tsx-p2 in regulated promoters.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2077">
                    <text>the activator complex cAMP-CRP recognized two sites in tsx-p2 in the regulated promoters.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2078">
                    <text>the activator complex cAMP-CRP recognized two sites in tsx-p2.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2079">
                    <text>the activator complex cAMP-CRP recognizes two sites in tsx-p2.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2080">
                    <text>the activator complex cAMP-CRP specifically recognized two sites in tsx-p2.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2081">
                    <text>the activator complex cAMP-CRP that has recognized two sites in tsx-p2 was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2082">
                    <text>the activator complex cAMP-CRP that recognized two sites in tsx-p2 was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2083">
                    <text>the activator complex cAMP-CRP that recognizes two sites in tsx-p2 is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2084">
                    <text>the activator complex cAMP-CRP that recognizes two sites in tsx-p2 is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2085">
                    <text>the activator complex cAMP-CRP will recognize two sites in tsx-p2 in regulated promoters.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2086">
                    <text>the cAMP-CRP activator complex also binds to these 727 sites but, unlike NarP, also recognized two sites in tsx-p2.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2087">
                    <text>the cAMP-CRP activator complex also binds to these sites 7-2-7, but, unlike NarP, it also recognized two sites in tsx-p2 .</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2088">
                    <text>the cAMP-CRP activator complex also binds to these sites 7-2-7, but, unlike NarP, it also recognized two sites in tsx-p2.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2089">
                    <text>the cAMP-CRP activator complex are able to recognize two sites in tsx-p2 in regulated promoters.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2090">
                    <text>the cAMP-CRP activator complex binds to these 727 sites but, unlike NarP, will also recognize two sites in tsx-p2.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2091">
                    <text>the cAMP-CRP activator complex binds to these sites 7-2-7, but, unlike NarP, it also recognizes two sites in tsx-p2 .</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2092">
                    <text>the cAMP-CRP activator complex can recognize two sites in tsx-p2 in regulated promoters.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2093">
                    <text>the cAMP-CRP activator complex has also joined these 727 sites but, unlike NarP, has also recognized two sites in tsx-p2.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2094">
                    <text>the cAMP-CRP activator complex is able to recognize two sites in tsx-p2 in regulated promoters.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2095">
                    <text>the cAMP-CRP activator complex recognized two sites in tsx-p2 in regulated promoters.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2096">
                    <text>the cAMP-CRP activator complex recognized two sites in tsx-p2 in the regulated promoters.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2097">
                    <text>the cAMP-CRP activator complex recognized two sites in tsx-p2.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2098">
                    <text>the cAMP-CRP activator complex recognizes two sites in tsx-p2.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2099">
                    <text>the cAMP-CRP activator complex that has recognized two sites in tsx-p2 was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2100">
                    <text>the cAMP-CRP activator complex that recognized two sites in tsx-p2 was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2101">
                    <text>the cAMP-CRP activator complex that recognizes two sites in tsx-p2 is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2102">
                    <text>the cAMP-CRP activator complex that recognizes two sites in tsx-p2 is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2103">
                    <text>the cAMP-CRP activator complex will recognize two sites in tsx-p2 in regulated promoters.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2104">
                    <text>the eukaryotic binding factor upstream (UBF) also binds to these 727 sites but, unlike NarP, also recognized the promoter of the RNA ribosomal gene.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2105">
                    <text>the eukaryotic binding factor upstream (UBF) also binds to these sites 7-2-7, but, unlike NarP, it also recognized the promoter of the RNA ribosomal gene .</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2106">
                    <text>the eukaryotic binding factor upstream (UBF) also binds to these sites 7-2-7, but, unlike NarP, it also recognized the promoter of the RNA ribosomal gene.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2107">
                    <text>the eukaryotic binding factor upstream (UBF) are able to recognize the promoter of the RNA ribosomal gene in regulated promoters.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2108">
                    <text>the eukaryotic binding factor upstream (UBF) binds to these 727 sites but, unlike NarP, will also recognize the promoter of the RNA ribosomal gene.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2109">
                    <text>the eukaryotic binding factor upstream (UBF) binds to these sites 7-2-7, but, unlike NarP, it also recognizes the promoter of the RNA ribosomal gene .</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2110">
                    <text>the eukaryotic binding factor upstream (UBF) has also joined these 727 sites but, unlike NarP, has also recognized the promoter of the RNA ribosomal gene.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2111">
                    <text>the eukaryotic binding factor upstream (UBF) is able to recognize the promoter of the RNA ribosomal gene in regulated promoters.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2112">
                    <text>the eukaryotic binding factor upstream (UBF) recognized the promoter of the RNA ribosomal gene in regulated promoters.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2113">
                    <text>the eukaryotic binding factor upstream (UBF) specifically recognized the promoter of the RNA ribosomal gene.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2114">
                    <text>the eukaryotic binding factor upstream (UBF) that has recognized the promoter of the RNA ribosomal gene was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2115">
                    <text>the eukaryotic binding factor upstream (UBF) that recognized the promoter of the RNA ribosomal gene was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2116">
                    <text>the eukaryotic binding factor upstream (UBF) that recognizes the promoter of the RNA ribosomal gene is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2117">
                    <text>the eukaryotic binding factor upstream (UBF) that recognizes the promoter of the RNA ribosomal gene is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2118">
                    <text>the eukaryotic binding factor upstream (UBF) will recognize the promoter of the RNA ribosomal gene in regulated promoters.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2119">
                    <text>the lowest form of Stat3, Stat3Beta are recognized by anti-Stat3 pAb with which the threads were probed.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="2120">
                    <text>the lowest form of Stat3, Stat3Beta are recognized by anti-Stat3 pAb with which the wires were probed.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="2121">
                    <text>the lowest form of Stat3, Stat3Beta are recognized by anti-Stat3 pAb.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="2122">
                    <text>the lowest form of Stat3, Stat3Beta is recognized by anti-Stat3 pAb by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="2123">
                    <text>the lowest form of Stat3, Stat3Beta is recognized by anti-Stat3 pAb by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="2124">
                    <text>the lowest form of Stat3, Stat3Beta is recognized by anti-Stat3 pAb that the litters were probed.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="2125">
                    <text>the lowest form of Stat3, Stat3Beta is recognized by anti-Stat3 pAb.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="2126">
                    <text>the lowest form of Stat3, Stat3Beta was recognized by anti-Stat3 pAb by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="2127">
                    <text>the lowest form of Stat3, Stat3Beta was recognized by anti-Stat3 pAb.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="2128">
                    <text>the lowest form of Stat3, Stat3Beta were recognized by anti-Stat3 pAb.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="2129">
                    <text>the lowest form of Stat3, Stat3Beta will be recognized by anti-Stat3 pAb.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="2130">
                    <text>the lowest form of Stat3, Stat3Beta will be recognized by the anti-Stat3 pAb.</text>
                    <arg n="0">anti-Stat3 pAb</arg>
                    <arg n="1">the lowest form of Stat3, Stat3Beta</arg>
                </example>
                <example src="PERMUTATE" no="2131">
                    <text>the promoter of the RNA ribosomal gene are recognized by the eukaryotic binding factor upstream (UBF) with which the threads were probed.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2132">
                    <text>the promoter of the RNA ribosomal gene are recognized by the eukaryotic binding factor upstream (UBF) with which the wires were probed.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2133">
                    <text>the promoter of the RNA ribosomal gene are recognized by the eukaryotic binding factor upstream (UBF).</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2134">
                    <text>the promoter of the RNA ribosomal gene are recognized by the upstream eukaryotic binding factor (UBF) with which the threads were probed.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2135">
                    <text>the promoter of the RNA ribosomal gene are recognized by the upstream eukaryotic binding factor (UBF) with which the wires were probed.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2136">
                    <text>the promoter of the RNA ribosomal gene are recognized by the upstream eukaryotic binding factor (UBF).</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2137">
                    <text>the promoter of the RNA ribosomal gene could be recognized in immunoprecipitatio with the eukaryotic binding factor upstream (UBF), since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2138">
                    <text>the promoter of the RNA ribosomal gene could be recognized in immunoprecipitatio with the upstream eukaryotic binding factor (UBF), since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2139">
                    <text>the promoter of the RNA ribosomal gene has been recognized by the eukaryotic binding factor upstream (UBF).</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2140">
                    <text>the promoter of the RNA ribosomal gene is recognized by the eukaryotic binding factor upstream (UBF) by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2141">
                    <text>the promoter of the RNA ribosomal gene is recognized by the eukaryotic binding factor upstream (UBF) by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2142">
                    <text>the promoter of the RNA ribosomal gene is recognized by the eukaryotic binding factor upstream (UBF) that the litters were probed.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2143">
                    <text>the promoter of the RNA ribosomal gene is recognized by the upstream eukaryotic binding factor (UBF) by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2144">
                    <text>the promoter of the RNA ribosomal gene is recognized by the upstream eukaryotic binding factor (UBF) by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2145">
                    <text>the promoter of the RNA ribosomal gene is recognized by the upstream eukaryotic binding factor (UBF) that the litters were probed.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2146">
                    <text>the promoter of the RNA ribosomal gene is recognized by the upstream eukaryotic binding factor (UBF).</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2147">
                    <text>the promoter of the RNA ribosomal gene was recognized by the eukaryotic binding factor upstream (UBF) by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2148">
                    <text>the promoter of the RNA ribosomal gene was recognized by the upstream eukaryotic binding factor (UBF) by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2149">
                    <text>the promoter of the RNA ribosomal gene was recognized in the immunoprecipitatome with the eukaryotic binding factor upstream (UBF), because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2150">
                    <text>the promoter of the RNA ribosomal gene was recognized in the immunoprecipitatome with the upstream eukaryotic binding factor (UBF), because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2151">
                    <text>the promoter of the RNA ribosomal gene were recognized by the eukaryotic binding factor upstream (UBF).</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2152">
                    <text>the promoter of the RNA ribosomal gene were recognized by the upstream eukaryotic binding factor (UBF).</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2153">
                    <text>the promoter of the RNA ribosomal gene will be recognized by the eukaryotic binding factor upstream (UBF).</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2154">
                    <text>the promoter of the RNA ribosomal gene will be recognized by the the eukaryotic binding factor upstream (UBF).</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2155">
                    <text>the promoter of the RNA ribosomal gene will be recognized by the the upstream eukaryotic binding factor (UBF).</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2156">
                    <text>the promoter of the RNA ribosomal gene will be recognized in immunoprecipitatio with the eukaryotic binding factor upstream (UBF), since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2157">
                    <text>the promoter of the RNA ribosomal gene will be recognized in immunoprecipitatio with the upstream eukaryotic binding factor (UBF), since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2158">
                    <text>the promoter of the RNA ribosomal gene, cannot is recognized in immunoprecipitatio with the eukaryotic binding factor upstream (UBF), as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2159">
                    <text>the promoter of the RNA ribosomal gene, cannot is recognized in immunoprecipitatio with the upstream eukaryotic binding factor (UBF), as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2160">
                    <text>the promoter of the RNA ribosomal gene, cannot is recognized in the immunoprecipitaiton with the eukaryotic binding factor upstream (UBF) as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2161">
                    <text>the promoter of the RNA ribosomal gene, cannot is recognized in the immunoprecipitaiton with the upstream eukaryotic binding factor (UBF) as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2162">
                    <text>the promoter of the RNA ribosomal gene, could be recognized in the immunoprecipitaiton with the eukaryotic binding factor upstream (UBF) as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2163">
                    <text>the promoter of the RNA ribosomal gene, could be recognized in the immunoprecipitaiton with the upstream eukaryotic binding factor (UBF) as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2164">
                    <text>the promoter of the RNA ribosomal gene, has been recognized in the immunoprecipitaiton with the eukaryotic binding factor upstream (UBF) as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2165">
                    <text>the promoter of the RNA ribosomal gene, has been recognized in the immunoprecipitaiton with the upstream eukaryotic binding factor (UBF) as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2166">
                    <text>the promoter of the RNA ribosomal gene, was not recognized in the immunoprecipitaiton with the upstream eukaryotic binding factor (UBF) as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2167">
                    <text>the promoter of the RNA ribosomal gene, was unrecognized in immunoprecipitatio with the eukaryotic binding factor upstream (UBF), because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2168">
                    <text>the promoter of the RNA ribosomal gene, will be recognized in the immunoprecipitaiton with the eukaryotic binding factor upstream (UBF) as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the eukaryotic binding factor upstream (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2169">
                    <text>the promoter of the RNA ribosomal gene, will be recognized in the immunoprecipitaiton with the upstream eukaryotic binding factor (UBF) as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2170">
                    <text>the ribosomal RNA promoter is recognized by A0 (monoclonal anti-HA RAT antibody (Boehringer-Ingelheim) with which the screws were sound.</text>
                    <arg n="1">the ribosomal RNA promoter</arg>
                </example>
                <example src="PERMUTATE" no="2171">
                    <text>the upstream eukaryotic binding factor (UBF) also binds to these 727 sites but, unlike NarP, also recognized the RNA ribosomal gene promoter.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="2172">
                    <text>the upstream eukaryotic binding factor (UBF) also binds to these sites 7-2-7, but, unlike NarP, it also recognized the promoter of the RNA ribosomal gene .</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2173">
                    <text>the upstream eukaryotic binding factor (UBF) also binds to these sites 7-2-7, but, unlike NarP, it also recognized the promoter of the RNA ribosomal gene.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2174">
                    <text>the upstream eukaryotic binding factor (UBF) are able to recognize the promoter of the RNA ribosomal gene in regulated promoters.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2175">
                    <text>the upstream eukaryotic binding factor (UBF) binds to these 727 sites but, unlike NarP, will also recognize the RNA ribosomal gene promoter.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="2176">
                    <text>the upstream eukaryotic binding factor (UBF) binds to these sites 7-2-7, but, unlike NarP, it also recognizes the RNA ribosomal gene promoter .</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="2177">
                    <text>the upstream eukaryotic binding factor (UBF) binds to these sites 7-2-7, but, unlike NarP, it also recognizes the promoter of the RNA ribosomal gene .</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2178">
                    <text>the upstream eukaryotic binding factor (UBF) can recognize the promoter of the RNA ribosomal gene in regulated promoters.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2179">
                    <text>the upstream eukaryotic binding factor (UBF) has also joined these 727 sites but, unlike NarP, has also recognized the RNA ribosomal gene promoter.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="2180">
                    <text>the upstream eukaryotic binding factor (UBF) has also joined these 727 sites but, unlike NarP, has also recognized the promoter of the RNA ribosomal gene.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2181">
                    <text>the upstream eukaryotic binding factor (UBF) is able to recognize the RNA ribosomal gene promoter in regulated promoters.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="2182">
                    <text>the upstream eukaryotic binding factor (UBF) is able to recognize the promoter of the RNA ribosomal gene in regulated promoters.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2183">
                    <text>the upstream eukaryotic binding factor (UBF) recognized the RNA ribosomal gene promoter in regulated promoters.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="2184">
                    <text>the upstream eukaryotic binding factor (UBF) recognized the RNA ribosomal gene promoter in the regulated promoters.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="2185">
                    <text>the upstream eukaryotic binding factor (UBF) recognized the RNA ribosomal gene promoter.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="2186">
                    <text>the upstream eukaryotic binding factor (UBF) recognized the promoter of the RNA ribosomal gene in regulated promoters.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2187">
                    <text>the upstream eukaryotic binding factor (UBF) recognized the promoter of the RNA ribosomal gene in the regulated promoters.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2188">
                    <text>the upstream eukaryotic binding factor (UBF) recognized the promoter of the RNA ribosomal gene.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2189">
                    <text>the upstream eukaryotic binding factor (UBF) recognizes the RNA ribosomal gene promoter.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="2190">
                    <text>the upstream eukaryotic binding factor (UBF) recognizes the promoter of the RNA ribosomal gene.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2191">
                    <text>the upstream eukaryotic binding factor (UBF) specifically recognized the RNA ribosomal gene promoter.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="2192">
                    <text>the upstream eukaryotic binding factor (UBF) specifically recognized the promoter of the RNA ribosomal gene.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2193">
                    <text>the upstream eukaryotic binding factor (UBF) that has recognized the RNA ribosomal gene promoter was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="2194">
                    <text>the upstream eukaryotic binding factor (UBF) that has recognized the promoter of the RNA ribosomal gene was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2195">
                    <text>the upstream eukaryotic binding factor (UBF) that recognized the RNA ribosomal gene promoter was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="2196">
                    <text>the upstream eukaryotic binding factor (UBF) that recognized the promoter of the RNA ribosomal gene was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2197">
                    <text>the upstream eukaryotic binding factor (UBF) that recognizes the RNA ribosomal gene promoter is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="2198">
                    <text>the upstream eukaryotic binding factor (UBF) that recognizes the RNA ribosomal gene promoter is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="2199">
                    <text>the upstream eukaryotic binding factor (UBF) that recognizes the promoter of the RNA ribosomal gene is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2200">
                    <text>the upstream eukaryotic binding factor (UBF) that recognizes the promoter of the RNA ribosomal gene is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2201">
                    <text>the upstream eukaryotic binding factor (UBF) will recognize the RNA ribosomal gene promoter in regulated promoters.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the RNA ribosomal gene promoter</arg>
                </example>
                <example src="PERMUTATE" no="2202">
                    <text>the upstream eukaryotic binding factor (UBF) will recognize the promoter of the RNA ribosomal gene in regulated promoters.</text>
                    <arg n="0">the upstream eukaryotic binding factor (UBF)</arg>
                    <arg n="1">the promoter of the RNA ribosomal gene</arg>
                </example>
                <example src="PERMUTATE" no="2203">
                    <text>this antibody in PKR+/+MEFs recognized A1 (epitopes in the C muscle of LMP-1 in dilution 1:200.</text>
                    <arg n="0">this antibody in PKR+/+MEFs</arg>
                </example>
                <example src="PERMUTATE" no="2204">
                    <text>two sites in tsx-p2 are recognized by activating complex cAMP-CRP with which the threads were probed.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2205">
                    <text>two sites in tsx-p2 are recognized by activating complex cAMP-CRP with which the wires were probed.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2206">
                    <text>two sites in tsx-p2 are recognized by activating complex cAMP-CRP.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2207">
                    <text>two sites in tsx-p2 are recognized by activating the cAMP-CRP complex with which the threads were probed.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2208">
                    <text>two sites in tsx-p2 are recognized by activating the cAMP-CRP complex with which the wires were probed.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2209">
                    <text>two sites in tsx-p2 are recognized by activating the cAMP-CRP complex.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2210">
                    <text>two sites in tsx-p2 are recognized by activator complex cAMP-CRP with which the threads were probed.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2211">
                    <text>two sites in tsx-p2 are recognized by activator complex cAMP-CRP with which the wires were probed.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2212">
                    <text>two sites in tsx-p2 are recognized by activator complex cAMP-CRP.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2213">
                    <text>two sites in tsx-p2 are recognized by the activator complex cAMP-CRP with which the threads were probed.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2214">
                    <text>two sites in tsx-p2 are recognized by the activator complex cAMP-CRP with which the wires were probed.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2215">
                    <text>two sites in tsx-p2 are recognized by the activator complex cAMP-CRP.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2216">
                    <text>two sites in tsx-p2 are recognized by the cAMP-CRP activator complex with which the threads were probed.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2217">
                    <text>two sites in tsx-p2 are recognized by the cAMP-CRP activator complex with which the wires were probed.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2218">
                    <text>two sites in tsx-p2 could be recognized in immunoprecipitatio with activating complex cAMP-CRP, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2219">
                    <text>two sites in tsx-p2 could be recognized in immunoprecipitatio with activating the cAMP-CRP complex, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2220">
                    <text>two sites in tsx-p2 could be recognized in immunoprecipitatio with activator complex cAMP-CRP, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2221">
                    <text>two sites in tsx-p2 could be recognized in immunoprecipitatio with the activator complex cAMP-CRP, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2222">
                    <text>two sites in tsx-p2 could be recognized in immunoprecipitatio with the cAMP-CRP activator complex, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2223">
                    <text>two sites in tsx-p2 has been recognized by activating complex cAMP-CRP.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2224">
                    <text>two sites in tsx-p2 has been recognized by activator complex cAMP-CRP.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2225">
                    <text>two sites in tsx-p2 has been recognized by the activator complex cAMP-CRP.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2226">
                    <text>two sites in tsx-p2 has been recognized by the cAMP-CRP activator complex.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2227">
                    <text>two sites in tsx-p2 is recognized by activating complex cAMP-CRP by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2228">
                    <text>two sites in tsx-p2 is recognized by activating complex cAMP-CRP by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2229">
                    <text>two sites in tsx-p2 is recognized by activating complex cAMP-CRP that the litters were probed.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2230">
                    <text>two sites in tsx-p2 is recognized by activating complex cAMP-CRP.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2231">
                    <text>two sites in tsx-p2 is recognized by activating the cAMP-CRP complex by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2232">
                    <text>two sites in tsx-p2 is recognized by activating the cAMP-CRP complex by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2233">
                    <text>two sites in tsx-p2 is recognized by activating the cAMP-CRP complex that the litters were probed.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2234">
                    <text>two sites in tsx-p2 is recognized by activator complex cAMP-CRP by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2235">
                    <text>two sites in tsx-p2 is recognized by activator complex cAMP-CRP by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2236">
                    <text>two sites in tsx-p2 is recognized by activator complex cAMP-CRP that the litters were probed.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2237">
                    <text>two sites in tsx-p2 is recognized by activator complex cAMP-CRP.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2238">
                    <text>two sites in tsx-p2 is recognized by the activator complex cAMP-CRP by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2239">
                    <text>two sites in tsx-p2 is recognized by the activator complex cAMP-CRP by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2240">
                    <text>two sites in tsx-p2 is recognized by the activator complex cAMP-CRP that the litters were probed.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2241">
                    <text>two sites in tsx-p2 is recognized by the activator complex cAMP-CRP.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2242">
                    <text>two sites in tsx-p2 is recognized by the cAMP-CRP activator complex by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2243">
                    <text>two sites in tsx-p2 is recognized by the cAMP-CRP activator complex that the litters were probed.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2244">
                    <text>two sites in tsx-p2 is recognized by the cAMP-CRP activator complex.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2245">
                    <text>two sites in tsx-p2 was recognized by activating complex cAMP-CRP by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2246">
                    <text>two sites in tsx-p2 was recognized by activating complex cAMP-CRP.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2247">
                    <text>two sites in tsx-p2 was recognized by activating the cAMP-CRP complex by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2248">
                    <text>two sites in tsx-p2 was recognized by activator complex cAMP-CRP by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2249">
                    <text>two sites in tsx-p2 was recognized by activator complex cAMP-CRP.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2250">
                    <text>two sites in tsx-p2 was recognized by the activator complex cAMP-CRP by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2251">
                    <text>two sites in tsx-p2 was recognized by the activator complex cAMP-CRP.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2252">
                    <text>two sites in tsx-p2 was recognized by the cAMP-CRP activator complex by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2253">
                    <text>two sites in tsx-p2 was recognized by the cAMP-CRP activator complex.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2254">
                    <text>two sites in tsx-p2 was recognized in the immunoprecipitatome with activating complex cAMP-CRP, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2255">
                    <text>two sites in tsx-p2 was recognized in the immunoprecipitatome with activating the cAMP-CRP complex, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2256">
                    <text>two sites in tsx-p2 was recognized in the immunoprecipitatome with activator complex cAMP-CRP, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2257">
                    <text>two sites in tsx-p2 was recognized in the immunoprecipitatome with the activator complex cAMP-CRP, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2258">
                    <text>two sites in tsx-p2 were recognized by activating the cAMP-CRP complex.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2259">
                    <text>two sites in tsx-p2 were recognized by activator complex cAMP-CRP.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2260">
                    <text>two sites in tsx-p2 were recognized by the activator complex cAMP-CRP.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2261">
                    <text>two sites in tsx-p2 will be recognized by activating complex cAMP-CRP.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2262">
                    <text>two sites in tsx-p2 will be recognized by activating the cAMP-CRP complex.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2263">
                    <text>two sites in tsx-p2 will be recognized by activator complex cAMP-CRP.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2264">
                    <text>two sites in tsx-p2 will be recognized by the activating complex cAMP-CRP.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2265">
                    <text>two sites in tsx-p2 will be recognized by the activating the cAMP-CRP complex.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2266">
                    <text>two sites in tsx-p2 will be recognized by the activator complex cAMP-CRP.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2267">
                    <text>two sites in tsx-p2 will be recognized by the the activator complex cAMP-CRP.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2268">
                    <text>two sites in tsx-p2 will be recognized by the the cAMP-CRP activator complex.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2269">
                    <text>two sites in tsx-p2 will be recognized in immunoprecipitatio with activating the cAMP-CRP complex, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2270">
                    <text>two sites in tsx-p2 will be recognized in immunoprecipitatio with activator complex cAMP-CRP, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2271">
                    <text>two sites in tsx-p2 will be recognized in immunoprecipitatio with the cAMP-CRP activator complex, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2272">
                    <text>two sites in tsx-p2, cannot is recognized in immunoprecipitatio with activating complex cAMP-CRP, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2273">
                    <text>two sites in tsx-p2, cannot is recognized in immunoprecipitatio with activating the cAMP-CRP complex, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2274">
                    <text>two sites in tsx-p2, cannot is recognized in immunoprecipitatio with activator complex cAMP-CRP, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2275">
                    <text>two sites in tsx-p2, cannot is recognized in immunoprecipitatio with the activator complex cAMP-CRP, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2276">
                    <text>two sites in tsx-p2, cannot is recognized in immunoprecipitatio with the cAMP-CRP activator complex, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2277">
                    <text>two sites in tsx-p2, cannot is recognized in the immunoprecipitaiton with activating complex cAMP-CRP as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2278">
                    <text>two sites in tsx-p2, cannot is recognized in the immunoprecipitaiton with activating the cAMP-CRP complex as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2279">
                    <text>two sites in tsx-p2, cannot is recognized in the immunoprecipitaiton with activator complex cAMP-CRP as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2280">
                    <text>two sites in tsx-p2, cannot is recognized in the immunoprecipitaiton with the cAMP-CRP activator complex as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2281">
                    <text>two sites in tsx-p2, could be recognized in the immunoprecipitaiton with activating complex cAMP-CRP as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2282">
                    <text>two sites in tsx-p2, could be recognized in the immunoprecipitaiton with activating the cAMP-CRP complex as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2283">
                    <text>two sites in tsx-p2, could be recognized in the immunoprecipitaiton with activator complex cAMP-CRP as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2284">
                    <text>two sites in tsx-p2, could be recognized in the immunoprecipitaiton with the cAMP-CRP activator complex as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2285">
                    <text>two sites in tsx-p2, has been recognized in the immunoprecipitaiton with activating complex cAMP-CRP as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2286">
                    <text>two sites in tsx-p2, has been recognized in the immunoprecipitaiton with activating the cAMP-CRP complex as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2287">
                    <text>two sites in tsx-p2, has been recognized in the immunoprecipitaiton with the activator complex cAMP-CRP as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2288">
                    <text>two sites in tsx-p2, has been recognized in the immunoprecipitaiton with the cAMP-CRP activator complex as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2289">
                    <text>two sites in tsx-p2, was not recognized in the immunoprecipitaiton with activating complex cAMP-CRP as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2290">
                    <text>two sites in tsx-p2, was not recognized in the immunoprecipitaiton with activator complex cAMP-CRP as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2291">
                    <text>two sites in tsx-p2, was not recognized in the immunoprecipitaiton with the activator complex cAMP-CRP as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2292">
                    <text>two sites in tsx-p2, was not recognized in the immunoprecipitaiton with the cAMP-CRP activator complex as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2293">
                    <text>two sites in tsx-p2, was unrecognized in immunoprecipitatio with activating complex cAMP-CRP, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2294">
                    <text>two sites in tsx-p2, was unrecognized in immunoprecipitatio with activating the cAMP-CRP complex, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2295">
                    <text>two sites in tsx-p2, was unrecognized in immunoprecipitatio with activator complex cAMP-CRP, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2296">
                    <text>two sites in tsx-p2, was unrecognized in immunoprecipitatio with the activator complex cAMP-CRP, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">the activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2297">
                    <text>two sites in tsx-p2, will be recognized in the immunoprecipitaiton with activating complex cAMP-CRP as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">activating complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2298">
                    <text>two sites in tsx-p2, will be recognized in the immunoprecipitaiton with activating the cAMP-CRP complex as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">activating the cAMP-CRP complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2299">
                    <text>two sites in tsx-p2, will be recognized in the immunoprecipitaiton with activator complex cAMP-CRP as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">activator complex cAMP-CRP</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="PERMUTATE" no="2300">
                    <text>two sites in tsx-p2, will be recognized in the immunoprecipitaiton with the cAMP-CRP activator complex as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the cAMP-CRP activator complex</arg>
                    <arg n="1">two sites in tsx-p2</arg>
                </example>
                <example src="REPLACE" no="1">
                    <text>A0 (the eukaryotic binding factor upstream (UBF), has recognized a series of Ags and activated the RNA polymerase I-mediated transcription through cooperative interactions with the specific factor of the species, SL1.</text>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="2">
                    <text>A0 (the eukaryotic binding factor upstream (UBF), recognized a number of Ags and activated the transcription mediated by RNA polymerase I through cooperative interactions with the specific factor of the species, SL1.</text>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="3">
                    <text>A0 (the eukaryotic binding factor upstream (UBF), will recognize a number of Ags and activate RNA polymerase I-mediated transcription through cooperative interactions with the specific factor of the species, SL1.</text>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="4">
                    <text>A0 (the eukaryotic binding factor upstream (UBF), will recognize a series of Ags and activate RNA polymerase I-mediated transcription through cooperative interactions with the specific factor of the species, SL1.</text>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="5">
                    <text>A0 (the upstream eukaryotic binding factor (UBF) will recognize a number of Ags and activate the RNN polymerase I-mediated transcription through cooperative interactions with the species-specific factor, SL1.</text>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="6">
                    <text>A0 (the upstream eukaryotic binding factor (UBF), recognized a number of Ags and activated RNA polymerase I-mediated transcription through cooperative interactions with the species specific factor, SL1.</text>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="7">
                    <text>A0 (the upstream eukaryotic binding factor (UBF), recognized a series of Ags and activated RNA polymerase I-mediated transcription through cooperative interactions with the species specific factor, SL1.</text>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="8">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that are recognized by Class and T cells specific to melanoma are the ones indicated.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                </example>
                <example src="REPLACE" no="9">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that are recognized by RNA supply apparatus are the ones indicated.</text>
                    <arg n="0">RNA supply apparatus</arg>
                </example>
                <example src="REPLACE" no="10">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that are recognized by autological serum are the ones indicated.</text>
                    <arg n="0">autological serum</arg>
                </example>
                <example src="REPLACE" no="11">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that are recognized by autologous serum are the ones indicated.</text>
                    <arg n="0">autologous serum</arg>
                </example>
                <example src="REPLACE" no="12">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that are recognized by class I melanoma-specific T cells are the ones indicated.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                </example>
                <example src="REPLACE" no="13">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that are recognized by one of the two monoclonal antibodies are the ones indicated.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                </example>
                <example src="REPLACE" no="14">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that are recognized by one of two monoclonal antibodies are the ones indicated.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                </example>
                <example src="REPLACE" no="15">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that are recognized by the RNA supply apparatus are the ones indicated.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                </example>
                <example src="REPLACE" no="16">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that are recognized by the autological serum are the ones indicated.</text>
                    <arg n="0">the autological serum</arg>
                </example>
                <example src="REPLACE" no="17">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that are recognized by the autologous serum are the ones indicated.</text>
                    <arg n="0">the autologous serum</arg>
                </example>
                <example src="REPLACE" no="18">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that are recognized by the reverse transcription apparatus are the ones indicated.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                </example>
                <example src="REPLACE" no="19">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that can be recognized by Class I melanoma-specific T cells are the ones indicated.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                </example>
                <example src="REPLACE" no="20">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that can be recognized by Class and T cells specific to melanoma are indicated.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                </example>
                <example src="REPLACE" no="21">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that can be recognized by Class and T cells specific to melanoma are the ones indicated.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                </example>
                <example src="REPLACE" no="22">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that can be recognized by RNA supply apparatus are indicated.</text>
                    <arg n="0">RNA supply apparatus</arg>
                </example>
                <example src="REPLACE" no="23">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that can be recognized by RNA supply apparatus are the ones indicated.</text>
                    <arg n="0">RNA supply apparatus</arg>
                </example>
                <example src="REPLACE" no="24">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that can be recognized by autological serum are indicated.</text>
                    <arg n="0">autological serum</arg>
                </example>
                <example src="REPLACE" no="25">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that can be recognized by autological serum are the ones indicated.</text>
                    <arg n="0">autological serum</arg>
                </example>
                <example src="REPLACE" no="26">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that can be recognized by autologous serum are indicated.</text>
                    <arg n="0">autologous serum</arg>
                </example>
                <example src="REPLACE" no="27">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that can be recognized by autologous serum are the ones indicated.</text>
                    <arg n="0">autologous serum</arg>
                </example>
                <example src="REPLACE" no="28">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that can be recognized by class I melanoma-specific T cells are indicated.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                </example>
                <example src="REPLACE" no="29">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that can be recognized by class I melanoma-specific T cells are the ones indicated.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                </example>
                <example src="REPLACE" no="30">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that can be recognized by one of the two monoclonal antibodies are indicated.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                </example>
                <example src="REPLACE" no="31">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that can be recognized by one of the two monoclonal antibodies are the ones indicated.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                </example>
                <example src="REPLACE" no="32">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that can be recognized by one of two monoclonal antibodies are indicated.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                </example>
                <example src="REPLACE" no="33">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that can be recognized by one of two monoclonal antibodies are the ones indicated.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                </example>
                <example src="REPLACE" no="34">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that can be recognized by the RNA supply apparatus are the ones indicated.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                </example>
                <example src="REPLACE" no="35">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that can be recognized by the autological serum are indicated.</text>
                    <arg n="0">the autological serum</arg>
                </example>
                <example src="REPLACE" no="36">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that can be recognized by the autological serum are the ones indicated.</text>
                    <arg n="0">the autological serum</arg>
                </example>
                <example src="REPLACE" no="37">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that can be recognized by the autologous serum are indicated.</text>
                    <arg n="0">the autologous serum</arg>
                </example>
                <example src="REPLACE" no="38">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that can be recognized by the autologous serum are the ones indicated.</text>
                    <arg n="0">the autologous serum</arg>
                </example>
                <example src="REPLACE" no="39">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that can be recognized by the reverse transcription apparatus are indicated.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                </example>
                <example src="REPLACE" no="40">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that can be recognized by the reverse transcription apparatus are the ones indicated.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                </example>
                <example src="REPLACE" no="41">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that have been recognized by Class I melanoma-specific T cells are as given.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                </example>
                <example src="REPLACE" no="42">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that have been recognized by Class I melanoma-specific T cells are the ones indicated.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                </example>
                <example src="REPLACE" no="43">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that have been recognized by Class and T cells specific to melanoma are the ones indicated.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                </example>
                <example src="REPLACE" no="44">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that have been recognized by RNA supply apparatus are as given.</text>
                    <arg n="0">RNA supply apparatus</arg>
                </example>
                <example src="REPLACE" no="45">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that have been recognized by RNA supply apparatus are the ones indicated.</text>
                    <arg n="0">RNA supply apparatus</arg>
                </example>
                <example src="REPLACE" no="46">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that have been recognized by autological serum are as given.</text>
                    <arg n="0">autological serum</arg>
                </example>
                <example src="REPLACE" no="47">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that have been recognized by autologous serum are as given.</text>
                    <arg n="0">autologous serum</arg>
                </example>
                <example src="REPLACE" no="48">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that have been recognized by autologous serum are the ones indicated.</text>
                    <arg n="0">autologous serum</arg>
                </example>
                <example src="REPLACE" no="49">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that have been recognized by class I melanoma-specific T cells are as given.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                </example>
                <example src="REPLACE" no="50">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that have been recognized by class I melanoma-specific T cells are the ones indicated.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                </example>
                <example src="REPLACE" no="51">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that have been recognized by one of the two monoclonal antibodies are as given.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                </example>
                <example src="REPLACE" no="52">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that have been recognized by one of the two monoclonal antibodies are the ones indicated.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                </example>
                <example src="REPLACE" no="53">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that have been recognized by one of two monoclonal antibodies are as given.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                </example>
                <example src="REPLACE" no="54">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that have been recognized by the RNA supply apparatus are the ones indicated.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                </example>
                <example src="REPLACE" no="55">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that have been recognized by the autological serum are the ones indicated.</text>
                    <arg n="0">the autological serum</arg>
                </example>
                <example src="REPLACE" no="56">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that have been recognized by the autologous serum are as given.</text>
                    <arg n="0">the autologous serum</arg>
                </example>
                <example src="REPLACE" no="57">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that have been recognized by the autologous serum are the ones indicated.</text>
                    <arg n="0">the autologous serum</arg>
                </example>
                <example src="REPLACE" no="58">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that have been recognized by the reverse transcription apparatus are the ones indicated.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                </example>
                <example src="REPLACE" no="59">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that were recognized by Class I melanoma-specific T cells are the ones indicated.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                </example>
                <example src="REPLACE" no="60">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that were recognized by Class and T cells specific to melanoma are the ones indicated.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                </example>
                <example src="REPLACE" no="61">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that were recognized by RNA supply apparatus are the ones indicated.</text>
                    <arg n="0">RNA supply apparatus</arg>
                </example>
                <example src="REPLACE" no="62">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that were recognized by class I melanoma-specific T cells are the ones indicated.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                </example>
                <example src="REPLACE" no="63">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that were recognized by one of the two monoclonal antibodies are the ones indicated.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                </example>
                <example src="REPLACE" no="64">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that were recognized by one of two monoclonal antibodies are the ones indicated.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                </example>
                <example src="REPLACE" no="65">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that were recognized by the RNA supply apparatus are the ones indicated.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                </example>
                <example src="REPLACE" no="66">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that were recognized by the autological serum are the ones indicated.</text>
                    <arg n="0">the autological serum</arg>
                </example>
                <example src="REPLACE" no="67">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that were recognized by the autologous serum are the ones indicated.</text>
                    <arg n="0">the autologous serum</arg>
                </example>
                <example src="REPLACE" no="68">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that were recognized by the reverse transcription apparatus are the ones indicated.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                </example>
                <example src="REPLACE" no="69">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that will be recognized by Class I melanoma-specific T cells are indicated.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                </example>
                <example src="REPLACE" no="70">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that will be recognized by Class I melanoma-specific T cells are the ones indicated.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                </example>
                <example src="REPLACE" no="71">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that will be recognized by Class and T cells specific to melanoma are indicated.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                </example>
                <example src="REPLACE" no="72">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that will be recognized by Class and T cells specific to melanoma are the ones indicated.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                </example>
                <example src="REPLACE" no="73">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that will be recognized by RNA supply apparatus are indicated.</text>
                    <arg n="0">RNA supply apparatus</arg>
                </example>
                <example src="REPLACE" no="74">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that will be recognized by RNA supply apparatus are the ones indicated.</text>
                    <arg n="0">RNA supply apparatus</arg>
                </example>
                <example src="REPLACE" no="75">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that will be recognized by autological serum are indicated.</text>
                    <arg n="0">autological serum</arg>
                </example>
                <example src="REPLACE" no="76">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that will be recognized by autological serum are the ones indicated.</text>
                    <arg n="0">autological serum</arg>
                </example>
                <example src="REPLACE" no="77">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that will be recognized by autologous serum are indicated.</text>
                    <arg n="0">autologous serum</arg>
                </example>
                <example src="REPLACE" no="78">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that will be recognized by autologous serum are the ones indicated.</text>
                    <arg n="0">autologous serum</arg>
                </example>
                <example src="REPLACE" no="79">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that will be recognized by class I melanoma-specific T cells are indicated.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                </example>
                <example src="REPLACE" no="80">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that will be recognized by class I melanoma-specific T cells are the ones indicated.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                </example>
                <example src="REPLACE" no="81">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that will be recognized by one of the two monoclonal antibodies are indicated.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                </example>
                <example src="REPLACE" no="82">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that will be recognized by one of the two monoclonal antibodies are the ones indicated.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                </example>
                <example src="REPLACE" no="83">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that will be recognized by one of two monoclonal antibodies are the ones indicated.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                </example>
                <example src="REPLACE" no="84">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that will be recognized by the RNA supply apparatus are indicated.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                </example>
                <example src="REPLACE" no="85">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that will be recognized by the RNA supply apparatus are the ones indicated.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                </example>
                <example src="REPLACE" no="86">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that will be recognized by the autological serum are indicated.</text>
                    <arg n="0">the autological serum</arg>
                </example>
                <example src="REPLACE" no="87">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that will be recognized by the autological serum are the ones indicated.</text>
                    <arg n="0">the autological serum</arg>
                </example>
                <example src="REPLACE" no="88">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that will be recognized by the autologous serum are indicated.</text>
                    <arg n="0">the autologous serum</arg>
                </example>
                <example src="REPLACE" no="89">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that will be recognized by the autologous serum are the ones indicated.</text>
                    <arg n="0">the autologous serum</arg>
                </example>
                <example src="REPLACE" no="90">
                    <text>A1 (the two forms of Stat3 (Stat3fm and Stat3sm) that will be recognized by the reverse transcription apparatus are the ones indicated.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                </example>
                <example src="REPLACE" no="91">
                    <text>Blots were surveyed with Class I melanoma-specific T cells recognizing a number of Ags.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="92">
                    <text>Blots were surveyed with Class I melanoma-specific T cells recognizing a series of Ags.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="93">
                    <text>Blots were surveyed with Class and T cells specific to melanoma recognizing a series of Ags.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="94">
                    <text>Blots were surveyed with RNA supply apparatus recognizing normal slice ligation.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="95">
                    <text>Blots were surveyed with autological serum recognizing epitopes.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="96">
                    <text>Blots were surveyed with autologous serum recognizing epitopes.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="97">
                    <text>Blots were surveyed with class I melanoma-specific T cells recognizing a series of Ags.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="98">
                    <text>Blots were surveyed with one of the two monoclonal antibodies recognizing COOH-terminal epitopes.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="99">
                    <text>Blots were surveyed with one of two monoclonal antibodies recognizing COOH-terminal epitopes.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="100">
                    <text>Blots were surveyed with one of two monoclonal antibodies recognizing cooled-terminal epitopes.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="101">
                    <text>Blots were surveyed with the RNA supply apparatus recognizing the normal splice binding.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="102">
                    <text>Blots were surveyed with the autologous serum recognizing epitopes.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="103">
                    <text>Blots were surveyed with the reverse transcription apparatus recognizing the normal junction of slice.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="104">
                    <text>COOH-terminal epitopes are recognized by one of the two monoclonal antibodies with which the threads were probed.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="105">
                    <text>COOH-terminal epitopes are recognized by one of the two monoclonal antibodies.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="106">
                    <text>COOH-terminal epitopes are recognized by one of two monoclonal antibodies with which the wires were probed.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="107">
                    <text>COOH-terminal epitopes could be recognized in immunoprecipitatio with one of the two monoclonal antibodies, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="108">
                    <text>COOH-terminal epitopes could be recognized in immunoprecipitatio with one of two monoclonal antibodies, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="109">
                    <text>COOH-terminal epitopes has been recognized by one of the two monoclonal antibodies.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="110">
                    <text>COOH-terminal epitopes has been recognized by one of two monoclonal antibodies.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="111">
                    <text>COOH-terminal epitopes is recognized by one of the two monoclonal antibodies by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="112">
                    <text>COOH-terminal epitopes is recognized by one of the two monoclonal antibodies by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="113">
                    <text>COOH-terminal epitopes is recognized by one of the two monoclonal antibodies that the litters were probed.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="114">
                    <text>COOH-terminal epitopes is recognized by one of two monoclonal antibodies by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="115">
                    <text>COOH-terminal epitopes is recognized by one of two monoclonal antibodies by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="116">
                    <text>COOH-terminal epitopes is recognized by one of two monoclonal antibodies that the litters were probed.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="117">
                    <text>COOH-terminal epitopes is recognized by one of two monoclonal antibodies.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="118">
                    <text>COOH-terminal epitopes was recognized by one of the two monoclonal antibodies.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="119">
                    <text>COOH-terminal epitopes was recognized by one of two monoclonal antibodies.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="120">
                    <text>COOH-terminal epitopes was recognized in the immunoprecipitatome with one of the two monoclonal antibodies, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="121">
                    <text>COOH-terminal epitopes was recognized in the immunoprecipitatome with one of two monoclonal antibodies, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="122">
                    <text>COOH-terminal epitopes were recognized by one of the two monoclonal antibodies.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="123">
                    <text>COOH-terminal epitopes will be recognized by one of the two monoclonal antibodies.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="124">
                    <text>COOH-terminal epitopes will be recognized by one of two monoclonal antibodies.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="125">
                    <text>COOH-terminal epitopes will be recognized by the one of the two monoclonal antibodies.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="126">
                    <text>COOH-terminal epitopes will be recognized by the one of two monoclonal antibodies.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="127">
                    <text>COOH-terminal epitopes will be recognized in immunoprecipitatio with one of the two monoclonal antibodies, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="128">
                    <text>COOH-terminal epitopes will be recognized in immunoprecipitatio with one of two monoclonal antibodies, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="129">
                    <text>COOH-terminal epitopes, cannot is recognized in immunoprecipitatio with one of the two monoclonal antibodies, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="130">
                    <text>COOH-terminal epitopes, cannot is recognized in the immunoprecipitaiton with one of the two monoclonal antibodies as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="131">
                    <text>COOH-terminal epitopes, cannot is recognized in the immunoprecipitaiton with one of two monoclonal antibodies as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="132">
                    <text>COOH-terminal epitopes, could be recognized in the immunoprecipitaiton with one of the two monoclonal antibodies as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="133">
                    <text>COOH-terminal epitopes, could be recognized in the immunoprecipitaiton with one of two monoclonal antibodies as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="134">
                    <text>COOH-terminal epitopes, has been recognized in the immunoprecipitaiton with one of the two monoclonal antibodies as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="135">
                    <text>COOH-terminal epitopes, has been recognized in the immunoprecipitaiton with one of two monoclonal antibodies as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="136">
                    <text>COOH-terminal epitopes, was not recognized in the immunoprecipitaiton with one of the two monoclonal antibodies as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="137">
                    <text>COOH-terminal epitopes, was not recognized in the immunoprecipitaiton with one of two monoclonal antibodies as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="138">
                    <text>COOH-terminal epitopes, was unrecognized in immunoprecipitatio with one of the two monoclonal antibodies, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="139">
                    <text>COOH-terminal epitopes, was unrecognized in immunoprecipitatio with one of two monoclonal antibodies, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="140">
                    <text>COOH-terminal epitopes, will be recognized in the immunoprecipitaiton with one of two monoclonal antibodies as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="141">
                    <text>Class I melanoma-specific T cells also binds to these 727 sites but, unlike NarP, also recognized a number of Ags.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="142">
                    <text>Class I melanoma-specific T cells also binds to these 727 sites but, unlike NarP, also recognized a series of Ags.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="143">
                    <text>Class I melanoma-specific T cells also binds to these sites 7-2-7, but, unlike NarP, it also recognized a number of Ags.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="144">
                    <text>Class I melanoma-specific T cells also binds to these sites 7-2-7, but, unlike NarP, it also recognized a series of Ags .</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="145">
                    <text>Class I melanoma-specific T cells are able to recognize a number of Ags in regulated promoters.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="146">
                    <text>Class I melanoma-specific T cells are able to recognize a series of Ags in regulated promoters.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="147">
                    <text>Class I melanoma-specific T cells binds to these 727 sites but, unlike NarP, will also recognize a number of Ags.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="148">
                    <text>Class I melanoma-specific T cells binds to these sites 7-2-7, but, unlike NarP, it also recognizes a number of Ags .</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="149">
                    <text>Class I melanoma-specific T cells can recognize a number of Ags in regulated promoters.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="150">
                    <text>Class I melanoma-specific T cells has also joined these 727 sites but, unlike NarP, has also recognized a number of Ags.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="151">
                    <text>Class I melanoma-specific T cells has also joined these 727 sites but, unlike NarP, has also recognized a series of Ags.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="152">
                    <text>Class I melanoma-specific T cells is able to recognize a number of Ags in regulated promoters.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="153">
                    <text>Class I melanoma-specific T cells is able to recognize a series of Ags in regulated promoters.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="154">
                    <text>Class I melanoma-specific T cells recognized A1 (epitopes in the C muscle of LMP-1 in dilution 1:200.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                </example>
                <example src="REPLACE" no="155">
                    <text>Class I melanoma-specific T cells recognized a number of Ags in regulated promoters.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="156">
                    <text>Class I melanoma-specific T cells recognized a number of Ags in the regulated promoters.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="157">
                    <text>Class I melanoma-specific T cells recognized a number of Ags.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="158">
                    <text>Class I melanoma-specific T cells recognized a series of Ags in regulated promoters.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="159">
                    <text>Class I melanoma-specific T cells recognized a series of Ags in the regulated promoters.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="160">
                    <text>Class I melanoma-specific T cells recognized a series of Ags.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="161">
                    <text>Class I melanoma-specific T cells recognizes a number of Ags.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="162">
                    <text>Class I melanoma-specific T cells recognizes a series of Ags.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="163">
                    <text>Class I melanoma-specific T cells specifically recognized a series of Ags.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="164">
                    <text>Class I melanoma-specific T cells that has recognized a number of Ags was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="165">
                    <text>Class I melanoma-specific T cells that has recognized a series of Ags was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="166">
                    <text>Class I melanoma-specific T cells that recognized a number of Ags was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="167">
                    <text>Class I melanoma-specific T cells that recognized a series of Ags was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="168">
                    <text>Class I melanoma-specific T cells that recognizes a number of Ags is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="169">
                    <text>Class I melanoma-specific T cells that recognizes a number of Ags is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="170">
                    <text>Class I melanoma-specific T cells that recognizes a series of Ags is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="171">
                    <text>Class I melanoma-specific T cells that recognizes a series of Ags is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="172">
                    <text>Class I melanoma-specific T cells will recognize a number of Ags in regulated promoters.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="173">
                    <text>Class I melanoma-specific T cells will recognize a series of Ags in regulated promoters.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="174">
                    <text>Class and T cells specific to melanoma also binds to these 727 sites but, unlike NarP, also recognized a series of Ags.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="175">
                    <text>Class and T cells specific to melanoma also binds to these sites 7-2-7, but, unlike NarP, it also recognized a series of Ags .</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="176">
                    <text>Class and T cells specific to melanoma also binds to these sites 7-2-7, but, unlike NarP, it also recognized a series of Ags.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="177">
                    <text>Class and T cells specific to melanoma are able to recognize a series of Ags in regulated promoters.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="178">
                    <text>Class and T cells specific to melanoma can recognize a series of Ags in regulated promoters.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="179">
                    <text>Class and T cells specific to melanoma has also joined these 727 sites but, unlike NarP, has also recognized a series of Ags.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="180">
                    <text>Class and T cells specific to melanoma is able to recognize a series of Ags in regulated promoters.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="181">
                    <text>Class and T cells specific to melanoma recognized A1 (epitopes in the C muscle of LMP-1 in dilution 1:200.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                </example>
                <example src="REPLACE" no="182">
                    <text>Class and T cells specific to melanoma recognized a series of Ags in regulated promoters.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="183">
                    <text>Class and T cells specific to melanoma recognized a series of Ags in the regulated promoters.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="184">
                    <text>Class and T cells specific to melanoma recognized a series of Ags.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="185">
                    <text>Class and T cells specific to melanoma recognizes a series of Ags.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="186">
                    <text>Class and T cells specific to melanoma specifically recognized a series of Ags.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="187">
                    <text>Class and T cells specific to melanoma that has recognized a series of Ags was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="188">
                    <text>Class and T cells specific to melanoma that recognized a series of Ags was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="189">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that Class I melanoma-specific T cells can recognize a number of Ags.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="190">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that Class I melanoma-specific T cells can recognize a series of Ags.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="191">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that Class and T cells specific to melanoma can recognize a series of Ags.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="192">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that RNA supply apparatus can recognize normal slice ligation.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="193">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that autologous serum can recognize the epitopes.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="194">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that class I melanoma-specific T cells can recognize a series of Ags.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="195">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that one of the two monoclonal antibodies can recognize COOH-terminal epitopes.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="196">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that one of two monoclonal antibodies can recognize COOH-terminal epitopes.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="197">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that the RNA supply apparatus can recognize the normal splice binding.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="198">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that the autologous serum can recognize epitopes.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="199">
                    <text>Footprint tests have suggested that these regulators protect a stretch of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that the reverse transcription apparatus can recognize the normal junction of slice.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="200">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that Class I melanoma-specific T cells has recognized a series of Ags.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="201">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that Class I melanoma-specific T cells recognized a number of Ags.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="202">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that Class I melanoma-specific T cells recognized a series of Ags.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="203">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that Class and T cells specific to melanoma has recognized a series of Ags.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="204">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that Class and T cells specific to melanoma recognized a series of Ags.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="205">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that RNA supply apparatus has recognized normal slice ligation.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="206">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that RNA supply apparatus recognized normal slice ligation.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="207">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that autological serum has recognized epitopes.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="208">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that autological serum recognized epitopes.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="209">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that autologous serum has recognized epitopes.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="210">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that autologous serum recognized epitopes.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="211">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that autologous serum recognized the epitopes.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="212">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that class I melanoma-specific T cells has recognized a series of Ags.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="213">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that class I melanoma-specific T cells recognized a series of Ags.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="214">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that one of the two monoclonal antibodies has recognized COOH-terminal epitopes.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="215">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that one of the two monoclonal antibodies recognized COOH-terminal epitopes.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="216">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that one of two monoclonal antibodies has recognized COOH-terminal epitopes.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="217">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that one of two monoclonal antibodies has recognized cooled-terminal epitopes.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="218">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that one of two monoclonal antibodies recognized COOH-terminal epitopes.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="219">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that one of two monoclonal antibodies recognized cooled-terminal epitopes.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="220">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that the RNA supply apparatus has recognized the normal splice binding.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="221">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that the RNA supply apparatus recognized the normal splice binding.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="222">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that the autological serum has recognized epiptopes.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="223">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that the autological serum recognized epiptopes.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="224">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that the autologous serum recognized epitopes.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="225">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that the reverse transcription apparatus has recognized the normal junction of slice.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="226">
                    <text>Footprint tests have suggested that these regulators protect a tranche of up to 20 bp in goal promoters, and multiple alignments of binding sites for a number of regulators have shown that the reverse transcription apparatus recognized the normal junction of slice.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="227">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where COOH-terminal epitopes is recognized by one of the two monoclonal antibodies.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="228">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where COOH-terminal epitopes is recognized by one of two monoclonal antibodies.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="229">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where COOH-terminal epitopes was recognized by one of the two monoclonal antibodies.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="230">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where COOH-terminal epitopes was recognized by one of two monoclonal antibodies.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="231">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where a number of Ags is recognized by Class I melanoma-specific T cells.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="232">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where a number of Ags was recognized by Class I melanoma-specific T cells.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="233">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where a series of Ags is recognized by Class I melanoma-specific T cells.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="234">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where a series of Ags is recognized by Class and T cells specific to melanoma.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="235">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where a series of Ags is recognized by class I melanoma-specific T cells.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="236">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where a series of Ags was recognized by Class I melanoma-specific T cells.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="237">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where a series of Ags was recognized by Class and T cells specific to melanoma.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="238">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where a series of Ags was recognized by class I melanoma-specific T cells.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="239">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where cooled-terminal epitopes is recognized by one of two monoclonal antibodies.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="240">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where cooled-terminal epitopes was recognized by one of two monoclonal antibodies.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="241">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where epiptopes is recognized by the autological serum.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="242">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where epiptopes was recognized by the autological serum.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="243">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where epitopes is recognized by autological serum.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="244">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where epitopes is recognized by autologous serum.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="245">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where epitopes is recognized by the autologous serum.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="246">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where epitopes was recognized by autological serum.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="247">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where epitopes was recognized by the autologous serum.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="248">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where normal slice ligation is recognized by RNA supply apparatus.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="249">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where normal slice ligation was recognized by RNA supply apparatus.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="250">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where the epitopes is recognized by autologous serum.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="251">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where the epitopes was recognized by autologous serum.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="252">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where the normal junction of slice is recognized by the reverse transcription apparatus.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="253">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where the normal junction of slice was recognized by the reverse transcription apparatus.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="254">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where the normal splice binding is recognized by the RNA supply apparatus.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="255">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence where the normal splice binding was recognized by the RNA supply apparatus.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="256">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with Class I melanoma-specific T cells which recognized a series of Ags and by the western inflorescence.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="257">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with Class I melanoma-specific T cells which recognized a series of Ags, and by Western blotting</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="258">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with Class I melanoma-specific T cells which recognizes a number of Ags, and by Western blotting</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="259">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with Class I melanoma-specific T cells which recognizes a series of Ags, and by Western blotting</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="260">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with Class and T cells specific to melanoma which recognized a series of Ags and by the western inflorescence.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="261">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with RNA supply apparatus which recognized normal slice ligation and by the western inflorescence.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="262">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with RNA supply apparatus which recognized normal slice ligation, and by Western blotting</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="263">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with autological serum which recognized epitopes, and by Western blotting</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="264">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with autological serum which recognizes epitopes, and by Western blotting</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="265">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with autologous serum which recognized epitopes and by the western inflorescence.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="266">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with autologous serum which recognized epitopes, and by Western blotting</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="267">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with autologous serum which recognized the epitopes and by the western inflorescence.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="268">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with autologous serum which recognized the epitopes, and by Western blotting</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="269">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with autologous serum which recognizes epitopes, and by Western blotting</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="270">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with autologous serum which recognizes the epitopes, and by Western blotting</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="271">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with class I melanoma-specific T cells which recognized a series of Ags and by the western inflorescence.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="272">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with class I melanoma-specific T cells which recognized a series of Ags, and by Western blotting</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="273">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with class I melanoma-specific T cells which recognizes a series of Ags, and by Western blotting</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="274">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with one of the two monoclonal antibodies which recognized COOH-terminal epitopes and by the western inflorescence.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="275">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with one of the two monoclonal antibodies which recognized COOH-terminal epitopes, and by Western blotting</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="276">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with one of the two monoclonal antibodies which recognizes COOH-terminal epitopes, and by Western blotting</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="277">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with one of two monoclonal antibodies which recognized COOH-terminal epitopes and by the western inflorescence.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="278">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with one of two monoclonal antibodies which recognized COOH-terminal epitopes, and by Western blotting</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="279">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with one of two monoclonal antibodies which recognized cooled-terminal epitopes and by the western inflorescence.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="280">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with one of two monoclonal antibodies which recognized cooled-terminal epitopes, and by Western blotting</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="281">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with one of two monoclonal antibodies which recognizes COOH-terminal epitopes, and by Western blotting</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="282">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with one of two monoclonal antibodies which recognizes cooled-terminal epitopes, and by Western blotting</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="283">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with the RNA supply apparatus which recognized the normal splice binding, and by Western blotting</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="284">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with the RNA supply apparatus which recognizes the normal splice binding, and by Western blotting</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="285">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with the autological serum which recognized epiptopes, and by Western blotting</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="286">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with the autological serum which recognizes epiptopes, and by Western blotting</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="287">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with the autologous serum which recognized epitopes and by the western inflorescence.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="288">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with the autologous serum which recognized epitopes, and by Western blotting</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="289">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with the autologous serum which recognizes epitopes, and by Western blotting</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="290">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with the reverse transcription apparatus which recognized the normal junction of slice and by the western inflorescence.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="291">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with the reverse transcription apparatus which recognized the normal junction of slice, and by Western blotting</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="292">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence with the reverse transcription apparatus which recognizes the normal junction of slice, and by Western blotting</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="293">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where COOH-terminal epitopes was recognized by one of the two monoclonal antibodies.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="294">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where COOH-terminal epitopes was recognized by one of two monoclonal antibodies.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="295">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where a number of Ags was recognized by Class I melanoma-specific T cells.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="296">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where a series of Ags was recognized by Class I melanoma-specific T cells.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="297">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where a series of Ags was recognized by Class and T cells specific to melanoma.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="298">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where cooled-terminal epitopes was recognized by one of two monoclonal antibodies.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="299">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where epiptopes was recognized by the autological serum.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="300">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where epitopes was recognized by autologous serum.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="301">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where epitopes was recognized by the autologous serum.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="302">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where normal slice ligation was recognized by RNA supply apparatus.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="303">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where the normal junction of slice was recognized by the reverse transcription apparatus.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="304">
                    <text>Individual cell clones were analyzed for the expression STAT1 by immunofluorescence, where the normal splice binding was recognized by the RNA supply apparatus.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="305">
                    <text>It is shown that Class I melanoma-specific T cells has recognized a number of Ags that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="306">
                    <text>It is shown that Class I melanoma-specific T cells has recognized a series of Ags that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="307">
                    <text>It is shown that Class and T cells specific to melanoma has recognized a series of Ags that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="308">
                    <text>It is shown that RNA supply apparatus has recognized normal slice ligation that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="309">
                    <text>It is shown that autologous serum has recognized epitopes that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="310">
                    <text>It is shown that autologous serum has recognized the epitopes that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="311">
                    <text>It is shown that class I melanoma-specific T cells has recognized a series of Ags that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="312">
                    <text>It is shown that one of the two monoclonal antibodies has recognized COOH-terminal epitopes that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="313">
                    <text>It is shown that one of two monoclonal antibodies has recognized COOH-terminal epitopes that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="314">
                    <text>It is shown that one of two monoclonal antibodies has recognized cooled-terminal epitopes that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="315">
                    <text>It is shown that the RNA supply apparatus has recognized the normal splice binding that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="316">
                    <text>It is shown that the autological serum has recognized epiptopes that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="317">
                    <text>It is shown that the autologous serum has recognized epitopes that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="318">
                    <text>It is shown that the reverse transcription apparatus has recognized the normal junction of slice that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) is centered around the position-74 bp.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="319">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that Class I melanoma-specific T cells are able to recognize a number of Ags.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="320">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that Class I melanoma-specific T cells are able to recognize a series of Ags.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="321">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that Class I melanoma-specific T cells can recognize a number of Ags.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="322">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that Class I melanoma-specific T cells can recognize a series of Ags.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="323">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that Class I melanoma-specific T cells has recognized a number of Ags.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="324">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that Class I melanoma-specific T cells has recognized a series of Ags.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="325">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that Class I melanoma-specific T cells recognized a series of Ags.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="326">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that Class and T cells specific to melanoma can recognize a series of Ags.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="327">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that Class and T cells specific to melanoma recognized a series of Ags.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="328">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that RNA supply apparatus are able to recognize normal slice ligation.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="329">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that RNA supply apparatus can recognize normal slice ligation.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="330">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that RNA supply apparatus has recognized normal slice ligation.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="331">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that RNA supply apparatus recognized normal slice ligation.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="332">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that autological serum are able to recognize epitopes.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="333">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that autological serum can recognize epitopes.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="334">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that autological serum has recognized epitopes.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="335">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that autological serum recognized epitopes.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="336">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that autologous serum are able to recognize epitopes.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="337">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that autologous serum are able to recognize the epitopes.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="338">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that autologous serum can recognize epitopes.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="339">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that autologous serum can recognize the epitopes.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="340">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that autologous serum has recognized epitopes.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="341">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that autologous serum recognized epitopes.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="342">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that autologous serum recognized the epitopes.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="343">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that class I melanoma-specific T cells are able to recognize a series of Ags.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="344">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that class I melanoma-specific T cells can recognize a series of Ags.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="345">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that class I melanoma-specific T cells has recognized a series of Ags.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="346">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that class I melanoma-specific T cells recognized a series of Ags.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="347">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that one of the two monoclonal antibodies are able to recognize COOH-terminal epitopes.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="348">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that one of the two monoclonal antibodies can recognize COOH-terminal epitopes.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="349">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that one of the two monoclonal antibodies has recognized COOH-terminal epitopes.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="350">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that one of the two monoclonal antibodies recognized COOH-terminal epitopes.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="351">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that one of two monoclonal antibodies are able to recognize COOH-terminal epitopes.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="352">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that one of two monoclonal antibodies can recognize COOH-terminal epitopes.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="353">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that one of two monoclonal antibodies has recognized COOH-terminal epitopes.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="354">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that one of two monoclonal antibodies recognized COOH-terminal epitopes.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="355">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that one of two monoclonal antibodies recognized cooled-terminal epitopes.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="356">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that the RNA supply apparatus are able to recognize the normal splice binding.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="357">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that the RNA supply apparatus can recognize the normal splice binding.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="358">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that the RNA supply apparatus has recognized the normal splice binding.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="359">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that the autological serum are able to recognize epiptopes.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="360">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that the autological serum can recognize epiptopes.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="361">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that the autological serum has recognized epiptopes.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="362">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that the autological serum recognized epiptopes.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="363">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that the autologous serum are able to recognize epitopes.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="364">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that the autologous serum can recognize epitopes.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="365">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that the autologous serum has recognized epitopes.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="366">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that the autologous serum recognized epitopes.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="367">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that the reverse transcription apparatus are able to recognize the normal junction of slice.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="368">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that the reverse transcription apparatus has recognized the normal junction of slice.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="369">
                    <text>Paperprinting tests have suggested that these regulators protect a segment of up to 20 bp in target promoters, and various alignments of binding sites for a number of regulators have shown that the reverse transcription apparatus recognized the normal junction of slice.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="370">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that Class I melanoma-specific T cells are able to recognize a series of Ags.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="371">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that RNA supply apparatus are able to recognize normal slice ligation.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="372">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that autological serum are able to recognize epitopes.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="373">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that autologous serum are able to recognize epitopes.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="374">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that autologous serum are able to recognize the epitopes.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="375">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that class I melanoma-specific T cells are able to recognize a series of Ags.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="376">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that one of the two monoclonal antibodies are able to recognize COOH-terminal epitopes.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="377">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that one of two monoclonal antibodies are able to recognize COOH-terminal epitopes.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="378">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that one of two monoclonal antibodies are able to recognize cooled-terminal epitopes.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="379">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that the RNA supply apparatus are able to recognize the normal splice binding.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="380">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that the autological serum are able to recognize epiptopes.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="381">
                    <text>Printing tests have suggested that these regulators protect a segment of up to 20 bp in goal promoters, and several alignments of binding sites for various regulators have shown that the autologous serum are able to recognize epitopes.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="382">
                    <text>RNA supply apparatus also binds to these 727 sites but, unlike NarP, also recognized normal slice ligation.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="383">
                    <text>RNA supply apparatus also binds to these sites 7-2-7, but, unlike NarP, it also recognized normal slice ligation .</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="384">
                    <text>RNA supply apparatus are able to recognize normal slice ligation in regulated promoters.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="385">
                    <text>RNA supply apparatus binds to these 727 sites but, unlike NarP, will also recognize normal slice ligation.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="386">
                    <text>RNA supply apparatus binds to these sites 7-2-7, but, unlike NarP, it also recognizes normal slice ligation .</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="387">
                    <text>RNA supply apparatus can recognize normal slice ligation in regulated promoters.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="388">
                    <text>RNA supply apparatus has also joined these 727 sites but, unlike NarP, has also recognized normal slice ligation.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="389">
                    <text>RNA supply apparatus is able to recognize normal slice ligation in regulated promoters.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="390">
                    <text>RNA supply apparatus recognized normal slice ligation in regulated promoters.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="391">
                    <text>RNA supply apparatus recognized normal slice ligation in the regulated promoters.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="392">
                    <text>RNA supply apparatus recognized normal slice ligation.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="393">
                    <text>RNA supply apparatus specifically recognized normal slice ligation.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="394">
                    <text>RNA supply apparatus that has recognized normal slice ligation was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="395">
                    <text>RNA supply apparatus that recognized normal slice ligation was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="396">
                    <text>RNA supply apparatus that recognizes normal slice ligation is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="397">
                    <text>RNA supply apparatus that recognizes normal slice ligation is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="398">
                    <text>RNA supply apparatus will recognize normal slice ligation in regulated promoters.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="399">
                    <text>The COOH-terminal epitopes is recognized by the one of the two monoclonal antibodies that the garbage was surveyed.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="400">
                    <text>The COOH-terminal epitopes was recognized by the one of the two monoclonal antibodies acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="401">
                    <text>The COOH-terminal epitopes was recognized by the one of the two monoclonal antibodies.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="402">
                    <text>The COOH-terminal epitopes was recognized by the one of two monoclonal antibodies acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="403">
                    <text>The COOH-terminal epitopes was recognized by the one of two monoclonal antibodies.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="404">
                    <text>The a number of Ags is recognized by the A0 (a monoclonal anti-HA RAT antibody (Boehringer-Ingelheim) with which the rostes were sounded.</text>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="405">
                    <text>The a number of Ags is recognized by the Class I melanoma-specific T cells that the garbage was surveyed.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="406">
                    <text>The a number of Ags was recognized by the Class I melanoma-specific T cells acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="407">
                    <text>The a number of Ags was recognized by the Class I melanoma-specific T cells.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="408">
                    <text>The a series of Ags is recognized by the A0 (a monoclonal anti-HA RAT antibody (Boehringer-Ingelheim) with which the rostes were sounded.</text>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="409">
                    <text>The a series of Ags is recognized by the Class I melanoma-specific T cells that the garbage was surveyed.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="410">
                    <text>The a series of Ags is recognized by the Class and T cells specific to melanoma that the garbage was surveyed.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="411">
                    <text>The a series of Ags is recognized by the class I melanoma-specific T cells that the garbage was surveyed.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="412">
                    <text>The a series of Ags was recognized by the Class I melanoma-specific T cells acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="413">
                    <text>The a series of Ags was recognized by the Class and T cells specific to melanoma acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="414">
                    <text>The a series of Ags was recognized by the Class and T cells specific to melanoma.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="415">
                    <text>The a series of Ags was recognized by the class I melanoma-specific T cells acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="416">
                    <text>The a series of Ags was recognized by the class I melanoma-specific T cells.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="417">
                    <text>The blots were investigated with Class I melanoma-specific T cells that recognized a number of Ags.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="418">
                    <text>The blots were investigated with Class I melanoma-specific T cells that recognized a series of Ags.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="419">
                    <text>The blots were investigated with Class and T cells specific to melanoma that recognized a series of Ags.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="420">
                    <text>The blots were investigated with autological serum that recognized epitopes.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="421">
                    <text>The blots were investigated with autologous serum that recognized epitopes.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="422">
                    <text>The blots were investigated with autologous serum that recognized the epitopes.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="423">
                    <text>The blots were investigated with one of the two monoclonal antibodies that recognized COOH-terminal epitopes.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="424">
                    <text>The blots were investigated with one of two monoclonal antibodies that recognized cooled-terminal epitopes.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="425">
                    <text>The blots were investigated with the RNA supply apparatus that recognized the normal splice binding.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="426">
                    <text>The blots were investigated with the autological serum that recognized epiptopes.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="427">
                    <text>The blots were investigated with the reverse transcription apparatus that recognized the normal junction of slice.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="428">
                    <text>The blots were probed with Class I melanoma-specific T cells recognizing A1 (epitopes in the C muscle of LMP-1 in 1:200 dilution.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                </example>
                <example src="REPLACE" no="429">
                    <text>The blots were probed with Class I melanoma-specific T cells that can recognize A1 (epitopes in the C muscle of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                </example>
                <example src="REPLACE" no="430">
                    <text>The blots were probed with Class I melanoma-specific T cells that can recognize a number of Ags.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="431">
                    <text>The blots were probed with Class I melanoma-specific T cells that can recognize a series of Ags.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="432">
                    <text>The blots were probed with Class I melanoma-specific T cells that recognized A1 (epitopes in the C muscle of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                </example>
                <example src="REPLACE" no="433">
                    <text>The blots were probed with Class and T cells specific to melanoma recognizing A1 (epitopes in the C muscle of LMP-1 in 1:200 dilution.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                </example>
                <example src="REPLACE" no="434">
                    <text>The blots were probed with Class and T cells specific to melanoma that can recognize A1 (epitopes in the C muscle of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                </example>
                <example src="REPLACE" no="435">
                    <text>The blots were probed with Class and T cells specific to melanoma that can recognize a series of Ags.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="436">
                    <text>The blots were probed with Class and T cells specific to melanoma that recognized A1 (epitopes in the C muscle of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                </example>
                <example src="REPLACE" no="437">
                    <text>The blots were probed with RNA supply apparatus recognizing A1 (epitopes in the C muscle of LMP-1 in 1:200 dilution.</text>
                    <arg n="0">RNA supply apparatus</arg>
                </example>
                <example src="REPLACE" no="438">
                    <text>The blots were probed with RNA supply apparatus that can recognize normal slice ligation.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="439">
                    <text>The blots were probed with RNA supply apparatus that recognized A1 (epitopes in the C muscle of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">RNA supply apparatus</arg>
                </example>
                <example src="REPLACE" no="440">
                    <text>The blots were probed with autological serum recognizing A1 (epitopes in the C muscle of LMP-1 in 1:200 dilution.</text>
                    <arg n="0">autological serum</arg>
                </example>
                <example src="REPLACE" no="441">
                    <text>The blots were probed with autological serum that can recognize A1 (epitopes in the C muscle of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">autological serum</arg>
                </example>
                <example src="REPLACE" no="442">
                    <text>The blots were probed with autological serum that can recognize epitopes.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="443">
                    <text>The blots were probed with autological serum that recognized A1 (epitopes in the C muscle of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">autological serum</arg>
                </example>
                <example src="REPLACE" no="444">
                    <text>The blots were probed with autologous serum recognizing A1 (epitopes in the C muscle of LMP-1 in 1:200 dilution.</text>
                    <arg n="0">autologous serum</arg>
                </example>
                <example src="REPLACE" no="445">
                    <text>The blots were probed with autologous serum that can recognize epitopes.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="446">
                    <text>The blots were probed with autologous serum that can recognize the epitopes.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="447">
                    <text>The blots were probed with autologous serum that recognized A1 (epitopes in the C muscle of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">autologous serum</arg>
                </example>
                <example src="REPLACE" no="448">
                    <text>The blots were probed with class I melanoma-specific T cells recognizing A1 (epitopes in the C muscle of LMP-1 in 1:200 dilution.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                </example>
                <example src="REPLACE" no="449">
                    <text>The blots were probed with class I melanoma-specific T cells that can recognize A1 (epitopes in the C muscle of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                </example>
                <example src="REPLACE" no="450">
                    <text>The blots were probed with class I melanoma-specific T cells that can recognize a series of Ags.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="451">
                    <text>The blots were probed with class I melanoma-specific T cells that recognized A1 (epitopes in the C muscle of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                </example>
                <example src="REPLACE" no="452">
                    <text>The blots were probed with one of the two monoclonal antibodies recognizing A1 (epitopes in the C muscle of LMP-1 in 1:200 dilution.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                </example>
                <example src="REPLACE" no="453">
                    <text>The blots were probed with one of the two monoclonal antibodies that can recognize A1 (epitopes in the C muscle of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                </example>
                <example src="REPLACE" no="454">
                    <text>The blots were probed with one of the two monoclonal antibodies that can recognize COOH-terminal epitopes.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="455">
                    <text>The blots were probed with one of the two monoclonal antibodies that recognized A1 (epitopes in the C muscle of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                </example>
                <example src="REPLACE" no="456">
                    <text>The blots were probed with one of two monoclonal antibodies that can recognize A1 (epitopes in the C muscle of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                </example>
                <example src="REPLACE" no="457">
                    <text>The blots were probed with one of two monoclonal antibodies that can recognize COOH-terminal epitopes.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="458">
                    <text>The blots were probed with one of two monoclonal antibodies that can recognize cooled-terminal epitopes.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="459">
                    <text>The blots were probed with one of two monoclonal antibodies that recognized A1 (epitopes in the C muscle of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                </example>
                <example src="REPLACE" no="460">
                    <text>The blots were probed with the RNA supply apparatus recognizing A1 (epitopes in the C muscle of LMP-1 in 1:200 dilution.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                </example>
                <example src="REPLACE" no="461">
                    <text>The blots were probed with the RNA supply apparatus that can recognize A1 (epitopes in the C muscle of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                </example>
                <example src="REPLACE" no="462">
                    <text>The blots were probed with the RNA supply apparatus that can recognize the normal splice binding.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="463">
                    <text>The blots were probed with the RNA supply apparatus that recognized A1 (epitopes in the C muscle of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                </example>
                <example src="REPLACE" no="464">
                    <text>The blots were probed with the autological serum recognizing A1 (epitopes in the C muscle of LMP-1 in 1:200 dilution.</text>
                    <arg n="0">the autological serum</arg>
                </example>
                <example src="REPLACE" no="465">
                    <text>The blots were probed with the autological serum that can recognize A1 (epitopes in the C muscle of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">the autological serum</arg>
                </example>
                <example src="REPLACE" no="466">
                    <text>The blots were probed with the autological serum that recognized A1 (epitopes in the C muscle of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">the autological serum</arg>
                </example>
                <example src="REPLACE" no="467">
                    <text>The blots were probed with the autologous serum recognizing A1 (epitopes in the C muscle of LMP-1 in 1:200 dilution.</text>
                    <arg n="0">the autologous serum</arg>
                </example>
                <example src="REPLACE" no="468">
                    <text>The blots were probed with the autologous serum that can recognize A1 (epitopes in the C muscle of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">the autologous serum</arg>
                </example>
                <example src="REPLACE" no="469">
                    <text>The blots were probed with the autologous serum that can recognize epitopes.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="470">
                    <text>The blots were probed with the autologous serum that recognized A1 (epitopes in the C muscle of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">the autologous serum</arg>
                </example>
                <example src="REPLACE" no="471">
                    <text>The blots were probed with the reverse transcription apparatus recognizing A1 (epitopes in the C muscle of LMP-1 in 1:200 dilution.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                </example>
                <example src="REPLACE" no="472">
                    <text>The blots were probed with the reverse transcription apparatus that can recognize A1 (epitopes in the C muscle of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                </example>
                <example src="REPLACE" no="473">
                    <text>The blots were probed with the reverse transcription apparatus that can recognize the normal junction of slice.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="474">
                    <text>The blots were probed with the reverse transcription apparatus that recognized A1 (epitopes in the C muscle of LMP-1 in a 1:200 dilution.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                </example>
                <example src="REPLACE" no="475">
                    <text>The cooled-terminal epitopes is recognized by the one of two monoclonal antibodies that the garbage was surveyed.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="476">
                    <text>The cooled-terminal epitopes was recognized by the one of two monoclonal antibodies acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="477">
                    <text>The cooled-terminal epitopes was recognized by the one of two monoclonal antibodies.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="478">
                    <text>The epiptopes is recognized by the the autological serum that the garbage was surveyed.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="479">
                    <text>The epiptopes was recognized by the the autological serum acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="480">
                    <text>The epiptopes was recognized by the the autological serum.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="481">
                    <text>The epitopes is recognized by the autological serum that the garbage was surveyed.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="482">
                    <text>The epitopes is recognized by the autologous serum that the garbage was surveyed.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="483">
                    <text>The epitopes is recognized by the the autologous serum that the garbage was surveyed.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="484">
                    <text>The epitopes was recognized by the autological serum.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="485">
                    <text>The epitopes was recognized by the autologous serum acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="486">
                    <text>The epitopes was recognized by the autologous serum.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="487">
                    <text>The epitopes was recognized by the the autologous serum.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="488">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with Class I melanoma-specific T cells that recognizes a number of Ags and by western blotting.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="489">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with Class I melanoma-specific T cells that recognizes a series of Ags and by western blotting.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="490">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with RNA supply apparatus that recognizes normal slice ligation and by western blotting.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="491">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with autological serum that recognizes epitopes and by western blotting.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="492">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with autologous serum that recognizes epitopes and by western blotting.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="493">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with autologous serum that recognizes the epitopes and by western blotting.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="494">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with class I melanoma-specific T cells that recognizes a series of Ags and by western blotting.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="495">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with one of two monoclonal antibodies that recognizes COOH-terminal epitopes and by western blotting.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="496">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with one of two monoclonal antibodies that recognizes cooled-terminal epitopes and by western blotting.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="497">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with the RNA supply apparatus that recognizes the normal splice binding and by western blotting.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="498">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with the autological serum that recognizes epiptopes and by western blotting.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="499">
                    <text>The individual cell clones were analyzed for STAT1 expression by immunofluorescence with the autologous serum that recognizes epitopes and by western blotting.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="500">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where COOH-terminal epitopes is recognized by one of the two monoclonal antibodies.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="501">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where COOH-terminal epitopes is recognized by one of two monoclonal antibodies.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="502">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where a number of Ags is recognized by Class I melanoma-specific T cells.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="503">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where a series of Ags is recognized by Class I melanoma-specific T cells.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="504">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where a series of Ags is recognized by class I melanoma-specific T cells.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="505">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where epiptopes is recognized by the autological serum.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="506">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where epitopes is recognized by autological serum.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="507">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where epitopes is recognized by autologous serum.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="508">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where epitopes is recognized by the autologous serum.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="509">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where normal slice ligation is recognized by RNA supply apparatus.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="510">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where the epitopes is recognized by autologous serum.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="511">
                    <text>The individual cell clones were analyzed for the expression of STAT1 by immunofluorescence, where the normal junction of slice is recognized by the reverse transcription apparatus.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="512">
                    <text>The normal slice ligation is recognized by the RNA supply apparatus that the garbage was surveyed.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="513">
                    <text>The normal slice ligation was recognized by the RNA supply apparatus acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="514">
                    <text>The normal slice ligation was recognized by the RNA supply apparatus.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="515">
                    <text>The the epitopes is recognized by the autologous serum that the garbage was surveyed.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="516">
                    <text>The the epitopes was recognized by the autologous serum acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="517">
                    <text>The the normal junction of slice was recognized by the the reverse transcription apparatus.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="518">
                    <text>The the normal splice binding is recognized by the the RNA supply apparatus that the garbage was surveyed.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="519">
                    <text>The the normal splice binding was recognized by the the RNA supply apparatus acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="520">
                    <text>The the normal splice binding was recognized by the the RNA supply apparatus.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="521">
                    <text>These bands can be detected with Class I melanoma-specific T cells that recognize A1 (the different non-muscle heavy chain isoforms of myosin (A and B)</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                </example>
                <example src="REPLACE" no="522">
                    <text>These bands can be detected with Class I melanoma-specific T cells that recognized A1 (the different non-muscle heavy chain isoforms of myosin (A and B)</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                </example>
                <example src="REPLACE" no="523">
                    <text>These bands can be detected with Class and T cells specific to melanoma that recognize A1 (the different non-muscle heavy chain isoforms of myosin (A and B)</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                </example>
                <example src="REPLACE" no="524">
                    <text>These bands can be detected with Class and T cells specific to melanoma that recognized A1 (the different non-muscle heavy chain isoforms of myosin (A and B)</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                </example>
                <example src="REPLACE" no="525">
                    <text>These bands can be detected with RNA supply apparatus that recognize A1 (the different non-muscle heavy chain isoforms of myosin (A and B)</text>
                    <arg n="0">RNA supply apparatus</arg>
                </example>
                <example src="REPLACE" no="526">
                    <text>These bands can be detected with RNA supply apparatus that recognized A1 (the different non-muscle heavy chain isoforms of myosin (A and B)</text>
                    <arg n="0">RNA supply apparatus</arg>
                </example>
                <example src="REPLACE" no="527">
                    <text>These bands can be detected with RNA supply apparatus that recognized A1 (the different non-muscular myosin heavy chain isoforms (A and B)</text>
                    <arg n="0">RNA supply apparatus</arg>
                </example>
                <example src="REPLACE" no="528">
                    <text>These bands can be detected with autological serum that recognize A1 (the different non-muscle heavy chain isoforms of myosin (A and B)</text>
                    <arg n="0">autological serum</arg>
                </example>
                <example src="REPLACE" no="529">
                    <text>These bands can be detected with autological serum that recognized A1 (the different non-muscle heavy chain isoforms of myosin (A and B)</text>
                    <arg n="0">autological serum</arg>
                </example>
                <example src="REPLACE" no="530">
                    <text>These bands can be detected with autologous serum that recognize A1 (the different non-muscle heavy chain isoforms of myosin (A and B)</text>
                    <arg n="0">autologous serum</arg>
                </example>
                <example src="REPLACE" no="531">
                    <text>These bands can be detected with autologous serum that recognized A1 (the different non-muscle heavy chain isoforms of myosin (A and B)</text>
                    <arg n="0">autologous serum</arg>
                </example>
                <example src="REPLACE" no="532">
                    <text>These bands can be detected with autologous serum that recognized A1 (the different non-muscular myosin heavy chain isoforms (A and B)</text>
                    <arg n="0">autologous serum</arg>
                </example>
                <example src="REPLACE" no="533">
                    <text>These bands can be detected with class I melanoma-specific T cells that recognize A1 (the different non-muscle heavy chain isoforms of myosin (A and B)</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                </example>
                <example src="REPLACE" no="534">
                    <text>These bands can be detected with class I melanoma-specific T cells that recognized A1 (the different non-muscle heavy chain isoforms of myosin (A and B)</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                </example>
                <example src="REPLACE" no="535">
                    <text>These bands can be detected with class I melanoma-specific T cells that recognized A1 (the different non-muscular myosin heavy chain isoforms (A and B)</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                </example>
                <example src="REPLACE" no="536">
                    <text>These bands can be detected with one of the two monoclonal antibodies that recognize A1 (the different non-muscle heavy chain isoforms of myosin (A and B)</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                </example>
                <example src="REPLACE" no="537">
                    <text>These bands can be detected with one of the two monoclonal antibodies that recognized A1 (the different non-muscle heavy chain isoforms of myosin (A and B)</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                </example>
                <example src="REPLACE" no="538">
                    <text>These bands can be detected with one of the two monoclonal antibodies that recognized A1 (the different non-muscular myosin heavy chain isoforms (A and B)</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                </example>
                <example src="REPLACE" no="539">
                    <text>These bands can be detected with one of two monoclonal antibodies that recognized A1 (the different non-muscle heavy chain isoforms of myosin (A and B)</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                </example>
                <example src="REPLACE" no="540">
                    <text>These bands can be detected with one of two monoclonal antibodies that recognized A1 (the different non-muscular myosin heavy chain isoforms (A and B)</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                </example>
                <example src="REPLACE" no="541">
                    <text>These bands can be detected with the RNA supply apparatus that recognize A1 (the different non-muscle heavy chain isoforms of myosin (A and B)</text>
                    <arg n="0">the RNA supply apparatus</arg>
                </example>
                <example src="REPLACE" no="542">
                    <text>These bands can be detected with the RNA supply apparatus that recognized A1 (the different non-muscle heavy chain isoforms of myosin (A and B)</text>
                    <arg n="0">the RNA supply apparatus</arg>
                </example>
                <example src="REPLACE" no="543">
                    <text>These bands can be detected with the RNA supply apparatus that recognized A1 (the different non-muscular myosin heavy chain isoforms (A and B)</text>
                    <arg n="0">the RNA supply apparatus</arg>
                </example>
                <example src="REPLACE" no="544">
                    <text>These bands can be detected with the autological serum that recognize A1 (the different non-muscle heavy chain isoforms of myosin (A and B)</text>
                    <arg n="0">the autological serum</arg>
                </example>
                <example src="REPLACE" no="545">
                    <text>These bands can be detected with the autological serum that recognized A1 (the different non-muscle heavy chain isoforms of myosin (A and B)</text>
                    <arg n="0">the autological serum</arg>
                </example>
                <example src="REPLACE" no="546">
                    <text>These bands can be detected with the autological serum that recognized A1 (the different non-muscular myosin heavy chain isoforms (A and B)</text>
                    <arg n="0">the autological serum</arg>
                </example>
                <example src="REPLACE" no="547">
                    <text>These bands can be detected with the autologous serum that recognized A1 (the different non-muscle heavy chain isoforms of myosin (A and B)</text>
                    <arg n="0">the autologous serum</arg>
                </example>
                <example src="REPLACE" no="548">
                    <text>These bands can be detected with the autologous serum that recognized A1 (the different non-muscular myosin heavy chain isoforms (A and B)</text>
                    <arg n="0">the autologous serum</arg>
                </example>
                <example src="REPLACE" no="549">
                    <text>These bands can be detected with the reverse transcription apparatus that recognize A1 (the different non-muscle heavy chain isoforms of myosin (A and B)</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                </example>
                <example src="REPLACE" no="550">
                    <text>These bands can be detected with the reverse transcription apparatus that recognized A1 (the different non-muscular myosin heavy chain isoforms (A and B)</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                </example>
                <example src="REPLACE" no="551">
                    <text>We show that Class I melanoma-specific T cells recognized a number of Ags that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="552">
                    <text>We show that Class I melanoma-specific T cells recognized a number of Ags that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="553">
                    <text>We show that Class I melanoma-specific T cells recognized a number of Ags that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="554">
                    <text>We show that Class I melanoma-specific T cells recognized a series of Ags that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="555">
                    <text>We show that Class I melanoma-specific T cells recognized a series of Ags that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="556">
                    <text>We show that Class I melanoma-specific T cells recognized a series of Ags that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="557">
                    <text>We show that Class I melanoma-specific T cells will recognize a number of Ags that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="558">
                    <text>We show that Class I melanoma-specific T cells will recognize a series of Ags that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="559">
                    <text>We show that Class I melanoma-specific T cells will recognize a series of Ags that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="560">
                    <text>We show that Class and T cells specific to melanoma recognized a series of Ags that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="561">
                    <text>We show that Class and T cells specific to melanoma recognized a series of Ags that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="562">
                    <text>We show that Class and T cells specific to melanoma recognized a series of Ags that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="563">
                    <text>We show that Class and T cells specific to melanoma will recognize a series of Ags that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="564">
                    <text>We show that Class and T cells specific to melanoma will recognize a series of Ags that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="565">
                    <text>We show that RNA supply apparatus recognized normal slice ligation that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="566">
                    <text>We show that RNA supply apparatus recognized normal slice ligation that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="567">
                    <text>We show that RNA supply apparatus recognized normal slice ligation that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="568">
                    <text>We show that RNA supply apparatus will recognize normal slice ligation that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="569">
                    <text>We show that RNA supply apparatus will recognize normal slice ligation that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="570">
                    <text>We show that autological serum recognized epitopes that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="571">
                    <text>We show that autological serum recognized epitopes that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="572">
                    <text>We show that autological serum will recognize epitopes that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="573">
                    <text>We show that autological serum will recognize epitopes that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="574">
                    <text>We show that autologous serum recognized epitopes that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="575">
                    <text>We show that autologous serum recognized epitopes that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="576">
                    <text>We show that autologous serum recognized epitopes that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="577">
                    <text>We show that autologous serum recognized the epitopes that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="578">
                    <text>We show that autologous serum recognized the epitopes that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="579">
                    <text>We show that autologous serum recognized the epitopes that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="580">
                    <text>We show that autologous serum will recognize epitopes that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="581">
                    <text>We show that autologous serum will recognize epitopes that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="582">
                    <text>We show that autologous serum will recognize the epitopes that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="583">
                    <text>We show that class I melanoma-specific T cells recognized a series of Ags that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="584">
                    <text>We show that class I melanoma-specific T cells recognized a series of Ags that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="585">
                    <text>We show that class I melanoma-specific T cells will recognize a series of Ags that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="586">
                    <text>We show that one of the two monoclonal antibodies recognized COOH-terminal epitopes that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="587">
                    <text>We show that one of the two monoclonal antibodies recognized COOH-terminal epitopes that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="588">
                    <text>We show that one of the two monoclonal antibodies recognized COOH-terminal epitopes that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="589">
                    <text>We show that one of the two monoclonal antibodies will recognize COOH-terminal epitopes that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="590">
                    <text>We show that one of the two monoclonal antibodies will recognize COOH-terminal epitopes that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="591">
                    <text>We show that one of two monoclonal antibodies recognized COOH-terminal epitopes that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="592">
                    <text>We show that one of two monoclonal antibodies recognized COOH-terminal epitopes that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="593">
                    <text>We show that one of two monoclonal antibodies recognized cooled-terminal epitopes that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="594">
                    <text>We show that one of two monoclonal antibodies will recognize COOH-terminal epitopes that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="595">
                    <text>We show that one of two monoclonal antibodies will recognize COOH-terminal epitopes that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="596">
                    <text>We show that one of two monoclonal antibodies will recognize cooled-terminal epitopes that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="597">
                    <text>We show that one of two monoclonal antibodies will recognize cooled-terminal epitopes that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="598">
                    <text>We show that the RNA supply apparatus recognized the normal splice binding that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="599">
                    <text>We show that the RNA supply apparatus recognized the normal splice binding that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="600">
                    <text>We show that the RNA supply apparatus will recognize the normal splice binding that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="601">
                    <text>We show that the RNA supply apparatus will recognize the normal splice binding that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="602">
                    <text>We show that the autological serum recognized epiptopes that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="603">
                    <text>We show that the autological serum recognized epiptopes that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="604">
                    <text>We show that the autological serum recognized epiptopes that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="605">
                    <text>We show that the autological serum will recognize epiptopes that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="606">
                    <text>We show that the autologous serum recognized epitopes that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="607">
                    <text>We show that the autologous serum recognized epitopes that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="608">
                    <text>We show that the autologous serum will recognize epitopes that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="609">
                    <text>We show that the reverse transcription apparatus recognized the normal junction of slice that are separated by 33 bp : a high affinity site (CRP-1) overlaps the region-35, and a low affinity site (CRP-2) focuses on the position-74 bp.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="610">
                    <text>We show that the reverse transcription apparatus recognized the normal junction of slice that separate by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="611">
                    <text>We show that the reverse transcription apparatus will recognize the normal junction of slice that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the 35 bp region, and a low-affinity site (CRP-2) is centered in the 74 bp position.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="612">
                    <text>We show that the reverse transcription apparatus will recognize the normal junction of slice that are separated by 33 bp: a high-affinity site (CRP-1) overlaps the region-35, and a low-affinity site (CRP-2) is centered on position-74 bp.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="613">
                    <text>a number of Ags are recognized by Class I melanoma-specific T cells with which the threads were probed.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="614">
                    <text>a number of Ags are recognized by Class I melanoma-specific T cells with which the wires were probed.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="615">
                    <text>a number of Ags are recognized by Class I melanoma-specific T cells.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="616">
                    <text>a number of Ags could be recognized in immunoprecipitatio with Class I melanoma-specific T cells, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="617">
                    <text>a number of Ags has been recognized by Class I melanoma-specific T cells.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="618">
                    <text>a number of Ags is recognized by A0 (monoclonal anti-HA RAT antibody (Boehringer-Ingelheim) with which the screws were sound.</text>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="619">
                    <text>a number of Ags is recognized by Class I melanoma-specific T cells by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="620">
                    <text>a number of Ags is recognized by Class I melanoma-specific T cells by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="621">
                    <text>a number of Ags is recognized by Class I melanoma-specific T cells that the litters were probed.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="622">
                    <text>a number of Ags is recognized by Class I melanoma-specific T cells.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="623">
                    <text>a number of Ags was recognized by Class I melanoma-specific T cells by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="624">
                    <text>a number of Ags were recognized by Class I melanoma-specific T cells.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="625">
                    <text>a number of Ags will be recognized by Class I melanoma-specific T cells.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="626">
                    <text>a number of Ags will be recognized by the Class I melanoma-specific T cells.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="627">
                    <text>a number of Ags will be recognized in immunoprecipitatio with Class I melanoma-specific T cells, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="628">
                    <text>a number of Ags, cannot is recognized in immunoprecipitatio with Class I melanoma-specific T cells, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="629">
                    <text>a number of Ags, cannot is recognized in the immunoprecipitaiton with Class I melanoma-specific T cells as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="630">
                    <text>a number of Ags, could be recognized in the immunoprecipitaiton with Class I melanoma-specific T cells as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="631">
                    <text>a number of Ags, has been recognized in the immunoprecipitaiton with Class I melanoma-specific T cells as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="632">
                    <text>a number of Ags, was not recognized in the immunoprecipitaiton with Class I melanoma-specific T cells as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="633">
                    <text>a number of Ags, was unrecognized in immunoprecipitatio with Class I melanoma-specific T cells, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="634">
                    <text>a number of Ags, will be recognized in the immunoprecipitaiton with Class I melanoma-specific T cells as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a number of Ags</arg>
                </example>
                <example src="REPLACE" no="635">
                    <text>a series of Ags are recognized by Class I melanoma-specific T cells with which the threads were probed.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="636">
                    <text>a series of Ags are recognized by Class I melanoma-specific T cells with which the wires were probed.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="637">
                    <text>a series of Ags are recognized by Class I melanoma-specific T cells.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="638">
                    <text>a series of Ags are recognized by Class and T cells specific to melanoma with which the threads were probed.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="639">
                    <text>a series of Ags are recognized by class I melanoma-specific T cells with which the threads were probed.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="640">
                    <text>a series of Ags are recognized by class I melanoma-specific T cells with which the wires were probed.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="641">
                    <text>a series of Ags are recognized by class I melanoma-specific T cells.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="642">
                    <text>a series of Ags could be recognized in immunoprecipitatio with Class I melanoma-specific T cells, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="643">
                    <text>a series of Ags could be recognized in immunoprecipitatio with class I melanoma-specific T cells, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="644">
                    <text>a series of Ags has been recognized by Class I melanoma-specific T cells.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="645">
                    <text>a series of Ags is recognized by A0 (monoclonal anti-HA RAT antibody (Boehringer-Ingelheim) with which the screws were sound.</text>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="646">
                    <text>a series of Ags is recognized by Class I melanoma-specific T cells by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="647">
                    <text>a series of Ags is recognized by Class and T cells specific to melanoma by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="648">
                    <text>a series of Ags is recognized by Class and T cells specific to melanoma by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="649">
                    <text>a series of Ags is recognized by Class and T cells specific to melanoma that the litters were probed.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="650">
                    <text>a series of Ags is recognized by Class and T cells specific to melanoma.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="651">
                    <text>a series of Ags is recognized by class I melanoma-specific T cells by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="652">
                    <text>a series of Ags is recognized by class I melanoma-specific T cells by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="653">
                    <text>a series of Ags is recognized by class I melanoma-specific T cells that the litters were probed.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="654">
                    <text>a series of Ags is recognized by class I melanoma-specific T cells.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="655">
                    <text>a series of Ags was recognized by Class I melanoma-specific T cells by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="656">
                    <text>a series of Ags was recognized by Class I melanoma-specific T cells.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="657">
                    <text>a series of Ags was recognized by Class and T cells specific to melanoma by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="658">
                    <text>a series of Ags was recognized by Class and T cells specific to melanoma.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="659">
                    <text>a series of Ags was recognized by class I melanoma-specific T cells by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="660">
                    <text>a series of Ags was recognized in the immunoprecipitatome with Class I melanoma-specific T cells, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="661">
                    <text>a series of Ags was recognized in the immunoprecipitatome with Class and T cells specific to melanoma, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="662">
                    <text>a series of Ags was recognized in the immunoprecipitatome with class I melanoma-specific T cells, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="663">
                    <text>a series of Ags were recognized by Class I melanoma-specific T cells.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="664">
                    <text>a series of Ags were recognized by class I melanoma-specific T cells.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="665">
                    <text>a series of Ags will be recognized by Class I melanoma-specific T cells.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="666">
                    <text>a series of Ags will be recognized by Class and T cells specific to melanoma.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="667">
                    <text>a series of Ags will be recognized by class I melanoma-specific T cells.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="668">
                    <text>a series of Ags will be recognized by the Class I melanoma-specific T cells.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="669">
                    <text>a series of Ags will be recognized by the Class and T cells specific to melanoma.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="670">
                    <text>a series of Ags will be recognized by the class I melanoma-specific T cells.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="671">
                    <text>a series of Ags will be recognized in immunoprecipitatio with Class I melanoma-specific T cells, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="672">
                    <text>a series of Ags will be recognized in immunoprecipitatio with Class and T cells specific to melanoma, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="673">
                    <text>a series of Ags will be recognized in immunoprecipitatio with class I melanoma-specific T cells, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="674">
                    <text>a series of Ags, cannot is recognized in immunoprecipitatio with Class I melanoma-specific T cells, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="675">
                    <text>a series of Ags, cannot is recognized in immunoprecipitatio with Class and T cells specific to melanoma, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="676">
                    <text>a series of Ags, cannot is recognized in immunoprecipitatio with class I melanoma-specific T cells, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="677">
                    <text>a series of Ags, cannot is recognized in the immunoprecipitaiton with Class I melanoma-specific T cells as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="678">
                    <text>a series of Ags, cannot is recognized in the immunoprecipitaiton with Class and T cells specific to melanoma as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="679">
                    <text>a series of Ags, cannot is recognized in the immunoprecipitaiton with class I melanoma-specific T cells as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="680">
                    <text>a series of Ags, could be recognized in the immunoprecipitaiton with Class I melanoma-specific T cells as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="681">
                    <text>a series of Ags, could be recognized in the immunoprecipitaiton with class I melanoma-specific T cells as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="682">
                    <text>a series of Ags, has been recognized in the immunoprecipitaiton with Class and T cells specific to melanoma as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="683">
                    <text>a series of Ags, has been recognized in the immunoprecipitaiton with class I melanoma-specific T cells as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="684">
                    <text>a series of Ags, was not recognized in the immunoprecipitaiton with Class I melanoma-specific T cells as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="685">
                    <text>a series of Ags, was not recognized in the immunoprecipitaiton with Class and T cells specific to melanoma as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="686">
                    <text>a series of Ags, was not recognized in the immunoprecipitaiton with class I melanoma-specific T cells as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="687">
                    <text>a series of Ags, was unrecognized in immunoprecipitatio with Class I melanoma-specific T cells, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="688">
                    <text>a series of Ags, was unrecognized in immunoprecipitatio with Class and T cells specific to melanoma, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">Class and T cells specific to melanoma</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="689">
                    <text>a series of Ags, was unrecognized in immunoprecipitatio with class I melanoma-specific T cells, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="690">
                    <text>a series of Ags, will be recognized in the immunoprecipitaiton with Class I melanoma-specific T cells as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">Class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="691">
                    <text>autological serum also binds to these 727 sites but, unlike NarP, also recognized epitopes.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="692">
                    <text>autological serum also binds to these sites 7-2-7, but, unlike NarP, it also recognized epitopes .</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="693">
                    <text>autological serum are able to recognize epitopes in regulated promoters.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="694">
                    <text>autological serum binds to these 727 sites but, unlike NarP, will also recognize epitopes.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="695">
                    <text>autological serum binds to these sites 7-2-7, but, unlike NarP, it also recognizes epitopes .</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="696">
                    <text>autological serum can recognize epitopes in regulated promoters.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="697">
                    <text>autological serum is able to recognize epitopes in regulated promoters.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="698">
                    <text>autological serum recognized A1 (epitopes in the C muscle of LMP-1 in dilution 1:200.</text>
                    <arg n="0">autological serum</arg>
                </example>
                <example src="REPLACE" no="699">
                    <text>autological serum recognized epitopes in regulated promoters.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="700">
                    <text>autological serum recognized epitopes in the regulated promoters.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="701">
                    <text>autological serum recognized epitopes.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="702">
                    <text>autological serum recognizes epitopes.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="703">
                    <text>autological serum specifically recognized epitopes.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="704">
                    <text>autological serum that has recognized epitopes was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="705">
                    <text>autological serum that recognized epitopes was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="706">
                    <text>autological serum that recognizes epitopes is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="707">
                    <text>autological serum that recognizes epitopes is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="708">
                    <text>autological serum will recognize epitopes in regulated promoters.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="709">
                    <text>autologous serum also binds to these 727 sites but, unlike NarP, also recognized epitopes.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="710">
                    <text>autologous serum also binds to these 727 sites but, unlike NarP, also recognized the epitopes.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="711">
                    <text>autologous serum also binds to these sites 7-2-7, but, unlike NarP, it also recognized epitopes .</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="712">
                    <text>autologous serum also binds to these sites 7-2-7, but, unlike NarP, it also recognized epitopes.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="713">
                    <text>autologous serum also binds to these sites 7-2-7, but, unlike NarP, it also recognized the epitopes .</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="714">
                    <text>autologous serum also binds to these sites 7-2-7, but, unlike NarP, it also recognized the epitopes.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="715">
                    <text>autologous serum are able to recognize epitopes in regulated promoters.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="716">
                    <text>autologous serum are able to recognize the epitopes in regulated promoters.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="717">
                    <text>autologous serum binds to these 727 sites but, unlike NarP, will also recognize epitopes.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="718">
                    <text>autologous serum binds to these 727 sites but, unlike NarP, will also recognize the epitopes.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="719">
                    <text>autologous serum binds to these sites 7-2-7, but, unlike NarP, it also recognizes epitopes .</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="720">
                    <text>autologous serum binds to these sites 7-2-7, but, unlike NarP, it also recognizes the epitopes .</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="721">
                    <text>autologous serum can recognize epitopes in regulated promoters.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="722">
                    <text>autologous serum can recognize the epitopes in regulated promoters.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="723">
                    <text>autologous serum has also joined these 727 sites but, unlike NarP, has also recognized epitopes.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="724">
                    <text>autologous serum has also joined these 727 sites but, unlike NarP, has also recognized the epitopes.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="725">
                    <text>autologous serum is able to recognize epitopes in regulated promoters.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="726">
                    <text>autologous serum is able to recognize the epitopes in regulated promoters.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="727">
                    <text>autologous serum recognized A1 (epitopes in the C muscle of LMP-1 in dilution 1:200.</text>
                    <arg n="0">autologous serum</arg>
                </example>
                <example src="REPLACE" no="728">
                    <text>autologous serum recognized epitopes in regulated promoters.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="729">
                    <text>autologous serum recognized epitopes.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="730">
                    <text>autologous serum recognized the epitopes in regulated promoters.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="731">
                    <text>autologous serum recognized the epitopes in the regulated promoters.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="732">
                    <text>autologous serum recognized the epitopes.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="733">
                    <text>autologous serum recognizes epitopes.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="734">
                    <text>autologous serum recognizes the epitopes.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="735">
                    <text>autologous serum specifically recognized the epitopes.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="736">
                    <text>autologous serum that has recognized epitopes was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="737">
                    <text>autologous serum that has recognized the epitopes was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="738">
                    <text>autologous serum that recognized the epitopes was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="739">
                    <text>autologous serum that recognizes epitopes is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="740">
                    <text>autologous serum that recognizes epitopes is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="741">
                    <text>autologous serum that recognizes the epitopes is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="742">
                    <text>autologous serum that recognizes the epitopes is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="743">
                    <text>autologous serum will recognize epitopes in regulated promoters.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="744">
                    <text>autologous serum will recognize the epitopes in regulated promoters.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="745">
                    <text>class I melanoma-specific T cells also binds to these 727 sites but, unlike NarP, also recognized a series of Ags.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="746">
                    <text>class I melanoma-specific T cells also binds to these sites 7-2-7, but, unlike NarP, it also recognized a series of Ags .</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="747">
                    <text>class I melanoma-specific T cells also binds to these sites 7-2-7, but, unlike NarP, it also recognized a series of Ags.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="748">
                    <text>class I melanoma-specific T cells binds to these 727 sites but, unlike NarP, will also recognize a series of Ags.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="749">
                    <text>class I melanoma-specific T cells is able to recognize a series of Ags in regulated promoters.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="750">
                    <text>class I melanoma-specific T cells recognized A1 (epitopes in the C muscle of LMP-1 in dilution 1:200.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                </example>
                <example src="REPLACE" no="751">
                    <text>class I melanoma-specific T cells recognized a series of Ags in regulated promoters.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="752">
                    <text>class I melanoma-specific T cells recognized a series of Ags in the regulated promoters.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="753">
                    <text>class I melanoma-specific T cells recognized a series of Ags.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="754">
                    <text>class I melanoma-specific T cells recognizes a series of Ags.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="755">
                    <text>class I melanoma-specific T cells specifically recognized a series of Ags.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="756">
                    <text>class I melanoma-specific T cells that has recognized a series of Ags was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="757">
                    <text>class I melanoma-specific T cells that recognized a series of Ags was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="758">
                    <text>class I melanoma-specific T cells that recognizes a series of Ags is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="759">
                    <text>class I melanoma-specific T cells that recognizes a series of Ags is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="760">
                    <text>class I melanoma-specific T cells will recognize a series of Ags in regulated promoters.</text>
                    <arg n="0">class I melanoma-specific T cells</arg>
                    <arg n="1">a series of Ags</arg>
                </example>
                <example src="REPLACE" no="761">
                    <text>cooled-terminal epitopes are recognized by one of two monoclonal antibodies with which the threads were probed.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="762">
                    <text>cooled-terminal epitopes are recognized by one of two monoclonal antibodies with which the wires were probed.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="763">
                    <text>cooled-terminal epitopes are recognized by one of two monoclonal antibodies.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="764">
                    <text>cooled-terminal epitopes could be recognized in immunoprecipitatio with one of two monoclonal antibodies, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="765">
                    <text>cooled-terminal epitopes has been recognized by one of two monoclonal antibodies.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="766">
                    <text>cooled-terminal epitopes is recognized by one of two monoclonal antibodies by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="767">
                    <text>cooled-terminal epitopes is recognized by one of two monoclonal antibodies by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="768">
                    <text>cooled-terminal epitopes is recognized by one of two monoclonal antibodies.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="769">
                    <text>cooled-terminal epitopes was recognized by one of two monoclonal antibodies by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="770">
                    <text>cooled-terminal epitopes was recognized by one of two monoclonal antibodies.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="771">
                    <text>cooled-terminal epitopes was recognized in the immunoprecipitatome with one of two monoclonal antibodies, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="772">
                    <text>cooled-terminal epitopes were recognized by one of two monoclonal antibodies.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="773">
                    <text>cooled-terminal epitopes will be recognized by one of two monoclonal antibodies.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="774">
                    <text>cooled-terminal epitopes will be recognized by the one of two monoclonal antibodies.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="775">
                    <text>cooled-terminal epitopes will be recognized in immunoprecipitatio with one of two monoclonal antibodies, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="776">
                    <text>cooled-terminal epitopes, cannot is recognized in immunoprecipitatio with one of two monoclonal antibodies, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="777">
                    <text>cooled-terminal epitopes, cannot is recognized in the immunoprecipitaiton with one of two monoclonal antibodies as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="778">
                    <text>cooled-terminal epitopes, could be recognized in the immunoprecipitaiton with one of two monoclonal antibodies as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="779">
                    <text>cooled-terminal epitopes, has been recognized in the immunoprecipitaiton with one of two monoclonal antibodies as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="780">
                    <text>cooled-terminal epitopes, was not recognized in the immunoprecipitaiton with one of two monoclonal antibodies as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="781">
                    <text>cooled-terminal epitopes, was unrecognized in immunoprecipitatio with one of two monoclonal antibodies, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="782">
                    <text>cooled-terminal epitopes, will be recognized in the immunoprecipitaiton with one of two monoclonal antibodies as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="783">
                    <text>epiptopes are recognized by the autological serum.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="784">
                    <text>epiptopes could be recognized in immunoprecipitatio with the autological serum, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="785">
                    <text>epiptopes has been recognized by the autological serum.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="786">
                    <text>epiptopes is recognized by the autological serum by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="787">
                    <text>epiptopes is recognized by the autological serum that the litters were probed.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="788">
                    <text>epiptopes is recognized by the autological serum.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="789">
                    <text>epiptopes was recognized by the autological serum.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="790">
                    <text>epiptopes were recognized by the autological serum.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="791">
                    <text>epiptopes will be recognized by the autological serum.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="792">
                    <text>epiptopes will be recognized by the the autological serum.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="793">
                    <text>epiptopes will be recognized in immunoprecipitatio with the autological serum, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="794">
                    <text>epiptopes, cannot is recognized in immunoprecipitatio with the autological serum, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="795">
                    <text>epiptopes, cannot is recognized in the immunoprecipitaiton with the autological serum as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="796">
                    <text>epiptopes, could be recognized in the immunoprecipitaiton with the autological serum as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="797">
                    <text>epiptopes, was not recognized in the immunoprecipitaiton with the autological serum as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="798">
                    <text>epiptopes, will be recognized in the immunoprecipitaiton with the autological serum as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="799">
                    <text>epitopes are recognized by autological serum with which the threads were probed.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="800">
                    <text>epitopes are recognized by autological serum with which the wires were probed.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="801">
                    <text>epitopes are recognized by autologous serum with which the threads were probed.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="802">
                    <text>epitopes are recognized by autologous serum with which the wires were probed.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="803">
                    <text>epitopes are recognized by the autologous serum with which the threads were probed.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="804">
                    <text>epitopes are recognized by the autologous serum.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="805">
                    <text>epitopes could be recognized in immunoprecipitatio with autological serum, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="806">
                    <text>epitopes could be recognized in immunoprecipitatio with autologous serum, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="807">
                    <text>epitopes could be recognized in immunoprecipitatio with the autologous serum, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="808">
                    <text>epitopes has been recognized by autological serum.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="809">
                    <text>epitopes has been recognized by autologous serum.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="810">
                    <text>epitopes has been recognized by the autologous serum.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="811">
                    <text>epitopes is recognized by autological serum by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="812">
                    <text>epitopes is recognized by autological serum by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="813">
                    <text>epitopes is recognized by autological serum that the litters were probed.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="814">
                    <text>epitopes is recognized by autologous serum by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="815">
                    <text>epitopes is recognized by autologous serum by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="816">
                    <text>epitopes is recognized by autologous serum that the litters were probed.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="817">
                    <text>epitopes is recognized by autologous serum.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="818">
                    <text>epitopes is recognized by the autologous serum by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="819">
                    <text>epitopes is recognized by the autologous serum by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="820">
                    <text>epitopes is recognized by the autologous serum that the litters were probed.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="821">
                    <text>epitopes is recognized by the autologous serum.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="822">
                    <text>epitopes was recognized by autological serum by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="823">
                    <text>epitopes was recognized by autological serum.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="824">
                    <text>epitopes was recognized by autologous serum by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="825">
                    <text>epitopes was recognized by the autologous serum by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="826">
                    <text>epitopes was recognized by the autologous serum.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="827">
                    <text>epitopes was recognized in the immunoprecipitatome with autologous serum, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="828">
                    <text>epitopes was recognized in the immunoprecipitatome with the autologous serum, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="829">
                    <text>epitopes were recognized by autological serum.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="830">
                    <text>epitopes were recognized by autologous serum.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="831">
                    <text>epitopes were recognized by the autologous serum.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="832">
                    <text>epitopes will be recognized by autological serum.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="833">
                    <text>epitopes will be recognized by autologous serum.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="834">
                    <text>epitopes will be recognized by the autologous serum.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="835">
                    <text>epitopes will be recognized in immunoprecipitatio with autological serum, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="836">
                    <text>epitopes will be recognized in immunoprecipitatio with the autologous serum, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="837">
                    <text>epitopes, cannot is recognized in immunoprecipitatio with autological serum, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="838">
                    <text>epitopes, cannot is recognized in immunoprecipitatio with autologous serum, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="839">
                    <text>epitopes, cannot is recognized in immunoprecipitatio with the autologous serum, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="840">
                    <text>epitopes, cannot is recognized in the immunoprecipitaiton with autological serum as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="841">
                    <text>epitopes, cannot is recognized in the immunoprecipitaiton with autologous serum as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="842">
                    <text>epitopes, cannot is recognized in the immunoprecipitaiton with the autologous serum as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="843">
                    <text>epitopes, could be recognized in the immunoprecipitaiton with autological serum as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="844">
                    <text>epitopes, could be recognized in the immunoprecipitaiton with the autologous serum as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="845">
                    <text>epitopes, has been recognized in the immunoprecipitaiton with autological serum as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="846">
                    <text>epitopes, has been recognized in the immunoprecipitaiton with autologous serum as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="847">
                    <text>epitopes, has been recognized in the immunoprecipitaiton with the autologous serum as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="848">
                    <text>epitopes, was not recognized in the immunoprecipitaiton with autologous serum as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="849">
                    <text>epitopes, was not recognized in the immunoprecipitaiton with the autologous serum as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="850">
                    <text>epitopes, was unrecognized in immunoprecipitatio with autological serum, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="851">
                    <text>epitopes, was unrecognized in immunoprecipitatio with autologous serum, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="852">
                    <text>epitopes, was unrecognized in immunoprecipitatio with the autologous serum, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="853">
                    <text>epitopes, will be recognized in the immunoprecipitaiton with autological serum as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">autological serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="854">
                    <text>epitopes, will be recognized in the immunoprecipitaiton with the autologous serum as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="855">
                    <text>normal slice ligation are recognized by RNA supply apparatus with which the threads were probed.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="856">
                    <text>normal slice ligation are recognized by RNA supply apparatus with which the wires were probed.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="857">
                    <text>normal slice ligation are recognized by RNA supply apparatus.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="858">
                    <text>normal slice ligation has been recognized by RNA supply apparatus.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="859">
                    <text>normal slice ligation is recognized by RNA supply apparatus by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="860">
                    <text>normal slice ligation is recognized by RNA supply apparatus by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="861">
                    <text>normal slice ligation is recognized by RNA supply apparatus that the litters were probed.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="862">
                    <text>normal slice ligation was recognized by RNA supply apparatus by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="863">
                    <text>normal slice ligation was recognized by RNA supply apparatus.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="864">
                    <text>normal slice ligation was recognized in the immunoprecipitatome with RNA supply apparatus, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="865">
                    <text>normal slice ligation were recognized by RNA supply apparatus.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="866">
                    <text>normal slice ligation will be recognized by the RNA supply apparatus.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="867">
                    <text>normal slice ligation will be recognized in immunoprecipitatio with RNA supply apparatus, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="868">
                    <text>normal slice ligation, cannot is recognized in the immunoprecipitaiton with RNA supply apparatus as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="869">
                    <text>normal slice ligation, could be recognized in the immunoprecipitaiton with RNA supply apparatus as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="870">
                    <text>normal slice ligation, has been recognized in the immunoprecipitaiton with RNA supply apparatus as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="871">
                    <text>normal slice ligation, was not recognized in the immunoprecipitaiton with RNA supply apparatus as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="872">
                    <text>normal slice ligation, was unrecognized in immunoprecipitatio with RNA supply apparatus, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="873">
                    <text>normal slice ligation, will be recognized in the immunoprecipitaiton with RNA supply apparatus as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">RNA supply apparatus</arg>
                    <arg n="1">normal slice ligation</arg>
                </example>
                <example src="REPLACE" no="874">
                    <text>one of the two monoclonal antibodies also binds to these 727 sites but, unlike NarP, also recognized COOH-terminal epitopes.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="875">
                    <text>one of the two monoclonal antibodies also binds to these sites 7-2-7, but, unlike NarP, it also recognized COOH-terminal epitopes .</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="876">
                    <text>one of the two monoclonal antibodies also binds to these sites 7-2-7, but, unlike NarP, it also recognized COOH-terminal epitopes.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="877">
                    <text>one of the two monoclonal antibodies are able to recognize COOH-terminal epitopes in regulated promoters.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="878">
                    <text>one of the two monoclonal antibodies binds to these 727 sites but, unlike NarP, will also recognize COOH-terminal epitopes.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="879">
                    <text>one of the two monoclonal antibodies binds to these sites 7-2-7, but, unlike NarP, it also recognizes COOH-terminal epitopes .</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="880">
                    <text>one of the two monoclonal antibodies can recognize COOH-terminal epitopes in regulated promoters.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="881">
                    <text>one of the two monoclonal antibodies has also joined these 727 sites but, unlike NarP, has also recognized COOH-terminal epitopes.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="882">
                    <text>one of the two monoclonal antibodies is able to recognize COOH-terminal epitopes in regulated promoters.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="883">
                    <text>one of the two monoclonal antibodies recognized COOH-terminal epitopes in the regulated promoters.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="884">
                    <text>one of the two monoclonal antibodies recognized COOH-terminal epitopes.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="885">
                    <text>one of the two monoclonal antibodies specifically recognized COOH-terminal epitopes.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="886">
                    <text>one of the two monoclonal antibodies that has recognized COOH-terminal epitopes was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="887">
                    <text>one of the two monoclonal antibodies that recognized COOH-terminal epitopes was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="888">
                    <text>one of the two monoclonal antibodies that recognizes COOH-terminal epitopes is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="889">
                    <text>one of the two monoclonal antibodies will recognize COOH-terminal epitopes in regulated promoters.</text>
                    <arg n="0">one of the two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="890">
                    <text>one of two monoclonal antibodies also binds to these 727 sites but, unlike NarP, also recognized COOH-terminal epitopes.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="891">
                    <text>one of two monoclonal antibodies also binds to these 727 sites but, unlike NarP, also recognized cooled-terminal epitopes.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="892">
                    <text>one of two monoclonal antibodies also binds to these sites 7-2-7, but, unlike NarP, it also recognized COOH-terminal epitopes .</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="893">
                    <text>one of two monoclonal antibodies also binds to these sites 7-2-7, but, unlike NarP, it also recognized COOH-terminal epitopes.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="894">
                    <text>one of two monoclonal antibodies also binds to these sites 7-2-7, but, unlike NarP, it also recognized cooled-terminal epitopes .</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="895">
                    <text>one of two monoclonal antibodies also binds to these sites 7-2-7, but, unlike NarP, it also recognized cooled-terminal epitopes.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="896">
                    <text>one of two monoclonal antibodies are able to recognize cooled-terminal epitopes in regulated promoters.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="897">
                    <text>one of two monoclonal antibodies binds to these 727 sites but, unlike NarP, will also recognize COOH-terminal epitopes.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="898">
                    <text>one of two monoclonal antibodies binds to these 727 sites but, unlike NarP, will also recognize cooled-terminal epitopes.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="899">
                    <text>one of two monoclonal antibodies binds to these sites 7-2-7, but, unlike NarP, it also recognizes COOH-terminal epitopes .</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="900">
                    <text>one of two monoclonal antibodies binds to these sites 7-2-7, but, unlike NarP, it also recognizes cooled-terminal epitopes .</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="901">
                    <text>one of two monoclonal antibodies can recognize COOH-terminal epitopes in regulated promoters.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="902">
                    <text>one of two monoclonal antibodies can recognize cooled-terminal epitopes in regulated promoters.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="903">
                    <text>one of two monoclonal antibodies has also joined these 727 sites but, unlike NarP, has also recognized COOH-terminal epitopes.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="904">
                    <text>one of two monoclonal antibodies has also joined these 727 sites but, unlike NarP, has also recognized cooled-terminal epitopes.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="905">
                    <text>one of two monoclonal antibodies is able to recognize COOH-terminal epitopes in regulated promoters.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="906">
                    <text>one of two monoclonal antibodies recognized A1 (epitopes in the C muscle of LMP-1 in dilution 1:200.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                </example>
                <example src="REPLACE" no="907">
                    <text>one of two monoclonal antibodies recognized COOH-terminal epitopes in the regulated promoters.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="908">
                    <text>one of two monoclonal antibodies recognized COOH-terminal epitopes.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="909">
                    <text>one of two monoclonal antibodies recognized cooled-terminal epitopes in regulated promoters.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="910">
                    <text>one of two monoclonal antibodies recognized cooled-terminal epitopes in the regulated promoters.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="911">
                    <text>one of two monoclonal antibodies recognized cooled-terminal epitopes.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="912">
                    <text>one of two monoclonal antibodies recognizes COOH-terminal epitopes.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="913">
                    <text>one of two monoclonal antibodies recognizes cooled-terminal epitopes.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="914">
                    <text>one of two monoclonal antibodies specifically recognized cooled-terminal epitopes.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="915">
                    <text>one of two monoclonal antibodies that has recognized COOH-terminal epitopes was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="916">
                    <text>one of two monoclonal antibodies that has recognized cooled-terminal epitopes was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="917">
                    <text>one of two monoclonal antibodies that recognized COOH-terminal epitopes was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="918">
                    <text>one of two monoclonal antibodies that recognized cooled-terminal epitopes was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="919">
                    <text>one of two monoclonal antibodies that recognizes COOH-terminal epitopes is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="920">
                    <text>one of two monoclonal antibodies that recognizes cooled-terminal epitopes is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="921">
                    <text>one of two monoclonal antibodies that recognizes cooled-terminal epitopes is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="922">
                    <text>one of two monoclonal antibodies will recognize COOH-terminal epitopes in regulated promoters.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">COOH-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="923">
                    <text>one of two monoclonal antibodies will recognize cooled-terminal epitopes in regulated promoters.</text>
                    <arg n="0">one of two monoclonal antibodies</arg>
                    <arg n="1">cooled-terminal epitopes</arg>
                </example>
                <example src="REPLACE" no="924">
                    <text>the RNA supply apparatus also binds to these 727 sites but, unlike NarP, also recognized the normal splice binding.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="925">
                    <text>the RNA supply apparatus also binds to these sites 7-2-7, but, unlike NarP, it also recognized the normal splice binding .</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="926">
                    <text>the RNA supply apparatus also binds to these sites 7-2-7, but, unlike NarP, it also recognized the normal splice binding.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="927">
                    <text>the RNA supply apparatus binds to these 727 sites but, unlike NarP, will also recognize the normal splice binding.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="928">
                    <text>the RNA supply apparatus binds to these sites 7-2-7, but, unlike NarP, it also recognizes the normal splice binding .</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="929">
                    <text>the RNA supply apparatus can recognize the normal splice binding in regulated promoters.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="930">
                    <text>the RNA supply apparatus recognized A1 (epitopes in the C muscle of LMP-1 in dilution 1:200.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                </example>
                <example src="REPLACE" no="931">
                    <text>the RNA supply apparatus recognized the normal splice binding in regulated promoters.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="932">
                    <text>the RNA supply apparatus recognized the normal splice binding in the regulated promoters.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="933">
                    <text>the RNA supply apparatus recognized the normal splice binding.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="934">
                    <text>the RNA supply apparatus recognizes the normal splice binding.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="935">
                    <text>the RNA supply apparatus specifically recognized the normal splice binding.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="936">
                    <text>the RNA supply apparatus that recognized the normal splice binding was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="937">
                    <text>the RNA supply apparatus that recognizes the normal splice binding is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="938">
                    <text>the RNA supply apparatus will recognize the normal splice binding in regulated promoters.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="939">
                    <text>the autological serum also binds to these sites 7-2-7, but, unlike NarP, it also recognized epiptopes .</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="940">
                    <text>the autological serum also binds to these sites 7-2-7, but, unlike NarP, it also recognized epiptopes.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="941">
                    <text>the autological serum are able to recognize epiptopes in regulated promoters.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="942">
                    <text>the autological serum binds to these 727 sites but, unlike NarP, will also recognize epiptopes.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="943">
                    <text>the autological serum binds to these sites 7-2-7, but, unlike NarP, it also recognizes epiptopes .</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="944">
                    <text>the autological serum can recognize epiptopes in regulated promoters.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="945">
                    <text>the autological serum has also joined these 727 sites but, unlike NarP, has also recognized epiptopes.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="946">
                    <text>the autological serum is able to recognize epiptopes in regulated promoters.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="947">
                    <text>the autological serum recognized A1 (epitopes in the C muscle of LMP-1 in dilution 1:200.</text>
                    <arg n="0">the autological serum</arg>
                </example>
                <example src="REPLACE" no="948">
                    <text>the autological serum recognized epiptopes in regulated promoters.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="949">
                    <text>the autological serum recognized epiptopes in the regulated promoters.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="950">
                    <text>the autological serum specifically recognized epiptopes.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="951">
                    <text>the autological serum that has recognized epiptopes was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="952">
                    <text>the autological serum that recognized epiptopes was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="953">
                    <text>the autological serum that recognizes epiptopes is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="954">
                    <text>the autological serum that recognizes epiptopes is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="955">
                    <text>the autological serum will recognize epiptopes in regulated promoters.</text>
                    <arg n="0">the autological serum</arg>
                    <arg n="1">epiptopes</arg>
                </example>
                <example src="REPLACE" no="956">
                    <text>the autologous serum also binds to these 727 sites but, unlike NarP, also recognized epitopes.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="957">
                    <text>the autologous serum also binds to these sites 7-2-7, but, unlike NarP, it also recognized epitopes .</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="958">
                    <text>the autologous serum also binds to these sites 7-2-7, but, unlike NarP, it also recognized epitopes.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="959">
                    <text>the autologous serum binds to these sites 7-2-7, but, unlike NarP, it also recognizes epitopes .</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="960">
                    <text>the autologous serum can recognize epitopes in regulated promoters.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="961">
                    <text>the autologous serum has also joined these 727 sites but, unlike NarP, has also recognized epitopes.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="962">
                    <text>the autologous serum is able to recognize epitopes in regulated promoters.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="963">
                    <text>the autologous serum recognized A1 (epitopes in the C muscle of LMP-1 in dilution 1:200.</text>
                    <arg n="0">the autologous serum</arg>
                </example>
                <example src="REPLACE" no="964">
                    <text>the autologous serum recognized epitopes in regulated promoters.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="965">
                    <text>the autologous serum recognized epitopes in the regulated promoters.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="966">
                    <text>the autologous serum recognized epitopes.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="967">
                    <text>the autologous serum recognizes epitopes.</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="968">
                    <text>the autologous serum that has recognized epitopes was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="969">
                    <text>the autologous serum that recognized epitopes was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="970">
                    <text>the autologous serum that recognizes epitopes is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">the autologous serum</arg>
                    <arg n="1">epitopes</arg>
                </example>
                <example src="REPLACE" no="971">
                    <text>the epitopes are recognized by autologous serum with which the threads were probed.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="972">
                    <text>the epitopes are recognized by autologous serum with which the wires were probed.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="973">
                    <text>the epitopes are recognized by autologous serum.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="974">
                    <text>the epitopes could be recognized in immunoprecipitatio with autologous serum, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="975">
                    <text>the epitopes has been recognized by autologous serum.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="976">
                    <text>the epitopes is recognized by autologous serum by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="977">
                    <text>the epitopes is recognized by autologous serum.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="978">
                    <text>the epitopes was recognized by autologous serum by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="979">
                    <text>the epitopes were recognized by autologous serum.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="980">
                    <text>the epitopes will be recognized by autologous serum.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="981">
                    <text>the epitopes will be recognized by the autologous serum.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="982">
                    <text>the epitopes will be recognized in immunoprecipitatio with autologous serum, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="983">
                    <text>the epitopes, cannot is recognized in immunoprecipitatio with autologous serum, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="984">
                    <text>the epitopes, cannot is recognized in the immunoprecipitaiton with autologous serum as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="985">
                    <text>the epitopes, could be recognized in the immunoprecipitaiton with autologous serum as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="986">
                    <text>the epitopes, has been recognized in the immunoprecipitaiton with autologous serum as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="987">
                    <text>the epitopes, was not recognized in the immunoprecipitaiton with autologous serum as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="988">
                    <text>the epitopes, was unrecognized in immunoprecipitatio with autologous serum, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">autologous serum</arg>
                    <arg n="1">the epitopes</arg>
                </example>
                <example src="REPLACE" no="989">
                    <text>the normal junction of slice are recognized by the reverse transcription apparatus with which the threads were probed.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="990">
                    <text>the normal junction of slice are recognized by the reverse transcription apparatus with which the wires were probed.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="991">
                    <text>the normal junction of slice could be recognized in immunoprecipitatio with the reverse transcription apparatus, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="992">
                    <text>the normal junction of slice has been recognized by the reverse transcription apparatus.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="993">
                    <text>the normal junction of slice is recognized by the reverse transcription apparatus by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="994">
                    <text>the normal junction of slice is recognized by the reverse transcription apparatus that the litters were probed.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="995">
                    <text>the normal junction of slice is recognized by the reverse transcription apparatus.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="996">
                    <text>the normal junction of slice was recognized by the reverse transcription apparatus by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="997">
                    <text>the normal junction of slice was recognized by the reverse transcription apparatus.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="998">
                    <text>the normal junction of slice was recognized in the immunoprecipitatome with the reverse transcription apparatus, because it is a location of elevation against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="999">
                    <text>the normal junction of slice were recognized by the reverse transcription apparatus.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="1000">
                    <text>the normal junction of slice will be recognized by the reverse transcription apparatus.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="1001">
                    <text>the normal junction of slice will be recognized by the the reverse transcription apparatus.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="1002">
                    <text>the normal junction of slice will be recognized in immunoprecipitatio with the reverse transcription apparatus, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="1003">
                    <text>the normal junction of slice, cannot is recognized in immunoprecipitatio with the reverse transcription apparatus, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="1004">
                    <text>the normal junction of slice, cannot is recognized in the immunoprecipitaiton with the reverse transcription apparatus as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="1005">
                    <text>the normal junction of slice, could be recognized in the immunoprecipitaiton with the reverse transcription apparatus as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="1006">
                    <text>the normal junction of slice, has been recognized in the immunoprecipitaiton with the reverse transcription apparatus as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="1007">
                    <text>the normal junction of slice, was not recognized in the immunoprecipitaiton with the reverse transcription apparatus as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="1008">
                    <text>the normal junction of slice, was unrecognized in immunoprecipitatio with the reverse transcription apparatus, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="1009">
                    <text>the normal junction of slice, will be recognized in the immunoprecipitaiton with the reverse transcription apparatus as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="1010">
                    <text>the normal splice binding are recognized by the RNA supply apparatus with which the threads were probed.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="1011">
                    <text>the normal splice binding are recognized by the RNA supply apparatus with which the wires were probed.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="1012">
                    <text>the normal splice binding could be recognized in immunoprecipitatio with the RNA supply apparatus, since it was elevated against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="1013">
                    <text>the normal splice binding has been recognized by the RNA supply apparatus.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="1014">
                    <text>the normal splice binding is recognized by the RNA supply apparatus by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="1015">
                    <text>the normal splice binding is recognized by the RNA supply apparatus by the acquisition of transduction laboratories (Lexington, KY).</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="1016">
                    <text>the normal splice binding is recognized by the RNA supply apparatus.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="1017">
                    <text>the normal splice binding was recognized by the RNA supply apparatus by purchasing Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="1018">
                    <text>the normal splice binding was recognized by the RNA supply apparatus.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="1019">
                    <text>the normal splice binding were recognized by the RNA supply apparatus.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="1020">
                    <text>the normal splice binding will be recognized by the RNA supply apparatus.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="1021">
                    <text>the normal splice binding will be recognized by the the RNA supply apparatus.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="1022">
                    <text>the normal splice binding will be recognized in immunoprecipitatio with the RNA supply apparatus, since it arises against a C-terminal region of Stat3 that lacks Stat3Beta.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="1023">
                    <text>the normal splice binding, cannot is recognized in immunoprecipitatio with the RNA supply apparatus, as it is high against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="1024">
                    <text>the normal splice binding, cannot is recognized in the immunoprecipitaiton with the RNA supply apparatus as it rises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="1025">
                    <text>the normal splice binding, could be recognized in the immunoprecipitaiton with the RNA supply apparatus as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="1026">
                    <text>the normal splice binding, was not recognized in the immunoprecipitaiton with the RNA supply apparatus as it was raised against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="1027">
                    <text>the normal splice binding, was unrecognized in immunoprecipitatio with the RNA supply apparatus, because it is susceptible to a C-terminal region of Stat3 that is recognized in Stat3Beta.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="1028">
                    <text>the normal splice binding, will be recognized in the immunoprecipitaiton with the RNA supply apparatus as it arises against a C-terminal region of Stat3 that is missing at Stat3Beta.</text>
                    <arg n="0">the RNA supply apparatus</arg>
                    <arg n="1">the normal splice binding</arg>
                </example>
                <example src="REPLACE" no="1029">
                    <text>the reverse transcription apparatus also binds to these sites 7-2-7, but, unlike NarP, it also recognized the normal junction of slice .</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="1030">
                    <text>the reverse transcription apparatus also binds to these sites 7-2-7, but, unlike NarP, it also recognized the normal junction of slice.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="1031">
                    <text>the reverse transcription apparatus are able to recognize the normal junction of slice in regulated promoters.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="1032">
                    <text>the reverse transcription apparatus binds to these sites 7-2-7, but, unlike NarP, it also recognizes the normal junction of slice .</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="1033">
                    <text>the reverse transcription apparatus can recognize the normal junction of slice in regulated promoters.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="1034">
                    <text>the reverse transcription apparatus has also joined these 727 sites but, unlike NarP, has also recognized the normal junction of slice.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="1035">
                    <text>the reverse transcription apparatus is able to recognize the normal junction of slice in regulated promoters.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="1036">
                    <text>the reverse transcription apparatus recognized A1 (epitopes in the C muscle of LMP-1 in dilution 1:200.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                </example>
                <example src="REPLACE" no="1037">
                    <text>the reverse transcription apparatus recognized the normal junction of slice in regulated promoters.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="1038">
                    <text>the reverse transcription apparatus recognized the normal junction of slice in the regulated promoters.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="1039">
                    <text>the reverse transcription apparatus recognized the normal junction of slice.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="1040">
                    <text>the reverse transcription apparatus recognizes the normal junction of slice.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="1041">
                    <text>the reverse transcription apparatus specifically recognized the normal junction of slice.</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="1042">
                    <text>the reverse transcription apparatus that has recognized the normal junction of slice was acquired from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="1043">
                    <text>the reverse transcription apparatus that recognized the normal junction of slice was acquired in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="1044">
                    <text>the reverse transcription apparatus that recognizes the normal junction of slice is purchased from Transduction Laboratories (Lexington, KY).</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
                <example src="REPLACE" no="1045">
                    <text>the reverse transcription apparatus that recognizes the normal junction of slice is purchased in transduction laboratories (Lexington, KY).</text>
                    <arg n="0">the reverse transcription apparatus</arg>
                    <arg n="1">the normal junction of slice</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
